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Abstract
Morphine-6-glucurinde is a more effective and longer lasting analgesic than 
morphine, with fewer side effects. Unfortunately, it well documented that the 
coupling proceedure between moiphine and glucuronic acid is a problematic one. 
This has led Lacy and Sainsbury to consider isosteres of M6G, where the oxygen 
linkage between the two moieties is replaced by a CH2 unit. In a continuation of this 
work, we have attempted to utilise free radical chemistry to achieve this coupling.
We also report on the synthesis of some 6P-alkyl codeine derivatives by
4
reduction of alkenyl codeines derived from dihydrocodeinone via Wittig chemistry. 
These compounds have shown activity comparable to the parent compound, codeine, 
in the mouse hot plate test.
Increased rigidity of ring C, as seen in Diels-Alder adducts of thebaine (3), 
assists in increasing opioid activity. We have attempted to fuse a new ring system to 
position C-7 and C-8 of the morphine skeleton. Initial attempts to use the Robinson 
annulation to form this new ring system have proved largley unsuccessful. However, 
an alternative route using Diels-Alder reactions have afforded several novel 
compounds.
The benzene address moiety in NTI (43) and SIOM (66) play an important role 
in determining their selectivity at the opioid receptor. NTI and SIOM are both potent,
4
5-selective ligands despite the fact that the benzene address is held rigidly in different 
conformations, co-planar in NTI and orthogonal to the plane in SIOM with respect to 
ring C. In an attempt to explore further the conformational requirements of the so 
called address moiety, we have synthesised successfully compound 82 in which the 
benzene ring is 90° to the plane of ring C.
-i-
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1.1. The Opium Alkaloids
Opium, the sun-dried extract obtained from the incised unripe capsules of 
Papaver somniferum, has been used for centuries as a narcotic agent and a pain killing 
substance. Crude opium contains a complex mixture of almost twenty-five alkaloids. 
The principle alkaloid, and the one chiefly responsible for analgesic activity is 
morphine (1), named after Morpheus, the Greek God of dreams. It was first isolated 
in the pure form in 1805 by the German pharmacist, Friedrich Sertumer1.
Although the functional groups present in morphine had been identified by 
1881, it was many years later that Gulland and Robinson finally established the now 
accepted structure of morphine2. The first total synthesis of morphine was achieved 
in 1952 by Gates and Tschudi3,4. The biosynthetic pathway to the alkaloid has also 






Opium also contains several other minor alkaloids of therapeutic importance. 
These include codeine (2), the 3-O-methyl ether of morphine, noscapine (narcotine, 
3), papaverine (4) and thebaine (5).
1.2. Nomenclature and Stereochemistry
The structure of morphine consists of five distinct ring systems (Figure 1): 
phenolic A, cyclohexane B, cyclohexenol C, N-methy 1-piperidine D and a partially 
saturated furan ring E. Morphine lends its name to a the morphinan family of 
alkaloids and has a full systematic name of 7,8-didehydro-4,5-epoxy-N-methyl- 
(5a,6a)-morphinan-3,6-diol.
The absolute stereochemistry of morphine was unambiguously determined by 
Mackay and Hodgkin in 1955 from an X-ray crystallographic analysis of morphine
the atoms of ring A, B and E lying in one plane, and the atoms of ring C and D in a 
second plane at right angles to the first
The B/C ring junction is cis fused. Ring C is almost boat shaped in the crystal 
form, while the nitrogen containing ring, D, adopts an almost regular chair 
conformation with the methyl group attached to nitrogen via an equatorial bond. The 
C-5 oxygen and the C-6 hydroxyl group are cis to each other.
Natural (-)-moiphine contains asymmetric centres at carbons 5(R), 6(S), 9(R), 
13(S) and 14(R) and it is this precise geometric arrangement which affords the 
familiar opioid pharmacological activity. (+)-Morphine, with the opposite geometry 
at each of the five asymmetric centres, is devoid of analgesic activity8.
Figure 1
hydroiodide dihydrate7. Morphine and its analogues are approximately T-shaped with
1.3. Morphine Analogues - The Search for Improved Opioid Analgesic Drugs
Morphine is still one of the best and most effective cheap analgesics available 
to man. It is used in the treatment of ‘deep’ chronic pain rather than ‘sharp* periodic 
pain. Morphine exerts its pharmacological actions on the central nervous system and 
appears to work by interacting with receptors in the brain to elevate the pain threshold.
Unfortunately, morphine also induces many undesirable side-effects including 
respiratory depression (death by morphine overdose is almost always as a result of 
respiratory collapse), drowsiness, nausea and vomiting. Repeated use produces 
tolerance so that the amount of drug required to obtain the same degree of relief 
becomes increasingly greater. Furthermore, continued use of morphine results in the 
development of physical dependence and cessation induces symptoms of withdrawal 
(abstinence syndrome). The sense of euphoria on morphine administration has led to 









Over the years a wealth of research has taken place in an attempt to divest 
morphine of its side-effects. One of the earliest attempts involved acetylation to give 
3,6-diacetylmorphine, or heroin (6). In 1898, heroin was introduced into clinical 
medicine as a drug superior in potency to morphine without its addictive character. 
However, the faulty nature of this claim was soon realised. It is now known that the 
faster onset of action and the 2-3 fold greater potency of the drug in man are due to 
increased lipophilic character and the ability of heroin to cross the blood-brain barrier 
more readily than morphine. In vivo, heroin is metabolised to 6-acetylmorphine (7)
and morphine. As heroin itself does not bind to the opiate receptor9, it has been 
proposed that its actions are due to these two metabolites
In the late 1930’s the search for a synthetic substitute for atropine (a 
antispasmodic muscle relaxant) culminated serendipitously in the discovery of 
meperidine (pethidine, 8), the first non-opioid derived analgesic with a much simpler 
structure than morphine10. This led to the belief that the true pain killing
4
pharmacophore was less complex than morphine itself and the so called ‘morphine 
rule* was proposed (Figure 2). This stated naively that, for analgesic activity, 
compounds must possess (i) an aromatic ring attached to (ii) a quaternary carbon atom 
and (iii) a tertiary am in o  group situated two carbon atoms farther away.
Figure 2
Methadone11 (9), synthesised in 1946, is an example of a drug fulfilling these 
criteria. It possesses pharmacological properties similar to those of morphine. The 
abstinence syndrome of methadone is slower in onset, lasts longer but is less intense 
than that experienced with morphine. For these reasons, and because of its oral 
effectiveness, methadone has found use in the treatment of drug addicts to wean them 






By the mid-1950’s further ‘simple* morphines, exemplified by levorphanol 
(10) and phenazocine (11), were synthesised. Levorphanol, a moiphinan, is about 
four times more potent than morphine and induces fewer side-effects at optimal doses 
either orally, or parenterally. Since levorphanol is not metabolised in the liver to the 
same extent as morphine, it also provides analgesia for up to 8 hours. Phenazocine12, 
a benzomoiphan, is also an effective analgesic for most types of severe pain at a 
parenteral dose of l-3mg. It is also active orally and is used in the treatment of 
chronic pain at a dose level of 2-5mg. Tolerance develops more slowly to the effects 
of phenazocine, compared to morphine, and it also appears to be less addictive. The 
morphinans and benzomorphans are only effective if they possess the same absolute 
stereochemistry as morphine.
For a good few years the trend was therefore to snip away at the morphine 
skeleton in an attempt to achieve a more efficacious analgesic. However, this process 
of simplification, which leads to more conformationally flexible products, was 
challenged by Bentley in the early 1960s.
Bentley and co-workers argued that if morphine and related compounds bind 
to receptors in order to initiate their responses, molecular flexibility would permit a 
molecule to adapt to a number of receptor types. This mobility would not only elicit 
the desired analgesic response, but in addition, the unwanted side-effects. He 
therefore reasoned that alkaloids more complex and, in particular, of greater rigidity 
than morphine might bind to the opiate receptor with more selectivity and thereby 
result in agents with superior analgesic properties, free of undesired side-effects. 
Although present knowledge of opioid receptors suggests that such a view is now an 
oversimplification of the situation, this novel approach more than 30 years ago led to 
the synthesis of a new class of compounds known collectively as the oripavines, 





Of particular interest in this series is etoiphine (12) which is approximately 
10,000 times more potent than moiphine14. The effect is due to the fact that it is a 
very hydrophobic molecule and can pass through the blood-brain barrier 300 times 
more easily than morphine, as well as its greater affinity for the analgesic receptor site 
due to better binding interactions. Unfortunately this potency is not translated into 
selectivity, and because of this its use has been restricted to veterinary medicine. 
However, a related compound buprenorphine (13), with low levels of dependence and 
respiratory depression, is used clinically for the control of moderate to severe pain15.
1.4. Opioid Antagonists and Mixed Agonist-Antagonists
The change from opiate agonist to antagonist, or mixed agonist-antagonist, on 
replacing the iV-methyl group of morphine analogues with an allyl unit was first 
observed with N-allylnorcodeine (14) in 1915. IV-Allylcodeine reverses the decrease 
in respiratory rate caused by morphine, i.e. it behaves as an antagonist of morphine. 
The significance of this finding was not fully realised until iV-allylnormorphine 
(nalorphine, 15)16 was synthesised and tested. Pharmacological data revealed that 
nalorphine, which provides an effective antidote for morphine overdose, also induces 
analgesia at a dose level comparable to morphine in man. However, its clinical 
acceptance as an analgesic agent was hampered due to psychotomimetic effects 
associated with its use.
-7-
The observation that a drug could have antagonist activity and still retain 
potent analgesia, i.e. act as a mixed agonist-antagonist or dualist, was extremely 
important and stimulated an intensive search for other such agents. Modification of 
the iV-substituent indicated that for optimum antagonist activity a straight chain of 
three carbons is required. Extending the chain by one carbon lowers activity, whereas 
a five-carbon chain or slightly more restores agonist activity. Morphine derivatives 
with aromatic side-chains, such as iV-phenethylnormorphine (16), have also been 
shown to behave as antagonists, in addition to exhibiting analgesic activity.
The fact that oxymorphone (17) is a more potent agonist than morphine, led
Fishman and Lewenstein to synthesise its N-allyl derivative. The hope was that this
compound might prove to be more potent than nalorphine yet show less of its
undesirable effects. Indeed, iV-allylnoroxymorphone (naloxone, 18) was subsequently
*
found to be 10-20 times more potent than nalorphine, as an antagonist but more 
importantly it did not possess any agonist activity of its own i.e. it is a pure antagonist 
Analogues of naloxone with cyclopropylmethyl (naltrexone, 19) or cyclobutylmethyl 
(nalbuphine, 20) groups were also shown to be antagonists of increased activity, but 
they exhibit some agonistic action.
NR
14 R1-CH3; R2«CH2CH«CH2
15 R1«H; R2-CH2CH=CH2 
16R1«H; R2=CH2CH2C6H5
17 18 R=CH2CH-CH2






The original concept of an opioid receptor was first postulated in 1954 by 
Beckett and Casy17. The theory was based on stereochemical evidence and structural 
features common to analgesics known at the time. Using natural (-)-morphine as a 
model, because of its rigid structure, the authors considered that the ‘active features’ 
on the opiate ligand should complement or ‘fit’ the active sites on the receptor surface. 
It was therefore proposed that the receptor has three key recognition sites:
1. a flat portion that allows binding with the aromatic ring of the analgesic 
drug through van der Waal type forces.
2. an anionic site that associates with the positively charged basic centre of the 
ligand.
3. a cavity suitably orientated with the two sites above to accommodate the 
projecting bimethylene (C-15, C-16) portion of the piperidine ring D that lies 
in front of the plane containing the aromatic ring and the basic centre.
The model adequately accommodates most structural variants of morphine as 
well as morphinan and benzomorphan ligands possessing the same absolute 
configuration. However, many other anomalies existed which could not be accounted 
for by such a simple single receptor model.
1.5.2. Multiple Opioid Receptors
The first conclusive evidence for the existence of multiple opioid receptors
was provided by Martin and co-workers in 197618. In behavioural studies performed
%
on the chronic spinal dog, differences in pharmacological responses to different 
narcotic analgesics and their inability to substitute for each other in suppressing 
withdrawal symptoms led them to postulate the existence of three distinct types of 
receptors. The receptors were named after the prototype drugs used in the studies: \i 
for morphine (1), k for ketazocine (21), and a  for SKF 10,047 (N-allylnormetazocine, 
22). However, it is now known that the c  receptor is not opioid in nature1^ .
Following the discovery of the enkephalins20 (vide infra), Kosterlitz’s group 
provided evidence for a further receptor type21. They found that electrically 
stimulated contractions of the isolated guinea pig ileum (GPI) were much more 
sensitive to inhibition by morphine and related opiate alkaloids than by enkephalins, 
whereas the opposite was observed with the mouse vas deferens (MVD). They 
suggested that the two bioassay systems contained different receptor populations. The 
major receptors present in the GPI prefer opiates and resemble ji  receptors, whereas
21 22
-10-
the vas deferens contain a preponderance of receptors that exhibit a higher affinity for 
enkephalins and their analogues. These receptors were named 5 (deferens) receptors.
The reputed effects mediated by the three main opioid receptor types are 
shown in Table 1. There is now evidence for subtypes of |i, k and 8 receptors, i.e. p i 
and JI2, k i, K2 and K3, and 5i and 52 have been reported.
Receptor Response on activation
p. (mu) analgesia, respiratory depression, euphoria,
reduced gastrointestinal movement




1.6. The Endogenous Opioid Peptides
The characterisation of biological receptors in mammalian brain tissue 
instigated the search for an ‘endogenous opioid* as it was considered unlikely that 
these receptors would have evolved solely for interaction with ligands exogenous to 
the body. In 1975, Hughes and Kosterlitz20 isolated extracts from pig brain which 
had opioid activity similar to that of the opiate alkaloids. This activity was shown to 
be due to a mixture of two peptides which were characterised and named Met- 
enkephalin (23) and Leu-enkephalin (24).
H- 0 -0 -'
Tyr-Gly-Gly-Phe-Met Tyr-Gly-Gly-Phe-Leu
23 Met-enkephalin 24 Leu-enkephalin
The two enkephalins aie pentapeptides which differ in a single, residue at the C 
terminus. The opioid peptides are formed by the proteolytic cleavage of three inactive 
protein precursors, proopiomelanocortin, proenkephalin and prodynorphin.
The enkephalins are metabolised rapidly in vivo primarily by two peptidases, 
enkephalinase A, which splits the Gly-Phe bond and enkephalinase B, which splits the 
Gly-Gly bond. It is this facile hydrolysis of the peptide bonds which limits the use of 
enkephalins as effective analgesics. From structural activity relationship studies, it 
has been shown that both the phenol ring and amino group of the tyrosine residue are 
essential for opioid activity. As the tyrosine fragment also forms an integral part of 
the morphine skeleton there have been suggestions that the activity of morphine is 
due, in part, to this tyrosine residue acting as a mimic of the same unit in enkephalih. 
Some authors have been tempted to overlay the peptides on a model of morphine, thus 
to suggest that this is the conformation they present at the receptor site.
-12-





2R ( A - V ^ ri
OR2
25 1R=2R=H; 3R=C02H
26 1R=Me; 2R=H; 3R=C02H
27 1R=2R=Ac; 3R=C02Me
28 1 R-Ac; 2R=H
29 1R=p-D-glucuronyl; 2R=H
30 1R=2R=p-D-glucuronyl
3 1 1R=P-OH; 2R=H; 3R=COzH
32 1R=a-Br; 2R=Ac; 3R=C02Me
33 1R=OC(NH)CCI3; 2RJPrCO;
3R=C02Me
Morphine is subject to enantio- and regioselective glucuronidation catalysed 
by liver microsomal UDP-glucuronosyltransferase22. Conjugation with glucuronic 
acid (31) is the major pathway of metabolism for morphine and the route accounts for 
two-thirds of administered morphine recovered in urine23.
The widely held view that only a single monoglucuronide, morphine-3- 
glucuronide (29 , M3G), is produced in man24 was dispelled nearly thirty years ago 
when morphine-6-glucuronide (25 , M6G) was isolated, in trace amounts, from 
patients administered with morphine25. Glucuronides of drugs have high water 
solubility, are rapidly excreted from the body and are generally regarded as 
pharmacologically inactive25. Indeed, M3G is devoid of analgesic a c t i v i t y 2 ^  
although more recent reports27 have suggested that M3G is able to antagonise the 
effects of both morphine and M6G.
Pharmacological studies carried out in 1971 by Japanese workers on M6G 
revealed that this minor metabolite, in contrast, is a potent analgesic28. After 
subcutaneous injection, M6G was reported to be approximately four times as potent as 
morphine with twice the duration of action in the mouse hot plate test, while after 
intracerebral administration it was 45 times more potent than the parent drug. The 
relatively small quantities of M6G available for further investigation impeded much
-13-
research into its properties over the next decade and few reports appeared in the 
literature during this period.
Renewed interest in the morphine metabolites came in the late 1980’s when 
Osbourne and his co-workers published a brief communication highlighting the 
analgesic activity of M6G in six human cancer patients29,30. Further detailed studies 
showed that M6G caused fewer gastrointestinal (e.g. sedation, nausea, vomiting) and 
respiratory side effects associated with normal morphine administration31. There is 
evidence to suggest that analgesia associated with M6G is mediated through the p.- 
type receptor32, although enhanced binding to 5-receptors has also been reported. Of 
interest is the ability of M6G to cross the blood-brain barrier33. The phenomenon has 
been ascribed to its ability to exist in a folded, more lipophilic form, particularly in 
media of low-polarity such as biological membranes34.
The emerging wealth of evidence suggesting that M6G, may in fact be the 
‘prodrug’ of morphine, has stimulated interest in the use of M6G as a therapeutic 
agent in its own right. However, for the benefits to be fully realised, a simple 
synthetic route to the morphine metabolite is required which in turn can be adopted on 
a large scale.
To date, several syntheses of M6G have been reported. Yoshimura et al. have 
utilised the Koenigs-Knorr reaction in the coupling of 3-acetylmorphine (28) and 
acetobromide derivative of glucuronic acid (32)35,36. The adduct 27 after subsequent 
deprotection affords M6G. Codeine-6-glucuronide (26 , C6G) was obtained in 
essentially the same fashion. Scheinmann and co-workers at Salford Ultrafine have 
reported an alternative method using the enzyme p-glucuronidase as a catalyst in the 
selective hydrolysis of morphine-3,6-di-p-D-glucuronide (30, M3,6diG) to M6G37. A 
patent application by the same authors3** also claim that M6G can be obtained by 
reaction of the imidate 33 with 3-acetylmorphine (28). Difficulties encountered by 
past members of our group in reproducing the results of both Yoshimura and the 
patent application have led to a modified synthesis of M6G by Lacy and Sainsbury39 
based on a significantly improved procedure for coupling 28 with 2a -
-14-
bromoglucuronate 32. The complications experienced by Lacy are corroborated by 
similar reports by Carroll et a /.40 in their recent synthesis of 30.
1.8. Recent Design Approaches to Selective Opioid Receptor Ligands
The universal opioid antagonists naloxone (18) and naltrexone (19) have been 
widely employed as tools in research. Indeed, their ability to antagonise an agonist 
effect is the key criterion employed for establishing the involvement of an opioid 
receptor mechanism. Since these antagonists interact with all three major opioid 
receptor types (p., 5 and k) their usefulness in elucidating the effects mediated by a 
single receptor type is limited. Naltrexone is superior to naloxone as an antagonist 
because of its greater potency and bioavailability and for these reasons many of the 
approaches to developing selective non-peptide opioid antagonists over the past 
decade have involved the chemical modification of naltrexone. Rationales for the 
design of naltrexone derived selective antagonists have centred on the use of the 
bivalent ligand model and message-address concept.
1.8.1. Bivalent Ligand Approach41
The tenn ‘bivalent ligand* is defined broadly as a molecule that contains two 
pharmacophores linked through a spacer42. The expectation of enhanced potency of a 
bivalent ligand over the monovalent analogue was based on a model in which 
recognition units of a bivalent ligand molecule bridge two neighbouring opiojd 
recognition sites. The neighbouring sites may be located on a single opioid receptor 







Figure 4 : The hypothetical case depicting the interaction of a bivalent ligand with neighbouring 
recognition sites on two receptor subtypes (A and B). In receptor type A, bridging of the bivalent 
ligand proceeds via the univalently bound state (II) to the totally bound state (III) which is favoured 
over occupation by two ligands (state IV). For receptor type B, only the univalently bound bivalent 
ligand state (II and ID) is possible because the spacer does not allow bridging of neighbouring sites.
The potency increase should be substantially greater than a statistical factor of 
two as the free pharmacophore of a univalently bound bivalent ligand is confined 
within the locus of the vacant neighbouring recognition site. This would be 
equivalent to a very high concentration of pharmacophore (Figure 4, state II). 
Consequently bivalent binding (state HI) should be favoured over univalent binding 
(state IV) if the spacer length permits bridging of the neighbouring sites. The 
simultaneous occupation of two recognition sites (state HI) leads to selectivity. Since 
it is possible, however, that opioid receptor subtypes posses different inter-receptor 
distances, high selectivity for a single subtype ( f i ,  8  or k ) may be achieved by 




Studies evaluating the role of the spacer length on opioid antagonist selectivity 
were initially carried out on guinea pig ileum (GPI) preparations which contain p.- and 
K-opioid receptors43. For bivalent naltrexone ligands (series 35) containing glycyl 
spacers whose length could be varied (n=l-4), peak antagonism of morphine (p- 
receptor selective agonist) was observed with a spacer containing 4 (n=2) glycyl units 
whilst maximum antagonism of ethylketazocine (34), a K-receptor selective agonist, 
was observed at the shortest spacer length (n=0). The increase in antagonist potency 
at p-receptors is consistent with either the bridging of two neighbouring receptor sites 
or two neighbouring subsites on a single p-opioid receptor. Replacement of one of the 
pharmacophores in 35 (n=2) with (+)-naltrexone, inactive as an opioid antagonist, to 
give the (-)-(+)-isomer (meso) significantly reduced antagonist potency indicating that 












Substitution of the succinyl group in the potent K-receptor antagonist 35 (n=0) 
with a fumaryl unit (36) resulted in the loss of K-receptor selective antagonism. This
suggested that the relative orientation of the two pharmacophores is important in the 
recognition process. The observations led to the investigation of bivalent ligands with 
pharmacophores immobilised by a short rigid spacer, because it was considered that 
immobilisation of the antagonist pharmacophores in the correct orientation might 
facilitate bridging of the neighbouring recognition sites.
Pyrrole was selected as spacer on the basis of its accessibility and its ability to 
‘freeze* the orientation of both pharmacophores through ring fusion with the 
morphinan structure. The first two members of the series, synthesised under modified 
Pilloty-Robinson conditions, were norbinaltorphimine (37, norBNI) and
binaltoiphimine (38, BNI)45. Both compounds displayed exceptionally high K-opioid 
receptor antagonist potency and selectivity46*47. Related derivatives of the parent 
compound have been prepared to examine the function of the pyiTole moiety in 
conferring K-selectivity at the opioid receptor48. The thiophene analogue (40) has a 
selectivity comparable with norBNI, while the pyran (41) is considerably less 
selective for the K-site. The results suggest that the pyrrole moiety in norNBI serves 
primarily as spacer.














From structure activity studies49,50, it was revealed that norBNI (37) may not
require a second pharmacophore for its high antagonist potency and selectivity. This
theory was supported by the reported increase in potency of mesonorBNI (39), which
contained the inactive (+)-naltrexone. The different geometry of the two molecules
(Figure 5) suggests that K-opioid antagonist selectivity cannot be ascribed to the
bridging of two neighbouring opioid receptors and provides additional support that
*





Figure 5 : Geometrical comparison between norBNI (37) and mera-norBNI (39)
From these results, Portoghese postulated that the (-)-naltrexone derived 
component of norBNI and its meso isomer bind to a recognition locus while the 
position of the basic nitrogen on the second pharmacophore serves as an Arg  ^mimic 
of the endogenous K-selective opioid peptide dynorphin. The Arg7 residue has been 
shown to be essential for K-opioid activity51. The importance of the second nitrogen 
was illustrated by the simplified BNI congener 4252. Compound 42 is less potent but 
twice as selective as norBNI at K-sites which strongly suggests that the peripheral 
groups of 37 do not play a key role in the determining K-selectivity.
1.8.2. Message-Address Concept
The message-address concept, proposed by Schwyer53, was used to analyse 
the structure-activity relationships of various peptide hormones. In essence, peptide 
hormones which are sychnologically organised, contain a message sequence and an 
address sequence of amino acid residues, each being close to one another in the 
peptide chain. The message component is responsible for signal transduction at the 
receptor, while the address component provides additional binding affinity and is not 
essential to the transduction process. For a group of peptides associated with more 
than one receptor type the message component is very similar or invariant while the
-20-
address segment is variable and a determinant of selectivity for a particular type of 
receptor.
Chavkin and Goldstein51 pointed out that the endogenous opioid peptides 
appear to conform to the message-address concept in that they contain a constant 
tetrapeptide sequence (Tyr-Gly-Gly-Phe) that can be viewed as the message and a 
variable sequence that can operate as an address in conferring selectivity. This 
address sequence is presumably complimentary to the receptor type that is unique for 
each opioid receptor site.
Another interpretation of the message-address concept as applied to opioid 
peptides, is that the tyrosine residue comprises the message component and the 
sequence commencing from Phe4 constitutes the address, in this context Gly2-Gly3 
serves as a spacer54. This alternate view is consistent with the well known structure 
activity relationships of non-peptide opioid ligands (e.g. morphine) that contain only 
one aromatic ring which presumably mimics the tyrosine residue.
This concept was examined by Lipkowski and co-workers55 who reported that 
a typical ^-selective ligand such as oxymorphone (17) can be transformed into a 5- 
selective ligand by attachment of an enkephalin dipeptide unit (Phe-Leu) through a 
hydrazone spacer to the C-6 position of the opiate (Figure 6). Similarly, a K-selective 
ligand can be synthesised by attachment of a dynorphin related ‘k-address’ (Phe-Leu- 
Arg-Arg-He-OMe). Although the message-address concept was originally proposed 
for endogenous agonists, the results suggested the feasibility of developing non­
peptide 5-selective opioid antagonists by the attachment of an appropriate non-peptide 









As with the bivalent ligands, the design of non-peptide 8-antagonists was 
explored using a naltrexone (19) as the ‘message’ component. The phenyl group of 
the Phe^ residue of enkephalin was considered to be the key 8-receptor ‘address’ 
component. An important consideration in the design was the conformational 
restriction of this benzene moiety because a rigid address moiety was thought to 
confer greater 8-selectivity by precluding possible conformation adaptation of the 
ligand in the binding to other opioid receptor types. The first candidate to fulfil the 












Indoles 43-47 were synthesised from naltrexone and the appropriate 
substituted phenylhydrazine under Fischer indole conditions56. In smooth muscle 
preparations, these indoles selectively antagonised 8-opioid agonists. The most potent 
member of the series is naltrindole (43, NTI). By way of comparison, the enkephalin 
analogue ICI174864 currently employed as a 8-antagonist possessed a potency of 
1/530 that of NTI. In terms of 8-receptor binding, NTI has over a 1000 fold greater 
affinity than ICI17486457. The importance of the benzene moiety in conferring 8-
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selectivity was shown by compounds 49 and 50. The former, which contains the 
pyrrole moiety only, was found to be a ^.-selective ligand while the reduced indole 
(50) is 8-selective but has considerably lower potency relative to NTL Other 
heterocyclic analogues of NTI containing benzofuran (48), quinoxiline (51), and 
quinoline (52), and 6-aryl-naltrexone derivatives (53 and 54) were synthesised to 
examine the role of the spacer58, 59. Analogues 48 and 50-54 were all opioid 
antagonists and bind selectively to 8-receptors indicating that other heterocycles can 
serve as spacers. The 6-aryl derivatives, however, possessed considerably lower 
opioid receptor antagonist potencies which was considered to be due to the 
conformational mobility of the aryl group and its location in the molecule.
The role of conformation of the 8-address was explored further60 with the 
benzylidene (55), 7a-benzyl (56), and epimeric anilino (57 and 58) compounds. All 
conformationally mobile analogues were shown to have relatively weak 8-opioid 
receptor antagonist potency as their aromatic groups are located in an area of space 




Attempts to transform NTI from a 6-antagonist to a 5-agonist by replacement 
of the cyclopropylmethyl with a methyl (59) and other //-substituted groups (60-65) 
were explored61* 62 As oxymoiphone (17) is a potent ^.-selective agonist, it was 
anticipated that oxymorphindole (59, OMI) might be a 8-selective agonist if the 
conformational requirements of 5-agonists and antagonists are similar. On the mouse 
vas deferens (MVD), OMI acted as a partial agonist (65% of maximum response), and
it was virtually inactive on the GPI. The fact that OMI was antagonised by NTI 
suggests that the agonist effect is mediated through the 8-receptor system. The partial 
8-agonist character of OMI raised an possibility that the receptor bound conformations 
of agonists and antagonists differ. Morphindoles 60 and 61 were shown to be agonists 
but in vivo pharmacology found that compound 60 was not antagonised significantly 












The retention of 8-antagonist activity by OMI prompted Portoghese to suggest 
that the conformation of the 8-address component in these compounds might 
preferentially stabilise an antagonist state of the 8-receptors in the CNS. This 
proposal led to the synthesis of spiroindanyloxymorphinone (66, SIOM) and 
spiroindanylnaltrexone (67, SINTX) where the benzyl moiety (address) of the indanyl 
substituent is rigidly held in the orthoganol position relative to ring C of the morphine 
skeleton6®* 6 .^ This position is considered to mimic the conformation of the Phe^
phenyl group of [T yr-D -Pen^-G ly-Phe-D -Pen^Jenkephalin  (D P D P E ), a 8i-agonist
selective peptide. Pharmacological evaluation of the naltrexone derivative 67 showed 
it to be a potent 8-receptor antagonist while the N-methyl analogue 66 is apparently 






66 R = Me (SIOM)
67 R = CPM (SINTX)
68 R = CPM







72 R1 = CPM; R2 = OH
73 R1 = CH3; R2 = OH
74 R1 = CH3; R2 = H
75 R1 = CPM; R2 = OH
76 R1 = CH3; R2 = OH
77 R1 = CH3; R2 = H
Further naltrexone, oxymorphone, and dihydromorphone derivatives in this 
series were synthesised which contained substituted spiroindanyl (68 and 69), 
benzospiroindanyl (70), spiroperinaphthyl (71), and spirobenzocyclohexyl (benzyl 
address is orientated differently in the 7a (75-77) and 7(3 (72-74) epimers) groups in 
an effort to explore structure-selectivity relationship of ligands that possess an 
orthogonal aromatic system relative to ring C of the morphinan64* 65. Although 
pharmacological results were far from conclusive, it was inferred that both coplanar 
and orthogonal conformations (relative to ring C of the opiate) of the aromatic address
-26-
moiety are capable of conferring 5-antagonist activity. However, 5 l agonisin 
appeared to be associated with an orthogonal-like conformation of the address. It also 
appears that the 14-hydroxy group of the opiate pharmacophore contributes 
significantly to the 5 agonist activity.
1.9. Project Aims
1.9.1. CHo isosteric analogues of M6G
The ability of M6G, and to a lesser extent M3G, to penetrate the blood brain
*
barrier has been attributed to the facility of these metabolites to display a high degree 
of lipophilicity over a wide pH range. Testa and co-workers have suggested that the 
glucuronides are able to behave as ‘molecular chameleons* by varying their polarity 
depending on that of the medium34. Theoretical studies show that M6G exists 
predominantly, at physiological pH, in a ‘folded* conformation with the sugar moiety 
eclipsing the morphine unit and is therefore able to mask a significant portion of its 
polar regions from the solvent. In contrast, the morphine and glucuronide moieties of 
the ‘extended* conformer interact minimally through space and are maximally 
exposed to the solvent The glucuronides therefore exist predominantly as extended, 
polar conformers in water and as folded, more lipophilic conformers in media of low 





An alternative view offered by Lacy suggests that M6G (30) could exist in
equilibrium with the open-chain (78) isomer66. This structure may have more
freedom to expose or mask its polar groups than the closed-ring conformation and it is
this which causes the variation in polarity and lipophilicity allowing a high level of 
blood transport with the ability to pass into biological membranes. To explore this 
possibility, compounds 79, 80 and 81 were proposed where the oxygen atom in the
-28-
glucuronide moiety or in the sugar-moiphine linkage or both have been replaced with
a CH2 isosteric unit respectively. All three compounds are therefore unable to exist in
*
the open-chain form but may equilibrate between the extended and folded forms 
described by Testa et al. It is anticipated that these targets may shed light on the 






Attempts by Lacy to synthesise the first of the CH2 isosteric targets, 
pseudosugar derivative 79, proved unsuccessful66. Several procedures were examined 
to effect the coupling between moiphine or codeine with a pseudosugar equivalent, 
but difficulties encountered in forming this ether linkage were parallel to those 
observed in the various attempted syntheses of M6G itself. In a continuation of this 
work, we examined possible routes to the second and third of Lacy s’ targets, i.e. 
compounds 80 and 81.
1.9.2. C-6.7-Ring Fused Morphines
The fact that M6G is a more potent analgesic than morphine suggests that 
there may be a cavity within the opioid receptor which specifically accommodates the 
sugar moiety to increase activity. We therefore considered that if  the steric bulk of 
ring C could be increased so that the groups attached ‘projected* into the same area of
-29-
the receptor site as the sugar residue (Figure 7), then these compounds should prove 




When considering suitable substituents to provide the steric bulk required at 
ring C, we thought that if the group could instil some extra rigidity to the system then 
activity may further be enhanced. Increased rigidity of ring C, as seen in Diels-Alder 
adducts of thebaine, assists in increasing opioid activity but it is not the sole criterion 
for high potency, i.e. variation of the ^ -substituent, changes in the conformation of the 
ring system, and the nature of the substituents also bring about dramatic changes in 
biological activity. If an additional ring system could be fused onto ring C of 
morphine, then various other polar or lipophilic groups attached to this ring could be 
included later providing a probe into receptor site requirements and analgesic activity.
1.9.3. Naltrindole Conjugates »
Utilisation of the message-address concept has shown that the conformation of 
the aromatic address moiety plays an important role in conferring selectivity at an 
opioid receptor. Studies thus far have centred on the synthesis of compounds where 
the benzene address moiety has been held rigidly in a co-planar or orthogonal plane 
with respect to ring C of the morphinan skeleton. These two positions are reported to 
mimic the orientations of the Phe^ residue of enkephalin and DPDPE respectively and
have led to the successful development of potent, non-peptide, opioids ligands such as 
NTI (43) and SIOM (66)which are 8-selective.
As conformational requirements of the so called address moiety play an 
important role in selectivity, we considered it of interest to study compounds of the 
type 82-85. We envisage that saturation of the 6,7-double bond of compounds like 
NTT and its conjugates would lead to structures in which the benzene moiety is held in 
a position 90’ to the plane of ring C of the moiphinan.
82 X=0; R1=R2=CH3; R3=H
83 X=NH;R1=R2=CH3;R3=H
84 X=0; R1=H; R2=CPM; R3«OH
85 X=NH; R1=H; R2=CPM; R3=OH
RO
Our initial targets would be compounds 82 and 83. The proposed two step 
synthetic route is shown in Scheme 1. Mitsunobu reaction of codeine (2) with the 
appropriately substituted 2-bromobenzene would generate intermediates 88 and 89 
respectively which, under radical cyclisation conditions, would be expected to 







88 X=0 82 X«0
89 X=NH 83 X-NH
Scheme 1
If the pathway is successful we hoped to extend the study to the synthesis of 












The key step in the syntheses of Lacy s’ second and third CH2 isosteric targets, 
compounds 80 and 81, involves the formation of the C-C link between the aglycon, a 
codeine derivative and a suitable glucuronide moiety. Interest, within our group, in 
radical chemistry led retrosynthetically to two precursors, 6-bromocodide (95) and 
sugar derivative 92 or 93.
*
As we were primarily interested in the coupling methodology between the two 
units and bearing in mind the often lengthy multi-step route to sugar compounds, we 
chose allyltri-/i-butyltin (94) as a simple model compound for both carbohydrate 
precursors 92 and 93 (Scheme 2).
MeO. MeO.
















An extensive literature search revealed several references describing the 
bromination of codeine. When gently boiled with hydrobromic acid, codeine affords 
‘bromocodide* although yields are very low and the product difficult to isolate in the 
pure state67. Treatment with thionyl bromide also generates the bromocodide68. The 
method is nevertheless sensitive to excess thionyl bromide and bromination of the 
aromatic nucleus to give the dibromo compound, l,8p-dibromocodide (99) can result 




96P 1 R=allyl; 2R=H 
96a 1R=H; 2R=aI!yl 




97P 1R=allyl; 2R=H 
97a 1R=H; 2R=allyl 





Early work by Schryver and Lees utilised phosphorus tribromide as the 
bromination agent69. However, these workers could only speculate as to the identity 
of the bromo compound they had actually synthesised due to the lack of physical 
evidence available at this early date. Structural studies by Stork70 and later 
Jacobsen71 confirmed that the ‘bromocodide’ isolated by Schryver and other workers 
cited above, was in fact 8p-bromocodide (98 p). The formation of the 8p- 
bromocodide suggests that nucleophilic attack by bromide ion on the 
organophosphorus intermediate 100 takes place preferentially at the 8-position from 
the sterically least hindered p-face with allylic rearrangement (Sn 2*) to the major 
product. The sterically retarded 6-position is not accessible to the usual back-side 
attack (Sn 2) and therefore does not takes place. Sn I Substitution has not been
-34-
considered by previous authors, but cannot be ruled out even though only one product, 






Although we had initially envisaged coupling the 6-bromocodide (95) rather 
than the 8p-bromocodide (98p) with allyltri-«-butyltin, further consideration with 
respect to the allyl system in the moiphinoid meant that the position of the bromine in 
bromocodide is irrelevant since dehalogenation in the next step would give rise to the 
same allyl radical (101). Our principle concern for the next step however, was the 
regio- and stereoselectivity of the radical coupling between bromo compound and 
allyltri-rt-butyltin. The radical species (101) generated from debromination of 8J3- 
bromocodide could undergo coupling at either the 6- or the 8- position and, in 
addition, coupling from the a- or p-face is likely i.e. four compounds 96a, 96p, 97a 
and 97p are possible although it was hoped that there would be some degree of 
selectivity.
In the first step of the synthesis, we found that bromination of codeine (2) with 
phosphorus tribromide actually gave rise to a mixture of two regioisomers, the 
expected 8P-bromocodide (98P) and also 6p-bromocodide (95p) which were difficult 
to separate by column chromatography. The overall yield was 83% with an isomer 
ratio of 3:1 (by *H-NMR) in favour of the 8p-compound. This is in contrast to the 
result obtained by Stork who reported that the same reaction gave an isolated yield of 
55% of the 8P-bromocodide only70.
The allylation of halogenated substrates via a radical mechanism using allyl 
stannanes was first introduced by Keck in 1982 and has subsequently found use in a
-35-
large variety of syntheses72. The general process is summarised below in Scheme 3 
and the reaction is reported to be tolerant of a wide range of functional groups.




Our first attempts to effect the coupling between ‘bromocodide* and allyltri-/i- 
butyltin used a mixture of 6p-bromocodide and 8p-bromocodide, without separation. 
Addition of 0.15 equivalents of AIBN, as radical initiator, to the reaction mixture gave 
no reaction after 2 hours. Addition of further quantities of AIBN however, gave rise 
to a reaction yielding at least six different compounds (by TLC), of which unreacted 
starting material (isolated) was the major component Complete separation of the new 
minor compounds from the reaction mixture by column chromatography proved 
difficult due to their similar Rf values. Analysis of the separated fractions by *H- 
NMR spectroscopy did not reveal any additional proton signals in the chemical shift 
region 5.5-6.5ppm which would be synonymous with an allylic side chain. The 
absence of the target compound 96 from the mixture was supported by mass 
spectrometry data which showed the presence of unreacted starting material (M+ = 
362) but did not contain a mass ion peak at mlz 323 corresponding to compound 96.
Separation of the regioisomers by column chromatography and attempted 
coupling of pure 8P-bromocodide (98p) with allyltri-/z-butyltin again failed. 
Reactions carried out at the boiling temperature of toluene showed only rapid 
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Scheme 5
*
Reports also by Keck and Yates72 that thiocarbonylimidazole derivative 105 
underwent allylation to give pentose 106 as a single product (Scheme 4) prompted us 
to investigate this alternative coupling procedure. The reaction is assumed to proceed 
through the mechanism shown in Scheme 5. Attack by radical initiator 107, obtained 
from fission of AIBN, on the thio group followed by fragmentation of 109 affords the 
radical 111. Subsequent reaction of R# with allyltri-/z-butyltin generates the p-stannyl 
radical 112 which undergoes fragmentation by p-bond cleavage to afford the product 









6a-0- (Thiocarbonylimidazole)codeine (116) was prepared in 42% yield from 
codeine under essentially neutral conditions using NJJ’-thiocarbonyldiimidazole 
(115), according to the procedure of Barton73. However, attempted radical mediated 
allylation of 116 again yielded no clean coupled product, but instead gave very 
complex mixtures.
The failure of bromocodide and the thiocarbonylimidazole derivative to 
undergo allylation and the isolation of numerous products from the reaction mixtures, 
albeit unidentified, led us to believe that the morphinan radical (101) may undergo 
rapid decomposition before reaction with allyltri-n-butyltin can take place. This 
process may be exacerbated by the presence of the 7,8-double bond in 8p- 
bromocodide which extends the opportunity for intramolecular reactions to occur, 
perhaps leading to ring-opening of the reduced isoquinoline ring.
In order to test this theory, we decided to investigate the same coupling 
reaction using 6-bromodihydrocodide (119) in which the endocyclic 7,8-double bond 






















Initially, reduction of dihydrocodeinone (117) was attempted with sodium 
borohydride as this reagent had previously been used by Gates in the stereoselective 
conversion of codeinone to codeine74. Although the reduction proceeded in good 
overall yield (94%), TLC analysis of the reaction mixture showed the presence of two 
compounds, presumably the diastereomeric alcohols, which were difficult to separate 
by column chromatography. Although we recognised that it was unnecessary to 
control stereochemistry in this reduction, out of interest, the formation of two 
components prompted us to evaluate more sterically hindered reducing agents such as 
diisobutylaluminium hydride75 and K-Selectride76 for the transformation. Both 
reagents gave a clean conversion to a single alcohol (by TLC) in isolated yields of 
75% and 68% respectively. Molecular models suggest that attack by hydride ion is 
more likely to occur from the least hindered (3-face to afford the 6a-alcohol (118a). 
A difference nOe study confirmed this hypothesis whereby signal irradiation at 
4.04ppm (assigned H-6p) gave signal enhancements of 11.4, 5.7, and 2.1% for the 
assigned protons H-5, H-7a, and H-7p respectively.
-39-
Bromination of 118a using phosphorus tribromide gave a 52% yield of the 6p- 
bromodihydrocodide (119p). A separate attempt to brominate 118a with N- 
bromosuccinimide77 was not successful and only starting material was recovered. 
Reaction of 119p with allyltri-n-butyltin under standard conditions was again 
unsuccessful. The products which formed were unseparable by column 
chromatography and analysis of the mixtures by ^H-NMR spectroscopy did not show 









The difficulties encountered in forming the C-C bond between moiphinoid and 
allyltri-Tt-butyltin led us to examine some basic chemistry in this area. For example, 
we wished to know if dehalogenation of 6P-bromodihydrocodide (119p) with tri-n- 
butyltin hydride was a facile reaction. The replacement of halogen with hydride 
serving primarily to determine the efficiency of the radical reaction. It was hoped that 
this reduction would lead to the known compound dihydrodeoxycodeine D (122) in 
good yield.
Reaction of 6p-bromodihydrocodide with tri-rc-butyltin hydride (Scheme 8) 
however gave rise to a 1:1 mixture of two compounds which were later identified as 
the desired compound 122 and deoxycodeine C (123). The result showed that the 
initially formed moiphinyl radical is relatively unreactive to ‘external’ donors, even 
the ‘simple* reagent tri-rc-butyltin hydride prefers instead to eliminate a hydrogen 
atom. This did not bode well for coupling reactions with allyl radicals or their
-40-
equivalents. We now moved away from morphinyl radicals and turned our attention 
to the addition of radicals to methylenylmoiphines.
Pioneering work by Giese highlighting the formation of carbon-carbon bonds 
by addition of free radicals to alkenes78 led us to examine a further possible route to 
compound 126 ,  a simplified equivalent to target 8 1 . Reacting 0- 
(methylidenyl)dihydrodeoxycodeine (125), prepared from a Wittig reaction between 
dihydrocodeinone (117) and methylenetriphenylphosphorane (124)79, with 
cyclohexylbromide in the presence tri-n-butyltin hydride (Scheme 9) however gave no 















Simple molecular orbital theory states that the energy differences between the 
highest occupied molecular orbital (HOMO) and the lowest unoccupied molecular 
orbital (LUMO) of the reacting species are decisive in determining the rate of a 
reaction. The smaller the energy difference between these frontier orbitals, the greater 
the stabilising effect when the reactants approach one another. The frontier orbital of 
a free radical is the SOMO (single occupied molecular orbital) and this orbital will 
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Figure 8
For nucleophilic radicals containing electron donating groups, the energy of 
the SOMO will increase and so alkyl radicals, such as cyclohexyl (127), with their 
high energy SOMO will interact with the LUMO of the alkene (Figure 8). The 
incorporation of electron-withdrawing substituents into the alkene lowers the energy 
of the LUMO and as a consequence the SOMO-LUMO energy difference decreases, 
and the rate of free radical addition increases. However, in our case the opposite is 
true. Thus, a tentative explanation for the failure of our reaction is that the 
morphinene is insufficiently electron poor to decrease the energy of the LUMO 
enough. As a result there is only a weak SOMO-LUMO interaction which in turn 
disfavours the reaction between cyclohexyl radical and morphinene.
In view of the unsuccessful results obtained via the radical pathway in forming 




The Wittig reaction80, since its introduction in 1953, has found little 
application in the field of moiphine chemistry. Chadha and Rapoport79 first reported 
its use in the preparation of 6-(methyl)dihydrodeoxymoiphine (130) by reduction of 6- 
(methylidenyl)dihydrodeoxymorphine (129) although the stereochemistry at C-6 was 
unknown (Scheme 10). Indeed, this procedure works well and was utilised by us to 
prepare, in high yield, compound 125 for use in an attempted intermolecular radical 
coupling reaction (vide supra).
128 129 130
Scheme 10
Hahn and Fishman have also described the synthesis of several novel 6- 
methylene narcotic antagonists (131-134) based on naloxone (18) and naltrexone (19) 







131 1 R=allyl, 2R=Ac
132 1R=CPM, 2R=Ac




If target 81 in its simplest form i.e. compound 126 is considered, then one of 
our interests in the Wittig methodology stems from the realisation that the carbon- 
carbon linkage between 4,5-epoxymorphinan and cyclohexyl group (Scheme 11) 



























With this in mind, we envisaged two potentially viable routes to compound 
126. The first, route A, involves a double Wittig transformation, one to form the 
intermediate higher aldehyde 136 from dihydrocodeinone (117) whilst the second 
makes use of cyclohexyl triphenylphosphorane (137) to generate alkene 135. This 
route was of particular interest for two reasons i) chain extension at the C-6 position 
by one carbon unit would perhaps facilitate reactivity at this position due to reduced 
steric encumbrance (compared with direct reaction at the 6-position) and ii) the
-44-
carbonyl functionality provides an excellent handle to further elaborate the morphine 
skeleton.
The second potential route involves direct reaction of 117 with 
cyclohexylmethyl triphenylphosphorane (139) (one extra carbon in the side chain) to
ft
yield 138. Subsequent reduction of 135 or 138 would lead to target 126. A further 
intriguing question for us was to ascertain which stereoisomer would be formed after 
reduction of compounds 135 and 138.
Route A
Reaction of methoxymethyltriphenylphosphonium bromide (140) with 
dihydrocodeinone (117) gave the intermediate enol ether 141 as an inseparable 
mixture of configurational isomers in the ratio 2.5:1, the higher ratio presumably in 
favour of the E-isomer82. However, attempted hydrolysis of this intermediate to the 
desired aldehyde 136 using p-toluene sulphonic acid proved unsuccessful giving rise
ft
to a new compound, the phenol 143 doubtlessly via intermediate 142 (Scheme 12). 
As acid conditions are required for hydrolysis of enol ethers and bearing in mind that 
the ether bridge in morphine analogues are susceptible to such ring opening under 
acidic conditions we decided that this route was not plausible and therefore turned our 























In the second route, cyclohexylmethyl triphenylphosphonium bromide (139), 
generated by boiling cyclohexylmethylbromide (144) and triphenylphosphine in 
toluene83, was reacted with dihydrocodeinone (117) under standard Wittig conditions 
(Scheme 13). The reaction gave rise to 138 as a partially separable 1:1 mixture of E'Z, 









E x a m in a tio n  of molecular models showed that a distinction between the 
geometrical isomers of 138 could be made through a consideration of proton H-5 and 
vinylic proton Hx (Figure 9). Thus, a nOe between these two protons should be
4
observable in the £-138 isomer but absent in the Z-138 isomer. Indeed, this postulate 











In the next step, hydrogenation of 138 using palladium metal on charcoal at 
room temperature and atmospheric pressure proved unsuccessful. No reaction was 
observed (TLC) even when left over five days. Hydrogenation under more forcing 
conditions of higher pressure (45 atm) at room temperature and later increased 
temperature (50#C) also failed to induce any reaction. Acid promoted catalysis again 
at room temperature and atmospheric pressure returned mainly starting material but 











When N ^V-dimethylformamide was used as reaction solvent instead of 
absolute ethanol, morphinene 145 was again isolated in 65% yield and also 8% of 
compound 146. The results from catalytic hydrogenation of 138 are summarised in 
Table 2.
isolated yield (%)
conditions catalyst solvent 138 126 145 146
latm,rt, 
5 days.
Pd/C EtOH 100 0 0 0
latm,rt, 
HC1,3 hr
Pd/C EtOH 80 0 14 0
45atm, rt, 
24 hr




Pd/C EtOH 100 0 0 0
40atm, rt, 
18 hr
Pd/C DMF 0 0 65 8
Table 2
Due to the lack of success encountered during catalytic hydrogenation which 
we assumed to be a consequence of the inaccessibility of the catalyst surface to the 
sterically crowded trisubstituted double bond, we turned our attention to chemical 
methods of reduction. Triethylsilane and trifluroacetic acid have commonly been 
employed in the reduction of double bonds84. However, in our case the frailty of 
compound 138 to an acidic environment again prevailed, the ether bridge being 
cleaved to give morphinene 145 and compound 147.
-48-
Our next step was to use the diimide as reductant85. As diimide is unstable we 
chose to generate the species in situ by oxidation of hydrazine hydrate using hydrogen 
peroxide86. Initially we attempted a trial reduction of codeine (2) simply to determine 
the efficiency of the process. The reaction proceeded smoothly in under 3 hours 












Diimide reduction of a ElZ mixture 138 under similar reaction conditions 
required prolonged reaction time but gave a single product from TLC analysis. 
Subsequent work-up and purification by column chromatography gave compound 126 
as a colourless oil in 56% yield. The *H-NMR spectrum however, did reveal the 
presence of trace amounts of the unreduced isomer £-138 which would suggest a rate
ft






Although mass spectrometry, *H, and ^C-NMR gave satisfactory evidence
for compound 126, we were still not at this stage, totally certain of the stereochemical*
-49-
outcome of the reduction i.e. whether diimide reduction of the double bond had 
proceeded from the a  face to give 1260 or from the 0 face yielding 126a.
Data from the *H-NMR spectrum of 126, in particular the coupling constant 
between H-5 and H-6 of 8.3Hz would normally be indicative of a substituent with the 
a-stereochemistry when applied to the codeine system (typical values are in the region 
of 7-8Hz, whilst 0-substituents have coupling constants of 2-4Hz)87. However, this 
comparison is somewhat misleading as ring C of codeine is constrained in a boat 
conformation as a consequence of the 7,8-double bond, whereas in 7,8- 
dihydromorphinans, ring C lies in a chair conformation88. Thus, a correlation with a 
more accurate model such as 6a-dihydrocodeine (118a), obtained from diimide 
reduction of codeine (Scheme 14), was required. In this case the coupling constant is 
5.3Hz and from this data we conclude that the cyclohexylmethyl group be 0 to the 
plane.
A nOeSY experiment indicated H-5 to be within 2-4A of both H-15ax and H- 
15eq, but not to H-6 which again favours the cyclohexylmethyl substituent in the 0 
position i.e. diimide reduction of 138 proceeds stereoselectively from the a  face to 
afford 1260.
Although the reduction of 138 did not proceed as desired to give the a - 
stereochemistry at C-6, we were sufficiently encouraged by this result to search the 
literature for other morphine derivatives possessing substituents with the 60- 
stereochemistry with a view to gaining an insight to the biological activity of such 





The majority of examples are derived from isocodeine and include halides87, 
substituted amines89 and thiols90 as well as methyl and several phenyl compounds91. 
In the dihydroisomoiphine series, even fewer examples have been reported92* 9  ^
although of major importance is p-funaltrexamine94 (148, P-FNA). This compound is 
used as a highly selective .^-receptor antagonist. Thus, to explore the analgesic 
properties of compounds with 6p-substituents, we decided to synthesise several other 
compounds of this type and to evaluate them for analgesic activity.
The synthetic route to the second of our targets, 6p-(tetrahydro-2H-pyran-2- 
yl)methyldihydrodeoxycodeine (152) is shown in Scheme 15.




Phosphonium salt 150 was obtained in a 69% yield as a colourless crystalline 
powder from the readily available (±)-2- (bromomethyl)tetrahydro-2H-pyran (149) by 
reaction with triphenylphosphine in boiling toluene. Subsequent Wittig reaction with 
dihydrocodeinone (117) gave three new components by TLC with similar Rf values in
©  i) !BuOK 
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an overall yield of 97%. Separation, by column chromatography, of the first two 
components (1:1 mixture of isomers by *H-NMR with Rf=0.28 and 0.26) proved 
unsuccessful but the third, more polar component (Rf=0.22) could be partially 
separated in the pure state.
Although we initially considered these products to be a E:Z diastereomeric 
mixture of 151, this assumption was quashed when IR spectra of the single compound 
and also the mixture revealed a strong absorption band at 3172cm" 1, generally 
associated with an hydroxyl group. This data led us to believe that during the 
reaction, either the 4,5-ether ring of the 4,5-epoxymorphinan or the pyran ring of the 
side chain had been cleaved. Strong evidence suggesting the latter came from *fl- 
NMR data of the single product which clearly indicated a singlet at 54.90ppm 
associated with H-5 and therefore an unperturbed morphinan skeleton. More 
interesting, the *H-NMR spectrum showed 3 proton resonances in the 
olefinic/aromatic region of the spectrum with a spin coupling pattern characteristic of 
a conjugated diene system. We considered this collective evidence to favour 153 
(Scheme 16). Nevertheless, it was not possible to ascertain whether the structure 
contained an exocyclic (153) or endocyclic (154) double bond, although it is likely 





The possible mechanism of ring opening during the reaction is shown in 
Scheme 17 and builds on observations made by Schweizer and co-workers^ on a
similar system. Ylide 155, generated by base abstraction by potassium rm-butoxide 
of an acidic proton from salt 150, undergoes ring opening to oxy anion 156. This may 
then act as a intramolecular base and abstract an a  proton from the p-substituted 
vinylic phosphonium salt 156 to give allylic ylide 157. After rearrangement, 158 
undergoes the normal Wittig reaction with dihydocodeinone (117) to yield product 
153.















Diimide reduction of an unseparated mixture of the three compounds gave as 
the major product, 6-(6-hydroxyhexyl)dihydrodeoxycodeine (159), although 160 was 
also isolated as a minor product. The stereochemistry of the carbon side chain at C-6 
of 159 was assigned the P stereochemistry from the coupling constant between H-5 
and H-6 (/=7.8Hz) which is comparable to that in the cyclohexylmethyl analogue 
126p. A confirmation of the absolute configuration of 159 came from an x-ray 







Further compounds synthesised to assess the structure-activity relationships 6f  
the 6p alkyl substituents include 6-(rt-hexyl)dihydrodeoxycodeine (163) and 6-(Nfl- 
dimethylaminoethyl)dihydrodeoxycodeine (166). The former was obtained by Wittig 
reaction between dihydrocodeinone (117) and n-hexyltriphenylphosphonium bromide 







The amino derivative was made by diimide reduction of a E:Z (8:1) mixture of 
1 6  5 , formed on reacting 1 1 7  with readily available NiN- 
dimethylaminoethyltriphenylphosphonium bromide (164). Reduction of alkene 165 
however, also gave rise to 167 as a minor product, the N-oxide generated presumably 
via oxidation of the amino side chain by the excess hydrogen peroxide required to 
oxidise hydrazine to diimide in situ (Scheme 20).
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Also of interest was the synthesis of the 6P-(cyclohexyl)dihydrodeoxycodeine 
(170) using the same Wittig methodology (Scheme 21). Our major concern however 
was the steric strain imposed by the tetrasubstituted double bond in compound 169 
and whether this strain would inhibit the reaction between dihydrocodeinone (117) 
and the ylide 168.
Scheme 21
Reaction of 117 with cyclohexyltriphenylphosphonium bromide (137) 






more polar than the starting ketone. From the ^H- and l^C-NMR spectra it became 
apparent that morphinene 169 had not formed but instead the data was suggestive of a 
dimeric moiphinoid structure.
In the iH-NMR spectrum, the integration showed the presence of 42 protons 
including two //-methyl and two O-methyl signals at 52.36, 2.37, 3.81 and 3.90ppm 
respectively. In the aromatic region of the spectrum four protons were present, 
corresponding to the protons at positions 1 and 2 of the morphine skeleton, but of 
added interest was the presence of only one proton signal at 85.01ppm (singlet) for H- 
5. The absence of the second unperturbed H-5 signal in this region for the second 
dihydrocodeinone unit of the dimer suggests that ring cleavage at the ether bridge may 
have occurred during the reaction and that position 5 may be the point of linkage 
between the two molecules. A singlet at 85.96ppm was also detected which could be 
exchanged with deuterium oxide thus revealing a hydroxyl functionality.
The dimer, for it was now clear that a coupling had occurred, showed 36 
carbon signals in the l^C-NMR spectrum. Notably absent was the presence of any 
carbonyl resonance at around 8200ppm and again only one signal at 91ppm, 
corresponding to the carbon at position 5 of an intact 4,5-epoxymoiphinan, was 
present
From the results of 90° and 135° DEPT experiments, this compound was 
shown to contain 4 methyl, 9 methylene, 10 methine and 13 quartemary carbons. 
Mass spectrometry data revealed a mass ion (base peak) at mtz 599 (M++H) 
confirming a bimorphine structure, and finally the IR spectrum showed the presence 
of a OH stretching band at 3333cm"l.
From the aromatic region of the ^H-NMR spectrum of this compound, it was 
apparent that traces of phosphorane were still present and so an attempt to remove this 
impurity was made. Acid extraction using dilute HC1 however gave rise to a less 
polar compound (Rf=0.47) from TLC analysis. After work up, mass spectrometry 
data for this new product gave a mass ion at m!z 581 (M++H) showing a loss of 18 
mass units which we attributed to the dehydration of water. It was observed from the
new ^H-NMR spectrum that the hydroxy signal had shifted downfield from S5.96ppm 
to 87.46ppm. Treatment of this compound with ferric chloride solution gave a deep 
green colouration. This appeared to substantiate our initial idea of a phenolic group at 
position 4, which would have transpired from cleavage of one of the ether bonds of 
the dimer. From the 90* and 135* DEPT experiments determined on this product we 
observed that dehydration had caused a gain of one quaternary carbon at the expense 



















From the spectroscopic information we had gathered, we considered that the 
product initially formed from reaction between dihydrocodeinone (117) and ylide 168 
was bimorphine 173, which after treatment with dilute HC1, dehydrates to 174 as 
shown in Scheme 22. We believe that enolate 171 attacks a second molecule of 
dihydrocodeinone (117) and opens the ether ring at C-5 generating diketone
intermediate 172. This subsequently undergoes cyclisation to the dihydrofuran 
derivative 173.
A ll three com ponents, i . e.  dihydrocodeinone (117), 
cyclohexyltriphenylphosphonium bromide (137) and potassium rerf-butoxide, are 
required for the formation of 173 since separate reactions involving 117 and base in 
the absence of 137, or reaction of 117 and 137 without potassium rerr-butoxide, 
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The attack at C-5 by carbanions is not entirely without precedent since it is 
known that dihydrothebaine96 (175) reacts with methylmagnesium iodide to give 5- 
methyldihydrothebainone (177), used in the synthesis of metopon97 (178). 
Dihydrocodeinone enol acetate98 (176) and deoxycodeine C99 (123) have also been 
reported to react with Grignard reagents to give ether ring opened products. Although 
it is often necessary in this type of reaction to have an unsaturation in the p,y-positidn 
to the 4,5-ether oxygen atom (i.e. an allyl ether), Small and Rapoport have reported 
that dihydrocodeinone (117) behaves as a 6,7-unsaturated ether under forcing 







Ring closures of the type 172 to 173 have also been recently described by 
Gorlitzer101 in the morphine series whereby diketone 179 cyclises to pyran 180 which 
then undergoes dehydration to bimoiphinan 181 (Scheme 23).
We have also found that on rep lacing 1 3 7  with 
isopropyltriphenylphosphonium iodide (182), the Wittig reaction with 
dihydrocodeinone (117) also gives rise to the same bimorphinan 174, although in 
reduced yield (Scheme 24). Also isolated from the reaction mixture was product 184, 
formed by an aldol type condensation. Attempts to dehydrate 184 to the a,|3- 














Analgesia data from the effect of subcutaneous administration of some of these
*
novel compounds in the mouse hot plate test are shown in Appendix 5.2. None of the 
compounds however showed significantly improved analgesic activity compared with 
the parent compound codeine (2).
2.3. The Robinson annulation
The Robinson annulation102*103, commonly employed in organic synthesis for
the construction of polycyclic ring systems, offered a direct route to compounds 
possessing an enone ring system attached to C-6 and C-7 of the morphine skeleton. 
Furthermore, the functionality in this new ring system would provide an excellent 
opportunity for further transformations such as successive hydroxylation, thus 
approaching a fused mimic of glucuronic acid.
Many modifications of the annulation reaction have appeared in the literature 
since the publication of Robinson’s original paper104 in 1935, but the simplest 
procedure, using cyclohexanone (185) as an illustration (Scheme 25), involves the 
Michael addition of the enolate 186, generated from 185 by proton extraction by a 
suitable base, to methylvinyl ketone (MVK, 187). The intermediate diketone 188 then 
undergoes base-catalysed intramolecular aldol-type ring closure to the ketol 189, 







The Robinson procedure, applied to our substrate, dihydrocodeinone (117), 
posed two intriguing questions concerning the regio- and stereochemical nature of 





With respect to the former, enolates generated from unsymmetrical ketones 
generally undergo alkylation regioselectively at the more highly substituted position 
under both acid and basic conditions102 although this trend may be reversed as a result 
of severe steric interference at the more highly substituted a-carbon atom. In theory 
therefore, compound 194 may be generated. However, the formation of 194 requires 










Secondly, depending on the stereochemical outcome of conjugate addition of 
enolate 171 to MVK, the proton at C-7 of the final product 193, could possess one of 
two possible configurations in which H-7 is either below (a) the plane (relative to ring 
C), i.e. structure 193p or structure 193a, where it is above (p) the plane.
To date only a single application of the Robinson procedure in morphine 
chemistry has appeared in the literature. Portoghese and co-workers105 claim that 
ketol 195 is formed in 80% yield from a reaction between naltrexone (19) 
hydrochloride and MVK (Scheme 27). Acid induced dehydration of 195 then affords 
the enone 196 in 65% yield which, on heating at reflux for 48 hours, isomerises to the 













The conditions used for the synthesis of ketol 195 were somewhat unusual in 
that the reaction was carried out in IN sodium hydroxide solution. The Robinson 
annulation is normally performed in the presence of a strong base under anhydrous 
conditions.
Initially, following the procedure of Portoghese and co-workers, we reacted
dihydrocodeinone (117) hydrochloride with MVK in methanolic IN sodium
*
hydroxide solution. After 14 hours, TLC analysis of the reaction mixture revealed the 
complete disappearance of starting material and the presence of two new compounds. 
The major product from the reaction proved however, to be the free base, 
dihydrocodeinone. Unfortunately the minor product was difficult to obtain in the pure 
state since it had a similar Rf value to dihydrocodeinone. Analysis of this compound 
thus depended on mass spectrometry, which showed a molecular ion peak at mlz 352, 
corresponding to compound 193. Attempts to increase the yield of 193 by increasing 
the reaction time, temperature and quantity of MVK added were unsuccessful
The failure to effect a clean Robinson annulation of dihydrocodeinone via the 
route described by Portoghese led us to re-investigate more conventional methods. 
An alternative approach developed by Marshall and Fanta106 involves the generation
ft
of the ketone enolate using catalytic amounts of sodium ethoxide as base. In our 
hands, reaction of dihydrocodeinone with MVK at -10°C using a catalytic amount of 
sodium ethoxide showed little conversion of starting material. The presence of 4 new 
minor UV active components were nevertheless observed from TLC analysis. 
Separation of 193 from this mixture was achieved through column chromatography, 
although in low yield (4%).
Although at this stage IR, mass spectrometry, *H and ^C-NMR data were in 
agreement with 193, we were not as yet, certain of the stereochemistry at C-7 of the 
isolated product. A distinction between the two diastereoisomers was made from 
extended NMR spectroscopy studies.
Carbon signals were correlated with methylenes, methines or quartemary 
carbons by DEPT. ^H-^C-COSY analysis was employed to relate nuclei directly 
attached to the individual l^C  nuclei. From ^H-^H COSY measurement, the 
resonance of H-7 is coupled to both of the resonances of H-8a  and H-22a; the signal 
of H-8a  is coupled to the signal of H-8p and H-14; H-8p resonance is coupled to that 
of H-14; similarly the resonance of H-14 is coupled to that of H-9. Furthermore, the
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resonance of H-22a is coupled to that of H-22p and H-21a; the resonance of H-22p is 
coupled to that of H-21p; and similarly the signal of H-21a to the signal of H-21p.
The 3-dimensional structural relationships between protons 5 ,7 , 8a , Bp, 9,14, 
21a» 21 p, 22a and 22p were established from the nOe correlated 2D-NMR spectra. 
Thus, H-5 shows a close proximity to H-19; H-7 to H-8a  and H-22p; H-8a  to H-8p, 
H-10a and H-14; H-8p to H-14; H-9 to H-10a  and H-14; H-22a  to H-22p and H-21a ; 
H-22ptoH-21a .
Only structure 193p, with H-7 in the a  position, is consistent with the nOe 
data and the coupling constants between protons 8a, 8p, 9, 14, 22a, 22p. With 
respect to the latter, J8a,8/3 is consistent with geminal coupling (13.9Hz); J8a,7  and 
J8a,14 are large (13.7 and 10.8Hz) and are in agreement to cis pseudo diaxial and 
axial-pseudo axial coupling respectively. J8p,14 and J8p,7 of 7.9 and 7.0Hz
respectively are consistent with equatorial-axial and equatorial-equatorial couplings. 
Of further interest is the absence of any coupling between H-7, H-22p and H-22p, H- 
21a which is attributed to dihedral angles of approximately 90* between these two 
sets of protons. The above observations suggest that ring C of the opiate is in a half 
chair conformation while the new annulated ring is essentially planar. Compound 
193a was rejected as the possible structure because H-7 would be expected to exhibit 
an nOe with both H-8 and H-14 if its position was P to the plane. However, neither of 
the two relationships are observed in the 2D nOeS Y spectrum.
It is important to note that our assignment of the stereochemistry at C-7 for 
193P is the opposite of that for the same proton in Portoghese’s naltrexone derivative 
196. The reason may be due to the steric effects exerted by the hydroxyl group at C- 
14 of naltrexone.
As the reaction had not gone to completion we decided to carry out a series of 
reactions varying the amount of base used to catalyse the annulation procedure. 
Attempts using 0.5, 0.7 and 1 equivalent of sodium ethoxide however showed no 
improvement. TLC analysis indicated either little conversion of starting material (0.5 
and 0.7eq.) or decomposition (leq.) of dihydrocodeinone. Similar results were
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obtained using other bases such as sodium hydride and potassium rerf-butoxide107. A
final attempt at a lower temperature (-78#C) using lithium diisopropylamide (LDA) as 
base108 yielded 193p in only 3% yield.
The low yield of 193(3 obtained using ‘standard* conditions for the Robinson 
annulation can generally be accounted for by the poor reactivity of the electrophile, 
i.e. MVK is not sufficiently reactive enough to trap the enolate. A further drawback 
commonly reported in the literature using MVK is that it is prone to polymerisation. 
In our case however, this was not observed. That these problems can, in part, be 
circumvented by direct alkylation using a more reactive electrophile such as an alkyl 
halide or allyl halide which possess a masked carbonyl functionality led us to examine 
this avenue.
Two examples (Schemes 28 and 29) of electrophiles which undergo the 
modified Robinson annulation are l-bromo-3-benzyloxybutane (199) and 1,3- 
dichloro-2-butene (202), often referred to as the Wichterle reagent. In both cases the 
alkylated intermediates, 200 and 205 respectively, must be cyclised in a separate step 
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Scheme 29
Before using the above reagents, we decided to carry out a couple of model 
alkylations on dihydrocodeinone (117). Thus, using methyl iodide as a mimic for 
compound 199, we attempted the synthesis of 7-(methyl)dihydrocodeinone (204) 
using LDA to generate enolate 171. No coupling however, was observed on addition 
of methyl iodide and unreacted dihydrocodeinone was recovered. A similar attempt to 
prepare 7-(allyl)dihydrocodeinone (205) using allyl bromide also failed. These results 
using simple yet highly reactive electrophiles did not bode well for any future 
attempts and so this route was abandoned.
Reports that enolates generated from enol silyl ethers undergo alklation109*110 
were also examined. Silyl enol ether 206 was initially prepared in 44% yield from a 
reaction between dihydrocodeinone (117) and rm-butyldimethylsilyl chloride using 
sec-butyl lithium as base. However, an appreciable amount (16%) of tertiary alcohol 














In the next step, cleavage of the silyl group to regenerate the enolate using 
tetrabutyl ammonium fluoride111 in the presence of MVK however afforded only a 
near quantitative amount of our initial starting material dihydrocodeinone. Repetition 
of this reaction using an excess of MVK also failed. Surprisingly, on changing the 
fluoride source to anhydrous potassium fluoride112, we were able to isolate the P- 
hydroxy ketone intermediate 192 in 15% yield. An attempt to form 7- 













In light of the poor yield for the Robinson annulation reaction and the failure
of other electrophiles to couple with enolate 171, we decided to search for an
*




The failure to form cleanly a new six membered ring system fused to the C-6 
and C-7 position of the morphine framework via the Robinson annulation led us to 
examine an alternative route to ring synthesis using the Diels-Alder methodology. In 
the field of morphine chemistry, Bentley and co-workers ^  first applied the Diels- 
Alder reaction to thebaine (3) in the 1960’s for the synthesis of adducts with the 
general structure 208. Here, the new cyclohexene ring is bridged across position C-6 
and C-14 of the morphinan skeleton. Several compounds which possess this bridge 












Although, in our case, the substituted cyclohexene ring system in target 209
(Scheme 32) is fused at positions C-6 and C-7 of the morphine framework, we
envisaged that this may also be prepared via a Diels-Alder reaction between novel
diene 210 and an appropriate dienophile. For the route to be viable therefore, a
synthetic route to the key intermediate, diene 210, was required. For this, we
*
anticipated using a Stille113 type cross-coupling reaction between vinyl triflate 211 














Using the method of developed by McMurray114, vinyl triflate 211 was
prepared in 59% yield by trapping the enolate of dihydrocodeinone (117), generated
using LDA as base, with N-phenyltrifluoromethanesulfonimide.
In the next step, cross-coupling of 211 with tri-n-butylvinyltin (212),
*
previously prepared by a reaction between tri-n-butyltin chloride and vinylmagnesium 
bromide115, under standard Stille conditions afforded successfully diene 210 in 90% 
yield. The structure of 210 was confirmed by a single crystal X-ray study (Appendix 














To explore the reactivity of diene 210 in the Diels-Alder reaction, we decided 
initially to utilise simple symmetrical dienophiles as this would eliminate any 
problems concerning regioselectivity of addition. Thus, for preliminary investigations 
on our substrate, we chose maleic anhydride (213). Early reactions were however 
disappointing. Reaction of one equivalent of maleic anhydride with 210 at room
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temperature gave no reaction by TLC, nor did heating the reagents in boiling toluene. 
The use of excess dienophile also failed to induce a reaction at room temperature Or 
on heating. A report by Yates and Eaton116 highlighting the use of aluminium 
chloride as a catalyst to accelerate the Diels-Alder reaction caused us to use similar 
conditions. However, the addition an equimolar quantity of AICI3 and also two 













Undeterred by the negative results using maleic anhydride, we next carried out 
similar reactions using benzoquinone (215) and dimethyl acetylenedicarboxylate
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(217). With benzoquinone, no adduct was formed at room temperature or on heating 
a mixture of 210 and dienophile 215 in toluene at reflux. Addition of AIG3 to the 
reaction mixture also proved fruitless. Canadian workers have utilised boron 
trifluoride etherate117 to catalyse a Diels-Alder reaction between substituted 
benzoquinone 220 and diene 219 (Scheme 35) and this method was also tried. In our 
case however, addition of BF3.Et20  to the reaction mixture of 210 and benzoquinone 














Similar results were observed in the attempted preparation of the adduct 218. 
Reaction of diene 210 with 1 equivalent of dimethyl acetylenedicarboxylate and later, 
an excess of the dienophile at both room temperature and on heating at reflux for 24 
hours failed to cause a reaction. Attempted catalysis of the reaction with AICI3, boron 




















We next tried tetracyanoethylene (222, TCNE) since it is a powerful 
dienophile and has been reported to undergo the Diels-Alder addition readily with 1,3- 
dienes118. No conversion of starting material to adduct 223 was observed at room 
temperature after 24 hours although subsequent heating of this mixture for 2 hours in 
tetrahydrofuran resulted in the formation of a single new minor product with a 
retention factor higher than that of diene 210. Attempts to increase the yield of the 
product by heating the mixture for a prolonged period of time (24 hr) was 
unsuccessful. Separation of this novel compound from the starting diene was
ft
achieved by column chromatography albeit in low yield (3%).
The identity of this adduct was initially confirmed by mass spectrometry 
which showed a molecular ion peak at mlz 438 (M+H+) corresponding to the desired 
adduct 223. The *H- and ^C-NMR spectra were also in agreement with structure 
223. The *H-NMR spectrum, in particular, reveals the characteristic vinylic proton 
signal (H-19) at 6.09-6.14ppm. The stereochemistry of 223 at C-7 could not however, 
be determined by coupling data due to the extensive overlapping of the proton signals.
In the hope of gaining access to a heterocyclic ring system, we also attempted 
a Diels-Alder reaction between 210 and diethyl azodicarboxylate (227, DEAD). Yet 
again, reaction of diene 210 with 1 equivalent of diethyl azodicarboxylate at room 
temperature gave no reaction and on subsequent heating to 100#C, decomposition of
ft
the starting material was observed. Interestingly however, a reaction using 30 
equivalents of DEAD at 100°C for 14 hours yielded two new compounds. These two 
products possessed similar Rf values from TLC analysis and could only be partially 






Although we had presumed initially that the reaction had furnished a 
diastereomeric mixture of the adduct 224, the *H-NMR spectrum of the less polar 
component of the mixture possessed several idiosyncrasies which could not be 
accounted for by structure 224 alone. Firstly, the characteristic singlet which would 
normally be associated with the N-methyl protons at approximately 82.45ppm was 
notably absent from the spectrum. Furthermore, from the integration pattern, it was 
apparent that this compound possessed five additional protons which, from the 
chemical shifts values, suggested an extra ethoxycarbonyl group. Collectively, these 
facts indicate strongly the formation of the ethyl carbamate adduct 225. Mass 
spectrometry data obtained for this adduct revealed a molecular ion at mlz 541 
(M+H+), which is consistent with structure 225.
The formation of carbamates from tertiary amines using diethyl 
azodicarboxylate has been reported in the literature. For example, May and co­
workers119 have shown that ethyl carbamate derivative 228 may be prepared by 
heating together a mixture of N-methylbenzomorphan 226 and DEAD (Scheme 37). 
The intermediate was later hydrolysed to yield benzomoiphan 229. The overall route 
constitutes a method for the demethylation of tertiary amines.
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The limited success encountered using symmetrical dienophiles led us to turn 
our attention to Diels-Alder reactions involving unsymmetrical dienophiles. In the 
first instance we utilised acrylonitrile (230). Reaction of diene 210 with acryonitrile at 
80*C in toluene, generated two new compounds although TLC analysis also revealed 
unreacted starting diene. Unfortunately, these two compounds possessed similar 
retention factors (Rf = 0.48 and 0.50) but we were able nevertheless to isolate, from 












It is apparent that with unsymmetrical dienophiles such as acrylonitrile, C-21 
(232) and C-22 (231p) substituted derivatives could result However, a differentiation 
between which of the two regioisomers we had isolated was made from a 
consideration of the coupling relationships between protons H-7, H-19, H-20, H-21 
and H-22. Thus, if adduct 232 was formed, we would expect to observe H-7 coupled 
to the resonance of H-22 (methylene) which would in turn be coupled to that of H-21
(methine). Signal H-21 would then be coupled to that of H-20 (methylene) which 
would be coupled to the vinylic proton resonance H-19 (methine). Conversely, for 
regioisomer 231 p, the signal H-7 would be coupled to that of H-22 (methine). 
Resonance H-22, in turn, would then be coupled to the resonance of H-21 (methylene) 
which is coupled to that of H-20 (methylene) which would be coupled to the vinylic 
proton signal H-19 (methine).
lH-13C-COSY analysis was initially used to relate *H nuclei directly attached 
to the individual l^C nuclei. From the ^H-^H-COSY spectrum, the following
4
coupling relationships were observed. The resonance of the vinylic proton, H-19, is 
coupled to that of H-20a. The signal H-20a in turn is coupled to that H-20J3 as well 
as to that of the resonance H-21 (3; H-20p resonance is coupled to H-21 a; and that of 
H-21P is coupled to both the signals of H-21 a  and H-22; similarly the resonance H- 
21p is coupled to that of H-20p; and H-22 is also coupled to H-7. Other important 
relationships obtained from the ^H-^H-COSY spectrum concern protons H-7, H-8 and 
H-14. The resonance of H-7 is coupled to those of H-8a  and H-8p; and the signal due 
to H-8a  is coupled to H-8p and H-14; H-8p is coupled to H-14. The pertinent carbon 
atoms were correlated as methines and methylenes by 90* and 135’ DEPT. Thus, the 
resonances of C-7, C-19 and C-22 are methines while those of C-20 and C-21 are 
methylenes. From the facts above, it is therefore clear that the isolated product of the 
cycloaddition reaction is regioisomer 231p.
The stereochemistry at the two stereogenic centres, C-7 and C-22, were 
established from a combination of nOe correlated 2D-NMR spectra and the coupling 
constants between the appropriate protons. Thus with respect to the former, H-5 is 
within 2-4 Angstroms of H-19. Similar distances separate H-7 from H-8a  and H-22; 
H-8 a  from H-8p; H-8p from H-14; H-9 from H-14; H-19 from both H-20a  and H- 
20p; H-20a from H-20p and H-21 a- From molecular models, the nOe observed 
between H-7 and H-8a  and the absence of an nOe between H-7 and H-8p renders H-7 
as having the a  configuration. Likewise, the nOe between H-7 and H-22 also fixes 
the latter proton with the a  stereochemistry.
From the splitting pattern of the resonance of H-22 (ddd) at 82.73ppm, 
coupling constants of 11.6Hz, 5.5Hz and 3.1Hz are observed. Thus, the first coupling 
constant would be indicative of a dihedral angle of <15° between H-22 and H-7 which 
is consistent with the nOe data in that both these two protons are in the a  
configuration; the last two coupling constants are consistent with dihedral angles of 
approximately 30° and 60* between H-22 and H-21P and H-21a respectively. From 
the considerations above, only structure 23 lp  is in agreement with all the 
relationships.
From MM2 calculations, it appears that diastereoisomer 231a, with the cyano 
group a  to the plane, is marginally favoured over that of 23ip (547 kcal.mol"  ^versus 
557 kcal.moT* respectively). These data were obtained by PC Spartan. They should 
not be regarded as absolute values of molecular stability, but simply as an indication 
of relative stability. Although the second compound in the reaction mixture could not 





We also attempted the Diels-Alder reactions with two further unsymmetrical 
dienophiles, methylvinyl ketone and methyl acrylate. In the case of the former, 
reaction with diene 210 afforded again a mixture of two products from which adduct 
233 was isolated in 37% yield. With methyl acrylate two products were also 
generated in a total yield of 82%. These compounds however, could not separated by 
column chromatography and therefore from previous results, we presumed the 








We also attempted a Diels-Alder reaction of 210 with thebaine (3) to form 
adduct 235. This time, it was hoped that compound 210, bearing an exocyclic double 
bond, would behave as the dienophile and thebaine as the highly reactive diene. 
However, a reaction between 3 and 210 at room temperature and in boiling toluene 














r  ~ MeO.
NMe
88 X » 0
89 X °N H  
236 X = S
82 X - O
83 X = NH 
237 X = S
The Mitsunobu reaction120, utilising the diethyl azodicarboxylate (DEAD)- 
tnphenylphosphine (TPP) system, is a versatile method for the condensation of 
alcohols (ROH) and various nucleophiles (or acids, HA) to give the products (RA). 
This methodology has been employed successfully in the transformation of the 6a- 
hydroxy group of morphine and related compounds into 6p-hydroxy, 6 p-amino, and 
6P-thio derivatives via their corresponding benzoates, pthalimides, and thiolacetic 
acids90, l2l ‘l23. We considered that by using the appropriate substituted 2- 
bromobenzene we could, under similar conditions, generate intermediates 88,89, and 
236 which could then be cyclised to the corresponding naltrindole conjugates 82, 83, 
and 237.
Concentrating on the route to the oxygenated compound 82, we initially 
decided to carry out the coupling using phenol to determine the efficiency of the 
Mitsunobu reaction to form the alkyl aryl ether 239124,125. Reaction of codeine (2) 
with phenol (238) using 1.5 equivalents of the DEAD-TPP afforded 6P-(0- 
phenyl)codeine (239) albeit in low yield (17%).
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NMe 238 X -  H 




239 X = H 
88 X = Br
82
Scheme 40
The p-stereochemical arrangement of the phenyl group of 239 was assigned 
from the coupling constants J5,6 and J6,7 (0.7 and 5.7Hz respectively) which are 
comparable with literature values for other 6p-substituted codeines126. In the next 
reaction, codeine was reacted with 2-bromophenol (86) under similar conditions to 
afford 6p-0- (2 ’ -bromophenyl)codeine (88) in 41% yield. The chemical shifts of H-6 
for both 239 and 88 (84.92 and 54.95 respectively), when compared to isocodeine 
(241) (84.78), follow the trend of increasing downfield shift with increasing 








240 X -  0-PPh3 241 X = OH 243 X -  OC6H5
95(5 X = Br 244 X =0-oC6H5Br
242 X = N(C02Et)NHC02Et 245 X = N(C02Et)NHC02Et
In both reactions the corresponding 8p-aryl products 243 and 244, arising from 
a possible Sn2’ displacement of triphenylphosphine oxide from the activated alcohol 
240 were not detected. This follows the general trend observed for allylic alcohols in 
that Mitsunobu reactions principally proceed with clean inversion of stereochemistry
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at the hydroxy carbon127 although there are a few reported cases where Sn2’ products 
are formed128.
From examination of molecular models and by comparison with the behaviour 
of closely related systems in the literature129,130 we predicted that 88 would ring 
close to yield the 5,6-cw-fused product 82 via radicals 246 —>247. Indeed, treatment 
of 88 with tri-n-butyltin hydride and AIBN under standard radical coupling conditions 










The stereochemistry of 82, and in particular the geometry of the newly formed 
2,3-dihydrobenzofuran ring, was firmly established by extended NMR spectroscopy 
experiments. Carbon signals were assigned as methylenes, methines or quartemary 
carbons by 90* and 135* DEPT. ^H-^C-COSY analysis was employed to relate *H 
nuclei directly attached to the individual nuclei. In addition, from iH-^H COSY 
measurement, the resonance of H-5 is coupled to that of H-6; the signal of H-7 is 
coupled to both of the signals of H-6 and H-8ax*» and similarly the resonance of H-14 
is coupled to both the resonances of H-8ax and H-8eq. The steric relationships 
between protons 5 ,6,7 , 8ax> 8eq and 14 were established from the nOe correlated 2D- 
NMR spectra and were useful for elucidating the 3-dimensional structure. Thus, H-5 
shows a close proximity to H-15ax and H-15eq; H-7 is between 2-4A of H-6 and H- 
8ax; and similar distances separate H-14 from H-8eq and H-9.
Structure 82, with the 2,3-dihydrobenzofuran ring at right angles to the ring C 
of the moiphinan, is consistent with both the nOe data and the coupling constants
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between protons 5, 6, 7, 8ax, 8eq and 14. With respect to the latter, J  14,8ax 
consistent with trans diaxial coupling (13.7Hz); J l4 ,9  and Jl4,8eq  are relatively 
small (2.9Hz and 3.4Hz respectively) and are consistent with axial-equatorial 
coupling. The coupling constant between H-7 and H-8ax of 7.3Hz is again due to 
equatorial-axial coupling whilst the absence of any coupling with H-8eq is 
presumably due to a dihedral angle of approximately 90°. A dihedral angle of 
approximately <30* would account for the coupling constant of 9.3Hz between proton 
6 and 7. The small coupling constant between H-5 and H-6 (2.0Hz) is consistent with 
isomorphine type compounds where the 6 substituent is electronegative and p to the 
plane. Molecular modelling and minimisation studies also show structure 82 to be 
consistent with the NMR data.
The successful synthesis of compound 82 prompted us to examine the 
possibility of using the same methodology to prepare the fully saturated analogue 252. 
Our main concern was the acidity of 2-bromocyclohexanol (249). It has been reported 
that when the pKa of the hydrogen in the acidic component (HA) is larger than 11, the 
yield of product RA is reduced considerably, or the desired reaction does not 
proceed1^ 1. Our fears were realised when we attempted a model reaction using 
cyclohexanol (248). A reaction of codeine with 248, using 1 and also 1.5 equivalents 
of TPP-DEAD failed to give any coupled product. However, with 3 equivalents of 
TPP-DEAD we were able to isolate from the reaction 8P-(1,2- 







250 X = H




This can be explained by the fact that in the absence of an acidic component
ft
(HA) in the Mitsunobu reaction, iV^ V’-diethoxycarbonyl(dialkoxycarbonyl)hydrazines 
are produced132, thus, Sn2’ displacement of triphenylphosphine oxide by hydrazine 
anion 253, as opposed to the usual Sn2 pathway, is favoured presumably by steric 
effects.
Although the coupling reaction with cyclohexanol was unsuccessful we 
decided to attempt the same coupling using fraw.y-2-bromocyclohexanol (249), 
prepared from cyclohexene with aqueous N-bromosuccinimide133, in the hope that 
this substrate would be sufficiently acidic for the product 251 to form. The reaction 
was again unsuccessful. No coupled product was isolated from the reaction between 
codeine and 249 but we were however, able to isolate from the reaction mixture 6|3- 
bromocodide (95 p) in 16% yield. The postulated mechanism for its formation is
ft
shown in Scheme 42. Proton abstraction from 249 by hydrazide anion 253 generates 
the alkoxide species 255. This species undergoes intramolecular Sn2 displacement of 
bromide to generate cyclohexene oxide (256) in preference to intermolecular Sn2 
displacement of triphenylphosphine oxide from activated species 240 to yield 251. 
Finally it seems probable that bromide ion released in the process reacts with codeine 
or an equivalent to form 6p-bromocodide (95P)134 .
Et02C
/N—N 










' n - n + / '
254
249








By changing the aryl substrate from 2-bromophenol (86) to 2-bromoaniline 
(87), we anticipated that the nitrogenous analogue 83 could be obtained. Sammes135 
had previously reported the synthesis of N-benzylaniline by the coupling of aniline 
and benzyl alcohol under Mitsunobu conditions but the yield was significantly poor 
due to the inability of the amino group to transfer a proton to the hydrazine anion. 
However, since time was against us we attempted the reaction between codeine and 87 
using 1.5 equivalents of TPP-DEAD. After 40 hours, no reaction was observed by 
TLC and codeine was recovered quantitatively. For future work we considered that 
the acidity of the amino group could be increased by the acetylation of 2-bromoaniline 
(Scheme 43). The Mitsunobu coupling could then be repeated with the iV-acyl-2- 
bromoaniline derivative (257). Radical cyclisation of intermediate 258 and 









All solvents were dried and distilled before use. ‘Petroleum ether’ refers to 
petroleum ether boiling in the range 60-80°C. Column chromatography was 
performed using Amicon Matrix 60A silica gel under medium pressure using a small 
hand bellows. Thin layer chromatography was performed using aluminium backed 
250|im silica gel plates containing fluorescent indicator. Visualisation was achieved 
by illumination under short wavelength (254nm) ultra violet light where possible or 
developed by treatment with a 0.5% potassium permanganate, followed by warming 
the plate.
Melting points were determined on Electrothermal Mk m  apparatus and are
*
uncorrected. Mass spectra were recorded on a VG7070E mass spectrometer. 
Elemental micro-analysis were carried out using a Carlo-Erba elemental analyser. 
Infrared spectra were recorded in the range 4000-600cm'1 using a Peririn-Elmer 1310 
spectrometer.
lH- and l^C-nuclear magnetic resonance spectra were recorded on a Jeol 
GX270 (270MHz) or Jeol GX400 (400MHz) spectrometer. For l^C, the operating 
frequency was 67.8MHz, using 90° and 135° DEPT pulse sequences to aid 
multiplicity determinations. Samples were prepared in solutions of deuterated 
chloroform. 8 Values are expressed as parts per million downfield from 
tetramethylsilane (internal standard).
Codeine (2)
Rf = 0.25 (CHCl3:MeOH = 9:1); Mp. = 156-157°C; IR (Nujol) : 3111 (OH), 1652 
(C=C), 1635,1606 (ArC-C), 1500 (C-N), 1273 (ArC-0-Ol3), 1055 (C-O-C) can'1.
8h  (270MHz) : 1.78 (1H, dm, Jgem = 12.8Hz, H-15eq), 2.06 (1H, td, Jgem = 12.8Hz 
and ^ 15,16 = 5.1Hz, H-15ax), 2.30 (1H, dd, Jgem = 18.7Hz and /I0a ,9  = 6.2Hz, H- 
10a ), 2.36 (1H, dd, Jgem  = 12.6Hz and /16,15 = 5.6Hz, H-16ax), 2.44 (3H, s, N- 
CH3), 2.59 (1H, dm, Jgem = 12.5Hz, H-16eq), 2.67 (1H, m, H-14), 2.90 (1H, br. s, 
OH), 3.05 (1H, d, Jgem = 18.6Hz, H-lOp), 3.35 (1H, dd, /9,10 = 5.9Hz and /9,14 = 
3.3Hz, H-9), 3.84 (3H, s, O-CH3), 4.18 (1H, m, H-6), 4.90 (1H, d, /5 ,6  = 6.6Hz, H-
5), 5.30 (1H, dd, /8,7 = 9.9Hz and /8,14 = 2.6Hz, H-8), 5.71 (1H, dm, / 7,8 = 9.9Hz, 
H-7), 6.65 (1H, d, / i ,2 = 8.2Hz, H-l), 6.72 (1H, d, /2,1 = 8.2Hz, H-2).
6c (400MHz): 20.38 (C-10), 35.40 (C-15), 40.33 (C-14), 42.76 (N-£H3), 42.90 (C- 
13), 46.28 (C-16), 56.18 (O-CH3), 58.76 (C-9), 66.18 (C-6), 91.15 (C-5), 112.81 (C-
2), 119.39 (C-l), 126.71 (C-ll), 131.10 (C-12), 142.12 (C-3), 146.17 (C-4).
Bromination of codeine69
To a stirred solution of codeine (930mg, 3.1 mmol) dissolved in DCM (7ml) was 
added phosphorus tribromide (0.45ml, 4.7mmol). A pale yellow oil was formed at the 
bottom of the reaction flask. The reaction was monitored by TLC and when complete, 
the mixture was adjusted to pH 7 (5% NaHCC>3) and then extracted with DCM (x4). 
The organic phase was dried (MgS04) and DCM removed under reduced pressure to 
give a colourless crystalline solid. Purification by column chromatography usiijg 




Rf = 0.43 (CHCl3:MeOH:NH3 = 94:5:1); Mp. = 158'C (lit.1 3 6  = 162‘C); rrdz (El)
361.1 (M++H, 15%), 282.1 (M++H-Br, 100%); IR (Nujol): 1635 (C=Q, 1606 (AiC- 
Q , 1504 (C-N), 1281 (AiC-0 -CH3), 1246 (C-O-C) cur1.
8h  (270MHz) : 1.78 (1H, m, Jgem = 12.5Hz and /l5eq,16ax = 3.7Hz, H-15eq), 1.94 
(1H, td, Jgem ~ 12.3Hz and /l5ax,16eq = 5.1Hz, H-15ax)» 2.28 (1H, m, /gem =
12.1 Hz and /I6ax,15eq = 3.7Hz, H-16ax)» 2.43 (1H, dd, Jgem — 18.7Hz and /I0a,9 = 
6.1Hz, H-10a), 2.45 (3H, s, N-CH3), 2.51 (1H, m, Jgem = 12.3Hz and /I6eq,15ax*= 
5.1Hz, H-16eq), 2.73 (1H, dd, /14,8 = 9.9Hz and /14,9 = 2.8Hz, H-14), 3.08 (1H, d, 
Jgem = 18.9Hz, H-10p), 3.57 (1H, dd, /9,10a = 6.1Hz and /9,14 = 2.8Hz, H-9), 3.84 
(3H, s, 0-CH3), 4.13 (1H, m, /8,14 = 10.1Hz and /8,7 = 1.5Hz, H-8), 5.04 (1H, d, 
/5,6 = 3.3Hz, H-5), 5.69 (1H, m, /6 ,7 =10.5Hz and /6 ,5 = 3.3Hz, H-6), 6.05 (1H, dd, 
/7 ,6  = 10.4Hz and/7,8 = 1.5Hz, H-7), 6.65 (1H, d, / l ,2  = 8.2Hz, H-l), 6.72 (1H, d, 
/ 2,1 = 8.2Hz,H-2).
5 c  (400MHz): 19.50 (C-10), 35.21 (C-15), 42.75 (C-13), 43.11 (N-£H3), 46.64 (C- 
16), 47.08 (C-8), 49.18 (C-14), 56.32 (0-£H3), 56.99 (C-9), 86.36 (C-5), 113.45 (C-
2), 119.19 (C-l), 125.63 (C-7), 126.76 (C-ll), 128.37 (C-12), 135.30 (C-6), 143.33 
(C-3), 143.99 (C-4).
Found : C, 59.3; H, 5.5; N, 3.8%, C i8H20NO2Br requires C, 59.7; H, 5.6; N, 3.9%. 
6P~Bromocodide (95p)
Rf = 0.30 (CHCl3:MeOH:NH3 = 94:5:1).
5h (270MHz) : 1.86 (1H, dd, Jgem = 12.3Hz, H-15eq), 2.21 (1H, m, Jgem = 12.3Hz 
and /I5ax,16eq = 4.9Hz, H-15ax)» 2.34 (1H, dd, Jgem -  18.5Hz and/i0a,9 = 6.0Hz, 
H-10a), 2.41 (1H, m, Jgem = 12.3Hz, H-16ax), 2.46 (3H, s, N-CH3), 2.62 (1H, dd, 
Jgem — 12.1Hz and /l6eq,15eq = 3.8Hz, H-16eq), 3.10 (1H, d, Jgem — 18.5Hz, H-
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10p), 3.13 (1H, m, H-14), 3.40 (1H, dd, /9,10a = 6.0Hz and 79,14 = 3.3Hz, H-9),
ft
3.84 (3H, s, 0-CH3), 4.66 (1H, d, / 6,7 = 6.2Hz, H-6), 5.20 (1H, s, H-5), 5.64 (1H, dd, 
/8,7 = 9.5Hz and 78,14 = 2.0Hz, H-8), 6.03 (1H, m, 77,8 = 9.3Hz, 77,6 = 6.2Hz and 
77,14 = 2.9Hz, H-7), 6.58 (1H, d, 71,2 = 8.3Hz, H-l), 6.67 (1H, d, 72,1 = 8.3Hz, H-2).
8c (400MHz) : 20.46 (C-10), 29.70 (C-13), 36.34 (C-15), 39.96 (C-14), 43.09 (N- 
£H 3), 44.71 (C-6), 46.67 (C-16), 56.35 (0-£H3), 58.67 (C-9), 93.80 (C-5), 112.97 
(C-2), 119.29 (C-l), 127.38 (C -ll), 129.48 (C-7), 130.01 (C-12), 135.37 (C-8),
141.88 (C-3), 145.83 (C-4).
Attempted coupling between 8p-bromocodide (98/3) and allyltri-n-butyltin72
To a stirred solution of 98(3 (97mg, 0.26mmol) in degassed toluene (0.25ml) under N2 
was added allyltri-n-butyltin (0.2ml, 0.5mmol) and AIBN (6mg, 0.15eq). The 
reaction temperature was raised to 80#C and the reaction monitored by TLC. After 6 
hr, the complete disappearance of starting material was observed and the reaction 
mixture allowed to cool to room temperature. Attempted purification of the crude 
product by column chromatography on silica gel using CHCl3:MeOH (99:1) as eluent 
was unsuccessful. Analysis of the isolated fractions by mass spectrometry did not 
reveal the correct mass ion for the desired compound 96.
Preparation of 6cc-0-(thiocarbonylimidazole)codeine (116)
To a stirred solution of codeine (812mg, 2.7mmol) in DCM (20ml), at room 
temperature under nitrogen, was added N,N’-thiocarbonyldiimidazole73 (967mg, 
5.4mmol) portionwise. A colour change from colourless to yellow was observed. 
The reaction mixture was stirred at room temperature and monitored by TLC. After 8 
hr, the reaction mixture was washed with sat. NaHC03 (x3), water, and then sat. 
NH4CL The organic phase was dried (MgS04) and DCM evaporated off leaving a 
yellow oil. Purification by flash chromatography (CHCl3:MeOH = 95:5) afforded a
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yellow solid which after subsequent crystallisation from neat EtOAc gave the title
*
compound as white crystalline plates. Yield 482mg (42%).
R f=0.43 (CHCI3 : MeOH = 9:1); Mp. = 156-157‘C; m lz  (FAB) : 410 (M++H, 57%), 
282 (M++H - C4H3N2OS, 100%); IR (Nujol): 1639, 1607 (ArC-C), 1503 (C-N), 
1398,1348,1313,1279 (A1C-O-CH3), 1240,1214,1109,1003,950,799 cm'1.
5 h  (270MHz) : 1.90 (1H, m, Jgem = 12.3Hz and /l5eq,16ax = 3.8Hz, H-15eq), 2.05 
(1H, m, Jgem = 12.3Hz and /I5ax,16eq = 4.9Hz, H-15ax)» 2.33 (1H, dd, /gem = 
18.7Hz and /I0 a ,9  = 5.7Hz, H-10a), 2.37 (1H, m, Jgem -  12.1Hz and /I6ax,15eq = 
3.8Hz, H-16ax)» 2.45 (3H, s, N-CH3), 2.62 (1H, m, Jgem = 12.1Hz and/l6eq,15ax = 
4.9Hz, H-16eq), 2.82 (1H, m, H-14), 3.06 (1H, d, Jgem =18.7Hz, H-10p), 3.40 (1H, 
dd, /9,10a = 5.7Hz and /9,14 = 3.4Hz, H-9), 3.75 (3H, s, 0-CH3), 5.24 (1H, d, /5,6 = 
7.0Hz, H-5), 5.60 (1H, m, /8 ,7  = 10.1Hz, H-8), 5.75 (1H, dm, / 7,8 =10.3Hz, H-7), 
5.95 (1H, m, H-6), 6.60 (1H, d, / l ,2 = 8.3Hz, H-l), 6.68 (1H, d, / 2,1 = 8.3Hz, H-2),
7.03 (1H, q, Im-CH), 7.66 (1H, t, Im-CH), 8.32 (1H, s, Im-CH).
8c  (400MHz) : 20.18 (C-10), 35.08 (C-15), 40.46 (C-14), 42.44 (N-CH3), 42.98 (C-
13), 46.70 (C-16), 56.23 (O-CH3), 59.08 (C-9), 74.97 (C-6), 86.42 (C-5), 113.45 (C-
2), 118.29 (C-Im), 119.63 (C-l), 126.69 (C-ll), 126.73 (C-8), 130.24 (C-12), 130. 62 
(C-7), 130.75 (C-Im), 136.89 (C-Im), 142.25 (C-3), 146.02 (C-4), 183.55 (C=S).
Found: C, 64.5%; H, 5.7%; N, 10.1%; C22H23N3O3S requires C, 64.5%; H, 5.7%; 
N, 10.3%.
Attempted coupling of 116 with allyltri-n-butyltin
To a stirred solution of 116 (148mg, 0.4mmol) in degassed toluene (2ml) was added 
allyltri-w-butyltin (0.2ml, 0.7mmol) and AIBN (9mg, 0.15eq). The reaction 
temperature was raised to 80°C and the reaction monitored by TLC. The complete 
disappearance of starting material to at least 5 new components on TLC was observed
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after 6 hr. After cooling, attempted purification of the crude mixture by column 
chromatography using CHCl3:MeOH (95:5) as eluent proved unsuccessful. However, 
the mixed products were analysed by mass spectrometry but none of the fractions 
contained the desired compound 96.
Dihydrocodeinone (117) *
Rf = 0.40 (CHCl3:MeOH:NH3 = 90:9:1); Mp. = 195-196’C; IR (Nujol): 1716 (C=0), 
1607 (ArC-Q, 1500 (C-N), 1270 (ArC-0-CH3), 1180 (C-O-C) cm‘1.
8h  (270MHz) : 1.26 (1H, m, H-8eq), 1.78-1.90 (2H, m, H-8ax and H-15eq), 2.06 (1H, 
m, Jgem = 11.9Hz and /I5ax,16eq = 4.4Hz, H-15ax)» 2.19 (1H, m, Jgem ~ 12.0Hz 
and /l6ax,15eq = 3.5Hz, H-16ax)t 2.31 (1H, dd, Jgem — 18.7Hz and /l0tt,9  = 5.7Hz, 
H-10a), 2.31-2.46 (2H, m, H-7ax and H-7eq), 2.43 (3H, s, N-CH3), 2.53-2.60 (2H, m, 
H-14 and H-16eq), 3.04 (1H, d, Jgem = 18.7Hz, H-10p), 3.19 (1H, dd, /9 ,10a = 
5.4Hz and /9,14 = 2.8Hz, H-9), 3.90 (3H, s, O-CH3), 4.66 (1H, s, H-5), 6.64 (1H, d, 
J \2  = 8.2Hz, H-l), 6.70 (1H, d, / 2,1 = 8.2Hz, H-2).
4
8C (400MHz): 19.48 (C-10), 25.08 (C-8), 34.97 (C-15), 39.69 (C-7), 42.07 (C-14),
42.44 (N-£H3), 46.31 (C-16), 46.38 (C-13), 56.24 (O-CH3), 58.64 (C-9), 90.90 (C-5), 
114.05 (C-2), 119.28 (C-l), 125.90 (C-ll), 126.85 (C-12), 142.23 (C-3), 144.89 (C- 
4), 207.43 (C-6).
Reduction o f 117
(a) with sodium borohydride74
To a cooled (ice bath) solution of 117 (50mg, 0.16mmol) in methanol (5ml) was 
added sodium borohydride (13mg, 0.33mmol) portionwise. The mixture was then 
allowed to stir at room temperature. When the reaction was complete (by TLC) the 
mixture was concentrated to half its original volume, washed with 10% NaOH (25ml),
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water (10ml) and at d3 (x4). The organic phase was dried (MgS04), and chloroform 
evaporated under reduced pressure leaving a colourless oil. Column chromatography 
on silica gel (CHCl3:MeOH:NH3 = 90:9:1) afforded a mixture of 118a and 118(3 in 
the ratio 4.5:1 respectively. Overall yield 47mg (94%).
(b) with diisobutylaJuminium hydride 75
To a stirred solution of 117 (60mg, 0.2mmol) in dry THF (5ml) at -78*C was added 
diisobutylaluminium hydride (0.3ml, 0.4mmol) dropwise. After 1 hr, TLC analysis 
showed the absence of starting material and the reaction was quenched with Rochelle 
salts. The product was extracted with DCM (x3), dried (MgS04) and solvent 
evaporated under reduced pressure. The colourless oil was triturated with ether to 
afford 118a as a colourless powder (45mg, 75%).
(c) with K-selectride76
To a stirred solution of 117 (61mg, 0.2mmol) in THF (5ml) at -78*C was added K- 
Selectride (0.4ml, 0.4mmol) dropwise. The reaction was followed by TLC and when 
complete (1 hr) quenched with water. The product was extracted with DCM (x3), 
dried (MgS04) and solvent evaporated off leaving a yellow oil. Trituration with 
EtOAc gave 118a as a colourless powder (42mg, 68%).
6a-Dihydrocodeine (118a)
Rf = 0.36 (CHCl3:MeOH:NH3 = 18:1:1); Mp. = 111-112'C (tit.136 = 112-113‘C); mlz 
(FAB) : 302.2 (M++H, 92%); IR (neat) = 3119 (OH), 1602 (ArC-C), 1503 (C-N), 
1275 (A1C-O-CH3), 1205 (C-O-C) cm'l.
8h  (270MHz) : 1.16 (1H, m, H-8«), 1.42 (1H, m, H-8p), 1.47 (1H, m, H-7a ), 1.57 
(1H, m, H-7P), 1.70 (1H, m, Jgem = 12.2Hz, and /i5eq,16ax = 3.9Hz, H-15eq), 1.88 
(1H, td, Jgem = 12.2Hz, /diax = 12.2Hz and 7i5ax,16eq ~ 4.9Hz, H-15ax)» 2.08 (1H,
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br. s, OH), 2.21 (1H, m, /14,9 = 2.7Hz, H-14), 2.25 (1H, td, Jgem = 12.2Hz, /diax = 
12.2Hz and, /l6ax,15eq = 3.9Hz, H-16ax)» 2.38 (1H, dd, Jgem = 18.4Hz, and/i0a,9  
= 5.7Hz, H-10a), 2.40 (3H, s, N-CH3), 2.51 (1H, m, Jgem = 12.1Hz and /I6,15ax = 
4.9Hz, H-16eq), 3.00 (1H, d Jgem  = 18.4Hz, H-lOp), 3.08 (1H, dd, /9 ,10a = 5.7Hz 
and /9,14 = 2.7Hz, H-9), 3.87 (3H, s, O-CH3), 4.04 (1H, m, / 6,5 = 5.3Hz, H-6), 4.61 
(1H, d, /5 ,6  = 5.3Hz, H-5), 6.63 (1H, d, / l ,2 = 7.2Hz, H-l), 6.68 (1H, d, /2 ,1  = 
7.2Hz,H-2).
5C (400MHz): 19.08 (C-10), 19.96 (C-8), 27.17 (C-7), 37.37 (C-15), 40.66 (C-14), 
42.13 (C-13), 42.98 (N-Me), 46.79 (C-16), 56.30 (O-Me), 59.68 (C-9), 67.16 (C-6), 
90.42 (C-5), 113.05 (C-2), 119.14 (C-l), 126.91 (C-ll), 130.27 (C-12), 141.54 (C-3),
146.11 (C-4).
Found: C, 71.5%; H, 7.8%; N, 4.6%; C18H23NO3 requires C, 71.7%; H, 7.7%; N, 
4.7%.
6p-Dihydrocodeine (118p)
Rf = 0.18 (CHCI3:MeOH:NH3 = 18:1:1); mlz (FAB) = 302.2 (M++H, 100%)
5h (270MHz) : 0.97 (1H, m, Jgem — 13.0, J 8ax,7ax = 12.8Hz, /8ax,7eq = 2.6Hz, H- 
8ax)» 1«37 (1H, dq, / 7ax,8ax -  12.8Hz, Jgem = 12.6Hz, / 7ax,8eq = 3.0Hz, H-7ax)»
1.52-1.62 (1H, m, H-8eq), 1.69 (1H, ddd»Jgem -  12.3Hz, and J  15eq,16ax = 3.7Hz, H- 
15eq)» 1.79 (1H, m, Jgem -  12.6, / 7eq,6 = 6.6Hz, H-7eq), 1.86 (1H, m, Jgem =  
12.3Hz, and /l5ax,16eq = 5.0Hz, H-15ax), 2.13-2.21 (1H, m, H-14), 2.14 (1H, m, 
Jgem ~ 11.9Hz and J  16ax,15eq ~ 3.7Hz, H-16ax)» 2.35 (1H, dd, Jgem = 18.3HLz, and 
/10a,9 = 5.3Hz, H-10a ), 2.40 (3H, s, N-CH3), 2.54 (1H, dd, Jgem = H.9Hz and 
/I6,15ax = 4.4Hz, H-16eq), 3.01 (1H, d,Jgem = 18.5Hz, H-10p), 3.12 (1H, dd, 
/9,10a = 5.3Hz, H-9), 3.42 (1H, ddd, /6,7ax = 12.3Hz, /6,7eq = 6.6Hz and /6 ,5 -  
6.4Hz, H-6), 3.85 (3H, s, 0-Q i3), 4.38 (1H, d, /5,6 = 6.4Hz, H-5), 6.63 (1H, d, / l ,2 = 
8.2Hz, H-l), 6.71 (1H, d, / 2,1 = 8.3Hz, H-2).
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8C (400MHz): 20.08 (C-10), 23.72 (C-8), 30.19 (C-7), 35.44 (C-15), 42.76 (C-14 and 
N-CH3), 43.12 (C-13), 46.98 (C-16), 56.40 (O-CH3), 59.31 (C-9), 72.97 (C-6), 97.31 
(C-5), 113.29 (C-2), 118.89 (C-l), 126.57 (C -ll), 130.58 (C-12), 143.49 (C-3),
144.11 (C-4).
HRMS (FAB): found 302.1756, C18H24NO3 (M++H) requires 302.1756.
Brominadon of 118a
a) with phosphorus tribromide69
To a stirred solution of 118a (738mg, 2.5mmol) in distilled DCM (5ml) at room 
temperature was added PBr3 (0.35ml, 3.7mmol). When the reaction was complete, 
(by TLC) the mixture was adjusted to pH 7 (sat. NaHC03) and the product extracted 
with DCM (x4). After drying (MgSC>4), the organic phase was filtered and DCM 




To a stirred solution of 118 a  (170mg, 0.56mmol) in DCM was added 
triphenylphosphine (163mg, 0.6mmol) and N-bromosuccinimide (lllm g , 0.6mmol). 
The mixture was stirred at room temperature and the reaction followed by TLC. After 
24 hr, no reaction was observed and the starting material was recovered quantitatively.
6P~Bromodihydrocodide (119 p)
Rf = 0.61 (CHCl3:MeOH:NH3 = 90:10:1); Mp. = 158-159#C; m lz: Cl 364.0 (M++H, 
32%), 284.1 (M++H - Br, 100%); IR (Nujol) = 1633, 1609 (ArC-C), 1500 (C-N), 
1344,1321,1273 (ArC-0-CH3), 1184,1148,1100,1055,937,909,799 cm'l.
8h  (270MHz) : 1.01 (1H, m, Jgem = 12.8Hz, H-8a ), 1.58 (1H, m, H-8p), 1.70 (1H, 
m, J g ^  = 12.1Hz, and/i5eq,16ax = 3.7Hz, H-15eq), 1-83 (1H, dm, H-7a), 1.86 (1H, 
m, Jgem = 12.1Hz, and/i5ax,16eq = 4.6Hz, H -l5ax), 2.13 (1H, m, /14,9 = 2.9Hz, H-
14), 2.14 (1H, m, Jgem = H.9Hz and /I6ax,15eq = 3.7Hz, H-16ax), 2.27 (1H, m, H- 
7p), 2.33 (1H, dd, Jgem = 18.7Hz, and /I0a ,9  = 5.3Hz, H-10a ), 2.39 (3H, s, N-CH3), 
2.52 (1H, m, Jgem ~ 11.9Hz and /l6,15ax = 4.6Hz, H-16gq), 3.01 (1H, d, Jgem ~ 
18.5Hz, H-lOp), 3.07 (1H, dd, /9,10a = 5.3Hz and /9,14 = 2.9Hz, H-9), 3.75 (1H,
ft
ddd, /6,7diax = 13.0Hz, Jst5 = 7.5Hz and /6,7eq = 4.6Hz, H-6), 3.90 (3H, s, O-CH3), 
4.70 (1H, d, /5 ,6  = 7.5Hz, H-5), 6.67 (1H, d, / i ,2 = 8.2Hz, H-l), 6.68 (1H, d, / 2,1 = 
8.1Hz, H-2).
8C (400MHz): 19.99 (C-10), 26.10 (C-8), 33.80 (C-7), 35.68 (C-15), 42.36 (C-14), 
42.89 (N-CH3), 43.18 (C-13), 47.07 (C-16), 52.65 (C-6), 56.88 (O-CH3), 59.31 (C-9),
95.98 (C-5), 114.48 (C-2), 119.42 (C-l), 126.85 (C-ll), 129.39 (C-12), 143.67 (C-3), 
143.93 (C-4).
Found: C, 60.5; H, 6.2; N, 3.9%; Cl 8H22N02Br requires: C, 59.4; H, 6.1; N, 3.8%. 
Attempted coupling between 119Pand attyltri-n-butyltin72
ft
To a stirred solution of 119P (136mg, 0.4mmol) in degassed toluene (0.4ml) under N2 
was added aUyltri-/z-butyltin (0.2ml, 0.75mmol) and AIBN (9mg, 0.006mmol). The 
reaction temperature was raised to 80°C and the reaction left stirring for 8 hr. 
Attempted purification of the crude reaction mixture by column chromatography 
using CHCl3:MeOH:NH3 (90:9:1) as eluent was unsuccessful and mass spectrometric 
analysis of the mixed fractions did not reveal the appropriate mass ion for the desired 
compound 96.
Radical coupling between 119p and tri-n-butyltinhydride
To a stirred solution of 119(3 (212mg, 0.6mmol) in degassed toluene (2.5ml) under N2
was added tri-H-butyltinhydride (0.2ml, 0.7mmol). The reaction temperature was
raised to 80#C and a catalytic amount of AIBN added. A further amount of AIBN was
added after 1 hr and the disappearance of starting material was monitored by TLC.
After 3 hr, the reaction mixture was cooled to room temperature, toluene removed in
vacuo and the resultant residue dissolved in EtOAc. The organic layer was washed
(x2) with a 10% aqueous solution of tartaric acid, the combined aqueous extracts
made alkaline (pH 9) with conc. NH4OH and then extracted with chloroform (x3).
The combined chloroform layers were dried (MgS04) and removal of solvent
afforded a 1:1 mixture of 122 and 123 as a colourless oil. Attempted separation of the
•
two compounds by column chromatography was unsuccessful. Total yield 95mg. 
Dihydrodeoxycodeine-D (122)
Rf = 0.43 (CHCl3:MeOH = 9:1); m/z (FAB) = 286.1 (M++H, 99%).
8h  (400MHz) : 1.17-1.28 (2H, m, H-6 and H-7), 1.52-1.61 (2H, m, H-7 and H-8),
1.77-1.84 (1H, m, H-15eq), 1.87-1.97 (2H, m, H-8 and H-15ax)> 2.12-2.18 (1H, m, H-
6), 2.28 (1H, m, Jgem = 12.2Hz and /l6ax,15eq = 3.9Hz, H-16ax), 2.36 (1H, dd, 
Jgem = 18.1Hz, and 7i0a,9 = 5.4Hz, H-10a ), 2.38-2.45 (1H, m, H-14), 2.41 (3H, s, 
N-CH3), 2.49-2.56 (1H, m, H-16eq), 3.01 (1H, d,Jgem = 18.1Hz, H-lOp), 3.11 (1H, 
dd, 79,10a = 5.9Hz and 79,14 = 2.9Hz, H-9), 3.85 (3H, s, O-CH3), 4.60 (1H, t, 75,6 = 
8.0Hz, H-5), 6.63 (1H, d, 7i,2 = 8.3Hz, H-l), 6.72 (1H, d, 72,1 = 8.3Hz, H-2).
5C (400MHz): 19.96 (C-10), 21.53 (C-7), 24.29 (C-8), 29.18 (C-6), 35.43 (C-15), 
38.87 (C-14), 40.64 (C-13), 42.78 (N-CH3), 47.48 (C-16), 56.26 (O-CH3), 59.63 (C- 
9), 89.49 (C-5), 112.87 (C-2), 118.42 (C-l), 127.09 (C-ll), 130.16 (C-12), 143.42 (C-
3), 144.59 (C-4).
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HRMS (FAB) : found 286.1809, C18H24NO2 (M++H) requires 286.1809.
Deoxycodeine-C (123)
Rf = 0.43 (CHCl3:MeOH = 9:1); mJz (FAB) = 284.1 (M++H, 100%).
8h  (400MHz) : 0.83-0.95 (1H, m, H-8), 1.45-1.52 (1H, m, H-8), 1.66-1.73 (1H, m, H- 
15eq), 1.79 (2H, m, Jgem = 12.2Hz and /l5ax,16 = 4.9Hz, H-15ax), 2.08-2.20 (1H, 
m, H-14), 2.19 (1H, m, Jgem = 12.2Hz and /I6ax,15eq = 3.9Hz, H-16ax), 2.36 (1H, 
dd, Jgem = 18.1Hz, and /l0 a ,9  = 5.4Hz, H-10a ), 2.39 (3H, s, N-CH3), 2.49-2.56 
(1H, m, H-16eq), 3.02 (1H, d, Jgem = 18.1Hz, H-10p), 3.11 (1H, dd, /9,10a = 5.9Hz 
and /9,14 = 2.9Hz, H-9), 3.84 (3H, s, O-CH3), 4.95 (1H, s, H-5), 5.70 (1H, m, / 7,6 = 
10.3Hz and J jts = 3.5Hz, H-7), 5.84 (1H, ddd, /  = 10.3Hz, J = 5.9Hz and /  = 1.95Hz, 
H-6), 6.61 (1H, d, / 1,2 = 8.3Hz, H-l), 6.70 (1H, d, / 2,1 = 8.3Hz, H-2).
5C (400MHz): 19.76 (C-10), 24.86 (C-8), 35.47 (C-15), 42.31 (C-13), 43.02 (N-CH3), 
43.17 (C-14), 46.35 (C-16), 56.13 (O-CH3), 59.01 (C-9), 87.55 (C-5), 112.72 (C-2), 
118.37 (C-l), 124.53 (C-6), 127.09 (C-ll), 129.51 (C-12), 132.01 (C-7), 143.08 (C-
3), 143.95 (C-4).
%
HRMS (FAB) : found 284.1657, C18H21NO2 (M++H) requires 284.1650.
Preparation of 6-(methylidenyl)dihydrodeoxycodeine^ (125)
To a stirred, cooled (waterbath at 20°C) suspension of methyltriphenylphosphonium 
bromide (50) (1.19g, 3.34mmol) in THF (20ml) was added potassium ferr-butoxide 
(0.36g, 3.21mmol) in one portion. After 1 hr, 117 (0.50g, 1.67mmol) was added to 
the bright yellow ylide solution. The mixture was stirred for a 1 hr at 20#C, heated at 
reflux for 7 hr and then stirred overnight at room temperature. THF was removed in 
vacuo and the residue dissolved in DCM and washed with water (x3). The aqueous 
layer was re-extracted with DCM and the combined organic extracts were dried
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(MgS04) and solvent removed under reduced pressure. Purification by column 
chromatography on silica gel using CHCl3:MeOH: (9:1) afforded the tide compound 
as a colourless solid (0.34g, 71%).
R f=0.52 (CHCl3:MeOH = 9:1); Mp. = 123-125°C (lit.79 = 127-129'C); mfz (FAB) =
298.2 (M++H, 100%); IR (Nujol) = 1633 (C=C), 1609 (ArC-C), 1500 (C-N), 1271 
(ArC-0 -CH3) cm"l.
8h  (270MHz) : 0.94 (1H, m, Jgem = 12.8Hz and /8ax,7eq = 2.9Hz, H-8ax), 1.58 (1H, 
m, Jgem = 12.8Hz, H-8eq)» 1*75 (1H, m, Jgem ~ 12.1Hz, H-15eq)> 1.92 (1H, m, Jgem 
= 12.1Hz and /l5ax,16eq = 4.6Hz, H-15ax), 1.97-2.06 (1H, m, H-7), 2.20 (1H, m, 
Jgem « 12.0Hz, /I6ax,15eq = 3.7Hz, H-16ax), 2.23-2.39 (2H, m, H-14 and H-7), 2.32 
(1H, dd, Jgem = 18.5Hz and /I0a,9 = 4.8Hz, H-10a ), 2.41 (3H, s, N-CH3), 2.56 (1H, 
dd, Jgem = 12.0Hz and/l6eq,15ax = 4.4Hz, H-16eq)» 2.99 (1H, dyJgem = 18.5Hz, H- 
10p), 3.09 (1H, dd, /9,10a = 4.8Hz and /9,14 = 3.0Hz, H-9), 3.87 (3H, s, O-CH3), 
4.81 (1H, s, cis =CH), 4.91 (1H, s, H-5), 5.27 (1H, s, trans =CH), 6.60 (1H, d, / l ,2  = 
8.2Hz, H-l), 6.70 (1H, d, / 2,1 = 8.2Hz, H-2).
6C (400MHz): 19.83 (C-10), 26.11 (C-8), 32.23 (C-7), 35.03 (C-15), 42.55 (N-£H3),*
42.98 (C-14), 43.97 (C-13), 47.28 (C-16), 56.43 (O-CH3), 59.48 (C-9), 89.66 (C-5), 
110.74 (=£H2), 113.59 (C-2), 118.62 (C-l), 126.51 (C-ll), 128.99 (C-12), 142.75 (C-
3), 144.72 (C-4), 145.25 (C-6).
Found: C, 76.5; H, 7.9; N, 4.65%. C19H23NO2 requires: C, 76.7; H, 7.8; N, 4.7%.
Attempted coupling between 125 and cyclohexyl bromide 78
A mixture of 125 (153mg, 0.52mmol), tri-n-butyltin hydride (0.15ml, 0.56mmol) and 
cyclohexyl bromide (0.06ml, 0.49mmol) in toluene (2ml) was heated to 80°C before 
AIBN (catalytic) was added. The reaction was followed by TLC and a further three
portions of AIBN added after 45,120 and 180 min. After 4 hr TLC analysis showed 
no reaction and the starting material was recovered.
Preparation o f 6-(methoxymethyttdenyl)dihydrodeoxycodeine 82 (141)
To a stirred suspension of methoxymethyltriphenylphosphonium bromide (1.15g, 
3.34mmol) in THF (14ml), maintained at 20°C was added potassium rm-butoxide 
(0.37g, 3.34mmol) in one portion. After 1 hr, 117 (0.5g, 1.67mmol) was added to the 
deep red ylide solution. The mixture was stirred for 1 hr at 20°C, heated at reflux for 
11 hr and then stirred overnight at room temperature. THF was removed in vacuo and 
the residue diluted with water and extracted with DCM (x3). The organic extracts 
were dried (MgS04) and solvent removed under reduced pressure. Purification by 
column chromatography on silica gel using CHCl3:MeOH (95:5) as eluent afforded 
the product as a mixture of E:Z isomers in the ratio 2.5:1 respectively. Overall Yield 
0.56g (51%).
(E)-141
Rf = 0. 43 (CHCl3:MeOH = 9:1); m/z (FAB) : 328.2 (M++H, 100%); IR (neat) = 
1675 (C=CHOMe), 1633 (C=Q, 1604 (ArC-C), 1502 (C-N) cm' 1
ft
8h  (270MHz) : 0.80-1.00 (1H, m, H-7), 1.45-1.55 (1H, m, H-7), 1.72 (1H, dd, Jgem =
11.7Hz, H-15eq), 1.76-1.90 (2H, m, H-8ax and H-8eq), 1.93 (1H, m,Jgem = 11.7Hz 
and/i5ax,16eq = 5.2Hz, H-15ax), 2.12-2.35 (2H, m, H-16ax and H-14), 2.37 (1H, dd, 
Jgem = 18.5Hz and /l0 a ,9  = 5.9Hz, H-10a ), 2.41 (3H, s, N-CH3), 2.53 (1H, dd, 
Jgem — 11.6Hz and /I6cq,15eq = 5.2Hz, H-16eq), 2.98 (1H, d, Jgem — 18.5Hz, H- 
10p), 3.09 (1H, dd, / 9,10a  = 5.9Hz and /9,14 = 2.7Hz, H-9), 3.61 (3H, s, C6=C19H- 
O-CH3), 3.83 (3H, s, A1C-O-CH3), 5.37 (1H, d, /5 ,19 = 1.2Hz, H-5), 5.86 (1H, d, 
/19^ = 1.2Hz, c6=Cl9H-0-CH3), 6.58 (1H, d, J \t2 = 8.1Hz, H-l), 6.70 (1H, d , /2,1 
= 8.1Hz, H-2).
-100-
5c (400MHz): 20.21 (C-10), 22.67 (C-8), 22.97 (C-7 ), 35.36 (C-15), 39.48 (C-14), 
42.07 (C-13), 42.81 (N-£H3), 46.89 (C-16), 56.77 (ArC-0-£H3), 59.71 (C6=Cl9H- 
0-£H3), 60.06 (C-9), 87.11 (C-5), 111.74 (C-6), 114.06 (C-2), 118.27 (C-l), 127.21 
(C-ll), 129.94 (C-12), 142.23 (C-3), 144.86 (C-4), 146.19 (c6=C19H-0-CH3).
HRMS (FAB): found 328.1929, C20H26NO3 (M++H) requires 328.1913.
(Z)-141
5h (270MHz) includes : 3.53 (3H, s, C6=C19H-0 -CH3), 4.96 (1H, s, H-5), 6.29 (1H, 
s, C6=CH-0 -CH3).
5c (400MHz) includes: 89.37 (C-5), 113.18 (C-6), 145.26 (c6=£19H-0-CH3). 
Dehydration o f 141 using p-toluene sulfonic acid
A mixture of p-toluene sulfonic acid (49mg, 0.24mmol), water (4ml), 1,4-dioxane 
(10ml) and 141 (390mg, 1.19mmol) was heated at reflux for 16 hr. The cooled 
mixture was adjusted to pH 9 by the addition of NH4OH and extracted with DCM 
(x3). The combined organic extracts were dried (MgSC>4) and solvent removed under 
reduced pressure. Crystallisation of the resultant white solid from diethyl ether 
yielded pure 143 (285mg, 76%).
6-Formyl-4-hydroxy-3-methoxy-N-methylmorphinan-5-ene (143)
Rf = 0.30 (CHCl3:MeOH:NH3 = 90:9:1); Mp. = 177-178°C; mlz (FAB) : 314.2 
(M++H, 100%); IR (Nujol) = 3189 (OH), 2810, 2715 (CHO), 1676 (C=0), 1631 
(C=C), 1606 (ArC-C), 1580,1274 (ArC-0 -CH3) cm-1.
Sh (270MHz) : 1.52 (1H, m, H-8ax). 1.59-171 (1H, m, H-8eq), 1.78 (1H, m, Jgem =
11.4Hz and /I5ax,16eq = 4.7Hz, H-15ax), 1.90 (1H, br. d, /i4,8ax = 12.6Hz, H-14),
2.04 (1H, dd, Jgem = 11.4Hz and 7l5eq,16eq = 3.0Hz, H-15eq), 2.10-2.30 (2H, m, H-
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16ax H-7eq), 2.31 (1H, br. d, Jgem = 18.2Hz and / 7ax,8eq = 6.7Hz, H-7ax)» 2.40 
(3H, s, N-CH3), 2.58 (1H, m, Jgem = 11.9Hz and /l6eq,15eq = 3.0Hz, H-16eq), 2.69 
(1H, dd, Jgem = 18.3Hz and /l0a ,9  = 5.5Hz, H-10a), 3.00 (1H, d, /9,10a = 5.5Hz, 
H-9), 3.01 (1H, d, Jgem = 18.3Hz, H-lOp), 3.83 (3H, s, O-CH3), 6.63 (1H, d, J\j2  = 
8.2Hz, H-l), 6.70 (1H, d, / 2,1 = 8.2Hz, H-2), 7.69 (1H, s, H-5), 9.55 (1H, s, CHO).
6C (400MHz): 21.77 (C-7), 22.74 (C-8), 23.36 (C-10), 35.67 (C-15), 38.61 (C-13), 
42.38 (N-£H3), 43.06 (C-14), 47.50 (C-16), 55.88 (O-CH3), 57.43 (C-9), 108.75 (C- 
2), 118.72 (C-l), 125.12 (C-ll), 129.30 (C-12), 138.48 (C-6), 143.77 (C-3), 144.85 
(C-4), 158.55 (C-5), 195.60 (C=0).
HRMS (FAB): found 314.1756, C19H24NO3 (M++H) requires 314.1772.
Preparation o f cyclohexylmethyltriphenylphosphonium bromide^ (139)
A mixture of triphenylphosphine (lOg, 38mmol) and cyclohexylmethyl bromide 
(5.32ml, 38mmol) in toluene (20ml) were heated at reflux for 28 hr. After cooling, 
the resultant solid was collected and then washed with toluene to afford the title 
compound as a colourless powder (4.28g, 26%).
Mp. = 230-232°C (lit.83 = 230-233*C); mtz (FAB) = 359.2 (M+-Br, 100%); IR (Nujol) 
= 1115,994,893,814,793,746,723,691 cm-1.
8h  (270MHz) : 0.96-1.68 (11H, m, C6H11), 3.96 (2H, dd, Jgem = 12.9Hz and 7 = 
6.0Hz, C6Hll-CH2-PPh3), 7.67-7.94 (15H, m, (C6H5)3).
8c  (400MHz): 25.11,25.92,28.92,29.39 and 34.44 (CH2), 33.49 (CH), 34.54 (CH2- 
bridge), 118.51, 119.35, 129.71, 129.82, 130.33, 130.46, 130.69, .133.29, 133.47, 
133.58,133.86,133.99,134.86 and 134.90 (AiCH).
HRMS (FAB) : found 359.1929, C25H28P (M+ - Br) requires 359.1929.
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Preparation o f 6-(cycIohexylmethylidenyl)dihydrodeoxycodeine (138)
*
To a stirred, cooled (waterbath at 20°C) suspension of 139 (1.19g, 3.34mmol) in THF 
(28ml) was added potassium terr-butoxide (0.37g, 3.34mmol) in one portion. After 90 
min, 117 (0.50g, 1.67mmol) was added to the deep orange ylide solution. The 
mixture was stirred for 15 min at 20°C, heated at reflux for 6 hr and then stirred 
overnight at room temperature. THF was removed in vacuo and the residue dissolved 
in DCM and washed with water (x3). The organic extract was dried (MgS04) and 
solvent removed under reduced pressure. Purification of the resultant residue by 
column chromatography on silica gel using CHCl3:MeOH (9:1) as eluent afforded the 
title compound as a 1:1 mixture of ElZ isomers. Overall yield 0.58g (91%).
(Z)-138
*
Rf = 0.49 (CHCl3:MeOH:NH3 = 95:5:1); mlz (FAB) : 380.2 (M++H, 100%); IR 
(Nujol) = 1636 (C=C), 1607 (AiC-C), 1503 (C-N), 1275 (A1C-O-CH3) cm'1.
8h  (400MHz) : 0.89-1.03 (3H. m, H-8 and CH2-cyclohexyl), 1.09-1.18 (1H, m, CH2- 
cyclohexyl), 1.29-1.43 (3H, m, CH2-cyclohexyl), 1.45-1.52 (1H, m, H-8), 1.61-1.76 
(6H, m, H-15eq and CH?-cvclohexvD. 1.89 (1H, m, Jgem = 12.2Hz and /l5ax,16eq = 
4.9Hz, H-15ax), 2.00-2.03 (2H, m, H-7ax and H-7eq), 2.13-2.19 (1H, m, H-14), 2.14 
(1H, td, Jgem = 12.2Hz, /I6ax,15eq = 3.4Hz, H-16ax), 2.34 (1H, dd, Jgem = 18.6Hz 
and /I0a,9 = 5.9Hz, H-10a ), 2.40 (3H, s, N-CH3), 2.51 (1H, dd, Jgem = 12.2Hz and 
•Jl6eq,15ax = 3.9Hz, H-16eq), 2.68-2.78 (1H, m, CH-cyclohexyl), 2.98 (1H, d, Jgem 
= 18.6Hz, H-10p), 3.07 (1H, dd, /9,10a = 5.9Hz and /9,14 = 2.9Hz, H-9), 3.84 (3H, 
s, 0-C5I3), 5.11 (1H, d, /  = 9.8Hz, C6=CH-cyclohexyl), 5.20 (1H, d , J =  1.5Hz, H-5*), 
6.59 (1H, d, / i ,2 = 8.3Hz, H-l), 6.70 (1H, d, 72,1 = 8.3Hz, H-2).
5c (400MHz): 20.03 (C-10), 24.62 (C-8), 25.84, 25.93 and 26.17 (CH2-cyclohexyl), 
31.69 (C-7), 33.41 and 33.69 (£H 2-cyclohexyI), 36.49 (C-15), 37.29 (CH- 
cyclohexyl), 41.57 (C-14), 43.00 (N-£H3), 43.86 (C-13), 47.09 (C-16), 56.40 (O-
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£H 3), 59.88 (C-9), 89.63 (C-5), 113.29 (C-2), 118.38 (C-l), 127.32 (C -ll), 129.90 
(C-12), 131.75 (C-6), 137.86 (C6=CH-cyclohexyl), 142.43 (C-3), 145,63 (C-4).
HRMS (FAB): found 380.2608, C25H34NO2 (M++H) requires 380.2590.
(E)-138
Rf = 0.42 (CHQ3 :MeOH:NH3 = 95:5:1).
8h (400MHz) : 0.77-1.00 (2H, m, CH2-cyclohexyl), 1.03-1.40 (4H, m, CH2- 
cyclohexyl), 1.52-1.76 (8H, m, H-7ax» H-7eq, H-8, H-15eq and CH?-cyclohexyl).
1.88 (1H, m, Jgem = 12.2Hz and /I5ax,16eq = 4.9Hz, H-15ax), 2.01-2.13 (1H, m, 
CH-cyclohexyl), 2.17 (1H, m, Jgem = 12.2Hz, /l6ax,15eq = 3.4Hz, H-16ax)» 2.20- 
2.27 (1H, m, H-14), 2.30 (1H, dd, Jgem = 18.6Hz and /l0 a ,9  = 5.4Hz, H-10a ), 2.38-
2.44 (1H, m, H-8), 2.40 (3H, s, N-CH3), 2.53 (1H, dd, Jgem =  12.2Hz and/l6eq,15ax 
= 3.4Hz, H-16eq), 2.97 (1H, d, Jgem = 18.6Hz, H-lOp), 3.05 (1H, dd, /9,10a = 5.4Hz 
and /9.14 = 2.9Hz, H-9), 3.89 (3H, s, O-CH3), 4.84 (1H, s, H-5), 5.60 (1H, d, /  = 
8.8Hz, c 6=CH-cyclohexyl), 6.56 (1H, d , / i ,2 = 8.2Hz, H-l), 6.68 (1H, d, / 2,1 = 
8.2Hz, H-2).
5C (400MHz): 20.21 (C-10), 24.89 (C-8), 25.66, 25.77, 25.93 and 26.2 (C-7 and 
3xCH2-cyclohexyl), 33.16 and 33.34 (2xCH2-cyclohexyl), 35.86 (C-15), 36.03 (CH- 
cyclohexyl), 42.81 (C-14), 42.94 (N-CH3), 44.18 (C-13), 47.51 (C-16), 57.21 (O- 
£H 3), 59.88 (C-9), 91.48 (C-5), 114.37 (C-2), 118.65 (C-l), 127.34 (C -ll), 130.05 
(C-12), 132.11 (C6=CH-cyclohexyl), 133.10 (C-6), 142.94 (C-3), 145.61 (C-4).
Catalytic hydrogenation of 138
a) at atmospheric pressure
138 (55mg, 0.15mmol) dissolved in absolute ethanol (10ml) was hydrogenated at 
atmospheric pressure and room temperature using palladium catalyst on charcoal
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(8mg). TLC analysis of the reaction mixture after 5 days showed that no reaction had 
occurred.
b) at 45 atmospheres of pressure
The above reaction mixture was subjected to hydrogenation at 45 atmospheres of 
pressure and room temperature. TLC analysis of the reaction mixture after 24 hr 
revealed no reaction. The temperature of the reaction vessel was raised to 50*C for 21 
hr. TLC analysis of the mixture again showed no reaction. Filtration of the reaction 
mixture over Celite and subsequent evaporation of ethanol under reduced pressure 
afforded starting material quantitatively.
c) using NfN-dimethylformamide as reaction solvent
Hydrogenation of 138 (133mg, 0.35mmol) in A^N-dimethylformamide (7ml) using 
palladium catalyst on charcoal (31mg) was performed at room temperature and 40 
atmospheres of pressure. The disappearance of starting material was monitored by 
TLC and on complete reaction the reaction mixture was filtered over Celite and 
washed thoroughly with excess DMF. The filtrate was concentrated and the residue 
dissolved in EtOAc and washed with water (x3). After drying (MgS04), the organic 
solvent was removed under reduced pressure. Purification by column 
chromatography on silica gel using CHCl3:MeOH:NH3 (97:3:1) as eluent afforded 
145 (87mg, 65%) and 146 (16mg, 8%) as colourless oils.
d) acid catalysed
To a mixture of 138 (540mg, 1.42mmol), palladium on charcoal (80mg) in absolute
%
ethanol (20ml) was added conc. HC1 (1 drop). The reaction mixture was 
hydrogenated at room temperature and atmospheric pressure. After 3 hr the mixture 
was filtered through Celite and then washed through with excess ethanol (2x20ml). 
The solvent was removed under reduced pressure and the resultant residue purified by
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column chromatography using CHCl3:MeOH:NH3 (97:3:1) as eluent to give starting
ft
material 138 (430mg, 80%) and 145 (77mg, 14%).
6-Cyclohexylmethyl-5,6-didehydro-4-hydroxy-3-methoxy-N-methylmorphinan (145)
Rf = 0.37 (CHCI3:MeOH:NH3 = 95:5:1); mlz (FAB) = 382.1(M++H, 100%) ; IR 
(neat) = 3526 (OH), 1724 (C=C), 1606, 1581 (ArC-C), 1483 (C-N), 1278 (ArC-O- 
CH3) cm'l.
8h  (400MHz) : 0.76-0.90 (2H, m, cyclohexyl-axial), 1.11-1.19 (3H, m, cyclohexyl- 
axial), 1.37-1.45 (1H, m, CH-cyclohexyl), 1.48-1.54 (2H, m, H-8ax andH-8eq), 1.62-
1.72 (6H, m, H-15 and cyclohexyl-equitorial), 1.79-1.90 (5H, m, H-7, H-14, H-15, H- 
19ax and H-19eq), 2.02-2.22 (2H, m, H-7 and H-lfex), 2.39 (3H, s, N-CH3), 2.52 
(1H, m, Jgem = 10.7Hz and 7l6eq,15 = 2.9Hz, H-16eq), 2.65 (1H, dd, Jgem = 18.1Hz 
and /I0a ,9  = 5.6Hz, H-10a ), 2.92 (1H, br. s, H-9), 2.95 (1H, d, Jgem = 18.1Hz, H- 
10p), 3.82 (3H, s, 0-CH3), 5.95 (1H, br. s, OH), 6.23 (1H, s, H-5), 6.57 (1H, d, / l ,2 = 
8.3Hz, H-l), 6.64 (1H, d, /2,1 = 8.3Hz, H-2).
5c  (400MHz): 23.82 (C-10), 24.35 (C-8), 26.03,26.34 and 26.73 (cyclohexyl-£H2), 
28.90 (C-7), 32.78 and 33.68 (cyclohexyl-CH2), 35.69 (cyclohexyl-CH), 37.37 (C- 
15), 42.53 (N-£H3), 43.95 (C-14), 45.95 (6c-£H 2-cyclohexyl), 48.05 (C-16), 55.95 
(0-£H3), 57.93 (C-9), 108.05 (C-2), 118.15 (C-l), 127.84 (C-6), 129.74 (C -ll),
130.93 (C-5), 134.08 (C-12), 144.17 (C-3), 144.76 (C-4).
HRMS (FAB): found 382.2733, C25H36NO2 (M++H) requires 382.2746.
ft
6-(Cyclohexylmethylidenyl)-4-hydroxy-3-methoxy-N-methylmorphinan (146)
Rf = 0.22 (CHCl3:MeOH:NH3 = 97:3:1); Mp. = 217-218°C; mlz (FAB) 382.3 
(M++H, 100%); IR (neat) = 3519 (OH), 1721,1646,1608,1584, 1480,1442,1377, 
1279,1218,1146,1099,1060 cm'l.
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5h (270MHz) : 0.66-0.82 (1H, m, £H 2), 0.88-1.29 (6H, m, H-8, 5x£H2), 1.46-1.72 
(6H, m, H-8, H-15ax» 4x£H2), 1.74-1.92 (4H, m, H-5, H-7, H-14, H-15eq), 1.94-2.06 
(1H, m, £H-cyclohexyl), 2.05 (1H, m, Jgem = 12.3Hz and /I6ax,15 = 3.5Hz, H- 
16ax)> 2.37 (3H, s, N-CH3), 2.42-2.54 (2H, m, H-16eq, H-7), 2.60 (1H, dd, Jgem = 
18.3Hz and /l0 a ,9  = 5.5Hz, H-10a), 2.82 (1H, dd, /9,10a = 5.6Hz and /9,14*=  
3.0Hz, H-9), 2.91 (1H, d, Jgem = 18.3Hz, H-10p), 3.83 (1H, dd, Jgem = 19.5Hz and 
/5 ,19 = 1.5Hz, H-5), 3.84 (3H, s, O-CH3), 5.09 (1H, d, Jgem = 9.0Hz, H-19), 5.94 
(1H, s, OH), 6.55 (1H, d, / l ,2 = 8.2Hz, H-l), 6.66 (1H, d, / 2,1 = 8.1Hz, H-2).
5 c  (400MHz): 24.05 (C-10), 25.90 (C-8), 25.99,26.15 and 28.44 (cyclohexyl-£H2),
28.82 (C-7), 33.41 and 33.80 (cyclohexyl-£H2), 35.95 (cyclohexyl-£H), 37.95 (C- 
15), 40.11 (C-l3), 42.78 (N-£H3), 45.50 (C-5), 47.00 (C-14), 47.66 (C-16), 56.49 (O- 
£H 3), 57.68 (C-9), 108.39 (C-2), 118.01 (C-l), 125.47 (C-ll), 128.97 (C-19), 131.71 
(C-12), 134.18 (C-6), 144.51 (C-3), 144.64 (C-4).
HRMS (FAB) : found 382.2749, C25H36NO2 (M++H) requires 382.2746.
%
Reduction of 138 with triethylsilane and trifluroacetic acid,84
To a stirred solution of 138 (699mg, 1.84mmol) in trifluroacetic acid (4ml) was added 
triethylsilane (0.3ml, 1.88mmol). After stirring at room temperature for 48 hr, the 
reaction mixture was adjusted to pH 9 by the addition of saturated NaHC03 and 
extracted with DCM (x3). The combined organic extracts were dried (MgS04) and 
solvent removed under reduced pressure. Purification of the resultant residue on silica 
gel using CHCl3:MeOH:NH3 (95:5:1) as eluent afforded a mixture of 145 (160mg, 
23%) and 147 (340mg, 48%) as colourless oils.
6-Cyclohexylmethyl-4-hydroxy-3-methoxy-N-methylmorphinan (147)
*
Rf = 0.29 (CHCl3:MeOH:NH3 = 95:5:1); mlz (FAB) = 384.2 (M++H, 100%); IR 
(Nujol) = 3522 (O-H), 1603 (ArC-C), 1582,1481 (C-N), 1280 (A1C-O-CH3) cm'1.
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5h (400MHz) : 0.71-0.90 (3H, m, H-5 and CH2), 0.93-1.55 (10H, m, H-6, H-8ax, H- 
8eq, CEL, H-19ax, H-19eq and 4xCH2), 1.59-1.74 (9H, m, H-7ax, H-7eq, H-14, H- 
15ax» H-15eq, 4xCH2), 2.08 (1H, m, Jgem = 12.2Hz and /I6ax,15 = 3.4Hz, H-16ax),
2.40 (3H, s, N-CH3), 2.47 (1H, dd, Jgem = 12.2Hz and /I6eq,15 = 2.9Hz, H-16eq),
2.67 (1H, dd, Jgem = 18.1Hz and /I0a ,9  = 5.9Hz, H-10a), 2.81 (1H, br. s, /9,10a = 
5.9Hz, H-9), 2.93 (1H, d, Jgem = 18.1Hz, H-lOp), 3.36 (1H, d, Jgem = 12.7Hz, H-5),
3.84 (3H, s, O-CH3), 5.95 (1H, br. s, OH), 6.60 (1H, d, J \t2 = 8.3Hz, H-l), 6.68 (1H, 
d ,/2,l = 8.3Hz, H-2).
6c  (400MHz): 24.16 (C-10), 26.50 (C-8), 26.50,26.85 and 27.29 (£H2), 30.71 (CH), 
33.80 (CH2), 33.96 (C-7), 34.03 (£H2), 34.42 (C-6), 37.93 (C-13), 38.22 (C-15),
42.67 (N-£H3), 43.95 (C-5), 45.59 (C^-C^-CdHii), 46.73 (C-14), 47.59 (C-16),
56.29 (0-£H3), 57.88 (C-9), 108.30 (C-2), 118.27 (C-l), 121.91 (C-ll), 126.11 (C-
12), 131.86 (C-3), 144.49 (C-4).
HRMS (FAB): found 384.2906, C25H38NO2 (M++H) requires 384.2903.
Diimide^  reduction of codeine (2)
To a warmed (60°C), stirred mixture of 2 (60mg, 0.20mmol), hydrazine hydrate 
(0.12ml, 3.97mmol) and 95% ethanol (1.5ml) was added hydrogen peroxide [27.5%] 
(0.25ml, 2.02mmol) dropwise. The temperature was maintained at 40*C and the 
reaction monitored by TLC. After the complete disappearance of starting material, the 
solution was cooled, diluted with water and then extracted with DCM (x3). The 
combined organic extracts were washed with sat. NaHC03, dried (MgS04) and 
evaporated to dryness. Column chromatography on silica gel eluting with 
CHCl3:MeOH (9:1) afforded 118a as a colourless oil (22mg, 37%).
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Diimide reduction of 138
To a warmed (40°C), stirred mixture of 138 (475mg, 1.25mmol), hydrazine hydrate 
(1.17ml, 36mmol) and 95% ethanol (6ml) was added hydrogen peroxide [27.5%] 
(2.32ml, 1 Qmmol) dropwise. The temperature was maintained at 40#C and the 
reaction stirred for 60 hr. The solution was cooled, diluted with sat NaCl and then 
extracted with EtOAc (x3). The combined organic extracts were washed with sat 
NaCl, FeS04 solution, sat. NaHCC>3, and saturated NaCl before being dried (MgS04) 
and evaporated to dryness. Purification by column chromatography on silica gel 
eluting with CHCl3:MeOH (9:1) afforded 126(3 as a pale yellow oil. Yield 233mg 
(49%).
6p-(Cyclohexylmethyl)dihydrodeoxy codeine (126fi)
Rf = 0.51 (CHCl3:MeOH = 9:1); mlz (FAB) = 382.2 (M++H, 100%); IR (neat) = 
1634,1607 (AiC-C), 1501 (C-N), 1276 (A1C-O-CH3) cm'1.
8h  (400MHz) : 0.72-0.96 (4H, m, H-7, H-8 and 2xCH2-cyclohexyl), 1.09-1.25 (4H, 
m, lxCH2bridge and 3xCH2-cyclohexyl), 1.28-1.46 (2H, m, H-6 and CH- 
cyclohexyl), 1.47-1.69 (9H, m, H-7, H-8, H-15eq, lxCH2bridge and 5xCH2- 
cyclohexyl), 1.76 (1H, m, Jgem = 12.9Hz and /15,16 = 4.9Hz, H-15ax), 2.10-2.16 
(1H, m, H-14), 2.16 (1H, m, Jgem = 12.2Hz and /16,15 = 3.9Hz, H-16ax), 2.35 (1H, 
dd, Jgem = 18.6Hz and /i0 a ,9  = 5.4Hz, H-10a ), 2.39 (3H, s, N-CH3), 2.50 (1H, dd, /  
= 12.2Hz and /l6eq,15 = 4.9Hz, H-16eq), 3.00 (1H, d Jgem  = 18.6Hz, H-lOp), 3.05 
(1H, dd, /9,10a = 4.9Hz and /9,14 = 2.9Hz, H-9), 3.88 (3H, s, O-CH3), 4.11 (1H, d, 
/5,6 = 8.3Hz, H-5), 6.59 (1H, d, / l ,2 = 8.1Hz, H-l), 6.64 (1H, d, / 2,1 = 8.1Hz, H-2).
8c  (400MHz): 19.80 (C-10), 24.79 (C-8), 25.92,26.01 and 26.34 (CH2-cyclohexyl),
27.93 (C-7), 32.93 and 33.77 (CH2-cyclohexyl), 34.28 (CH-cyclohexyl), 35.38 (C- 
15), 36.62 (C-6), 42.31 (C-13), 42.56 (N-CH3), 43.09 (6C-£H2-cyclohexyl), 43.19
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(C-14), 47.16 (C-16), 56.70 (0-£H3), 59.37 (C-9), 96.06 (C-5), 113.94 (C-2), 118.04 
(C-l), 126.82 (C-ll), 130.69 (C-12), 143.13 (C-3), 144.23 (C-4).
HRMS (FAB): found 382.2750, C25H36NO2 (M++H) requires 382.2746.
Preparation of 2-(methyltriphenylphosphonium bromide)tetrahydro-2H-pyran 
(150)
A mixture of (±)-2-(bromomethyl)-tetrahydro-2H-pyran 149 (7.16ml, 56mmol), 
triphenylphosphine (14.66g, 56mmol) and toluene (25ml) were heated at reflux for 29 
hr. After cooling the resultant solid was collected and then washed with toluene to 
afford the title compound as a white powder (17g, 69%).
Mp. = 233-235°C; mlz (FAB) = 361.1 (M-Br, 100%); IR (Nujol) = 1586,1485,1440, 
1399, 1350, 1195, 1115, 1087, 1050, 1037, 994, 915, 850, 796, 763, 747, 714, 693 
cm‘l.
8h (270MHz) : 1.35-1.61 (4H, m), 1.80 (1H, br. d, /  = 5.3Hz), 2.23 (1H, br. d, /  = 
12.8Hz), 2.85 (1H, m, /  = 11.4Hz and J = 1.0Hz), 3.46-3.65 (3H, m), 4.45 (1H, t, /  = 
13.4Hz), 7.63-7.85 (15H, m, ArCH).
6c (400MHz) : 22.67 (CH2), 24.84 (CH2), 30.55 (CH-CH2-P4-), 32.29 (£H2-CH- 
£H 2-P+), 67.97 (-CH-CH2-O), 72.51 (CH), 119.23 (CH2-P+-ArC), 129.76, 129.89,
130.13,133.77,133.86,134.02,134.13,134.41 (ArCH).
Found: C, 65.3; H, 5.9%. C24H26B1OP requires: C, 65.3; H, 5.9%.
Wittig reaction between dihydrocodeinone (117) and 150
*
To a cooled, stirred suspension of 150 (3.32g, 7.52mmol) in THF (60ml) was added 
potassium ferr-butoxide (0.71g, 6.33mmol) in one portion. After 1 hr, 117 (1.50g, 
5.01mmol) was added to the deep red ylide solution. The mixture was stirred for a
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further 15 min at 20*C, heated at reflux for 8 hr and then stirred overnight at room
temperature. After removal of THF in vacuo, the resultant purple residue was purified
by column chromatography on silica gel using CHCl3:MeOH:NH3 (97:3:1) as eluent
*
to afford an unseparable 1:1 mixture of 153 and 154. Overall yield 1.86g (97%).
6-(6-Hydroxyhex-2-enylidenyl)dihydrodeoxycodeine (153)
Rf = 0.28 (CHCl3:MeOH:NH3 = 97:3:1); mlz (FAB) = 382.1 (M++H, 100%); IR 
(Nujol) : 3172 (OH), 1634 (ArC-C), 1602 (C=C-C=C), 1495 (C-N), 1257 (ArC-O- 
CH3) 1070,1037 (CH2OH) cm-1.
Found: C, 75.4; H, 8.2; N, 3.6. C24H31NO3 requires: C, 75.6; H, 8.2; N, 3.7%.
6-(6-Hydroxyhex-2 -enyl)deoxycodeine (154)
Rf = 0.22 (CHCI3:MeOH:NH3 = 97:3:1); mlz (FAB) = 382.2 (M++H, 100%) ; IR 
(neat) = 3384 (OH), 1735, 1634, 1607 (ArC-C), 1503 (C-N), 1445, 1372 (ArC-O- 
CH3) cm~l.
8h  (400MHz) : 0.84-0.94 (1H, m, H-8), 1.55-1.66 (3H, m, H-8, H-23ax, H-23eq),
I.70-1.81 (2H, m, H-15eq, H-22), 1.89 (1H, m, Jgem = 12.2Hz and /I5ax,16 = 4.9Hz, 
H-15ax)» 2.12-2.15 (2H, m, H-7ax, H-7eq), 2.18 (1H, m, Jgem = 12.2Hz and 716,15 = 
3.9Hz, H-16ax), 2.30 (1H, dd, Jgem = 18.6Hz and 7l0a,9 = 4.9Hz, H-10a ), 2.27-2.33 
(1H, m, H-14), 2.38 (3H, s, N-CH3), 2.52 (1H, dd, Jgem = 12.2Hz and /I6eq,15 = 
4.4Hz, H-16eq), 2.66 (1H, m, Jgem = 11.2Hz, H-22), 2.82 (1H, br. s, O-H), 2.98 (1H, 
d, Jgem = 18.6Hz, H-10p), 3.05 (1H, dd, /9,10p = 4.9Hz and /9,14 = 2.4Hz, H-9), 
3.60 (2H, t, /  = 6.6Hz, CH2-OH), 3.88 (3H, s, O-CH3), 4.90 (1H, s, H-5), 5.70 (1H, 
m, /21,20 = 14.7Hz, 721,22 = 7.3Hz, H-21), 6.20 (1H, dd, 720,21 = 14.7Hz, 720,19*=
II.2Hz, H-20), 6.37 (1H, d, 719,20 = 10.7Hz, H-19), 6.58 (1H, d ,7 l^  = 8.3Hz, H-l),
6.68 (1H, d, 72,1 = 8.3Hz, H-2).
- I l l -
5 c  (400MHz): 19.96 (C-10), 25.25 (C-8), 25.39 (C-22), 29.07 (C-7), 32.14 (C-23),
35.41 (C-15), 42.71 (N-£H3), 42.75 (C-14), 44.05 (C-13), 47.36 (C-16), 56.66 (O- 
£H3), 59.52 (C-9), 61.91 (£H2-OH), 90.48 (C-5), 113.74 (C-2), 118.62 (C-l), 124.73 
(C-19), 125.61 (C-20), 126.84 (C-ll), 129.45 (C-12), 134.41 (C-21), 135.63 (C-6), 
142.76 (C-3), 144.98 (C-4).
HRMS (FAB): found 382.2367, C24H32NO3 (M++H) requires 382.2382 
Diimide reduction o f alkenes 153 and 154
To a warmed (40°C), stirred unseparated mixture of alkenes 153 and 154 (541mg, 
1.42mmol), hydrazine hydrate (0.88ml, 28mmol) and 95% ethanol (7ml) was added 
hydrogen peroxide [27.5%] (1.76ml, 14mmol) dropwise. The reaction mixture was 
maintained at 40°C for a further 8 hr and then stirred at room temperature overnight 
The solution was diluted with sat. NaCl and extracted with EtOAc (x3). The 
combined organic extracts were washed with sat. NaCl, FeS04 solution, sat 
NaHC03, and sat. NaCl before being dried (MgS04) and evaporated to dryness. 
Purification by column chromatography on silica gel eluting with CHCl3:MeOH (9:1) 




Rf = 0.33 (CHCl3:MeOH = 9:1); Mp. = 118-119°C; mlz (FAB) = 386.1 (M++H, 
100%); IR (neat) = 3378 (OH), 1633,1606 (ArC-C), 1503 (C-N), 1276 (ArC-0-CH3) 
cm"l.
8h (400MHz) : 0.85-0.98 (2H, m, CH2), 1.24-1.45 (8H, m), 1.49-1.66 (5H, m), 1.69 
(1H, dd, Jgem — 12.2Hz and 7i5eq,16eq = 3.9Hz, H-15eq), 1.85 (1H, m, /gem = 
12.2Hz and /I5ax,16eq = 4.9Hz, H-15ax)> 2.22 (1H, m, Jgem  = 12.2Hz and 
/I6ax,15eq = 3.4Hz, H-16ax), 2.20-2.30 (1H, m, H-14), 2.43 (1H, dd, Jgem = 18.1Hz
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and /I0a ,9  ® 5.4Hz, H-10a ), 2.45 (3H, s, N-CH3), 2.59 (1H, dd, Jgem = 12.2Hz and 
/I6eq,15ax = 4.4Hz, H-16eq), 3.00 (1H, d, Jgem = 18.1Hz, H-10p), 3.13 (1H, hr. s, 
H-9), 3.62 (2H, t, Jgem = 6.4 Hz, CH2-OH), 3.87 (3H, s, O-CH3), 4.16 (1H, d, Jgem 
= 7.8 Hz, H-5), 6.62 (1H, d, / l ,2  = 8.3Hz, H-l), 6.72 (1H, d, /2,1 = 8.3Hz, H-2).
6c  (400MHz): 20.31 (C-10), 25.08 (C-8), 25.64,26.65 and 27.63 (3x£H2), 29.50 (C- 
7), 32.77 and 34.60 (2x£H2), 35.35 (C-15), 40.01 (C-6), 42.45 (C-13), 42.67 (N- 
CH3), 42.98 (C-l4), 47.68 (C-16), 56.77 (0-£H3), 59.95 (C-9), 62.98 (QH2-OH),
95.45 (C-5), 113.88 (C-2), 118.49 (C-l), 126.44 (C-ll), 130.56 (C-12), 143.56 (C-3), 
144.49 (C-4).
Found: C, 74.9; H, 9.2; N, 3.55%. C24H35NO3 requires: C, 74.8; H, 9.15; N, 3.6%. 
6-{6-Hydroxyhex-l -enylidene)dihydrodeoxycodeine (160)
Rf = 0.28 (CHCl3:MeOH = 9:1); mlz (FAB) = 384.1 (M++H, 100%) ; IR (neat) = 
3378 (OH), 1715 (O C), 1635,1609 (AiC-C), 1501 (C-N), 1276 (ArC-0-CH3) cnr*.
8h  (400MHz) : 0.79-0.94 (1H, m, CH2), 1.11-1.17 (2H, m, H-8ax andH-8eq), 1.24- 
1.32 (2H, m, CH2), 1.44 (2H, m, C6=CH-CH2). 1.51-1.81 (3H, m, H-7, H-15eq and 
CH2), 1.90 (1H, m, Jgem = 12.7Hz and /I5ax,16 = 4.9Hz, H-15ax), 1-91-2.00 (2H, m, 
CH2), 2.04 (1H, s, OH), 2.20 (1H, m, Jgem = 12.2Hz and/i6,15eq = 3.9Hz, H-16ai), 
2^8-2.30 (1H, m, H-14), 2.32 (1H, dd, Jgem = 18.1Hz and 7i0a,9 = 5.4Hz, H-10a ),
2.40 (3H, s, N-CH3), 2.45 (1H, m, Jgem = 14.2Hz and 77,8 = 3.4Hz, H-7), 2.54 (1H, 
dd, Jgem = 12.2Hz and /I6eq,15ax = 4.4Hz, H-16eq), 2.98 (1H, d, Jgem ~ 18.6Hz, H- 
10p), 3.07 (1H, dd, 79,10a = 5.4Hz, H-9), 3.53 (1H, t, 7 = 6.4, Hz, C6=CH-Qi2), 
3.62 (1H, t, 7 = 6.4Hz, C6=CH-CH2), 3.89 (3H, s, O-CH3), 4.87 (1H, s, H-5), 5.74 
(1H, t, 7  = 7.3Hz, C6=CH), 6.59 (1H, d, 7 i,2  = 8.3Hz, H-l), 6.69 (1H, d, 72,1 = 
8.3Hz, H-2).
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5 c  (400MHz): 20.14 (C-10), 24.82 (C-7), 24.91 (C-8), 25.55,26.74 Mid 29.19 (CH2), 
32.61 (C6=CH-£H2), 35.57 (C-15), 42.49 (N-£H3), 42.85 (C-14), 44.18 (C-13), 
47.53 (C-16), 56.86 (0 -£H3), 59.73 (C-9), 62.82 (QH2-OH), 91.15 (C-5), 113.77 (C- 
2), 118.65 (C-l), 125.62 (C6=£H-CH2), 127.08 (C-ll), 129.88 (C-12), 134.47 (C-6),
142.92 (C-3), 145.34 (C-4).
HRMS (FAB): found 384.2543, C24H34NO3 (M++H) requires 384.2539.
Catalytic reduction o f 153 using palladium on charcoal
153 (219mg, 0.57mmol) in 95% ethanol (20ml) was hydrogenated at room 
temperature at atmospheric pressure using palladium on charcoal (36mg) as catalyst 
The disappearance of starting material was monitored by TLC and on completion the 
mixture was filtered through Celite and the filter contents washed thoroughly with 
excess ethanol. The filtrate was concentrated under diminished pressure to afford a 
colourless oil. Purification by column chromatography on silica gel using 
CHCl3:MeOH (97:3) as eluent afforded 5,6-dihydro-4-hydroxy-6-(6-hydroxyhexyl)- 
3-methoxy-N-methylmoiphinan (61mg, 28%) as a colourless oil.
5,6’Dihydro-4-hydroxy-6-(6-hydroxyhexyl)-3-methoxy-N-methylmorphinan
Rf = 0.28 (CHCl3:MeOH = 9:1); mlz (FAB) = 386.3 (M++H, 100%); IR (neat) = 
3516, 3312 (OH), 1723,1661,1607 (ArC-C), 1580,1480 (C-N), 1442,1278 (ArC-O- 
CH3), 1146,1108,1057,936,849,793,743 cm-1.
8h (400MHz) : 1.28-1.37 (4H, m, CH2), 1.44 (2H, m, CH2), 1.50-1.59 (4H, m, H-8ax 
and H-8eq, H-15ax and H-15eq), 1.68 (1H, m, J = 12.2Hz and J  = 4.9Hz, CH2), 1.85-
1.92 (3H, m, CH2, H-14), 1.97-2.12 (3H, m, CH2, H-7ax and H-7eq), 2.09 (1H, m, 
Jgem = 12.2Hz and/i6ax,15eq = 3.4Hz, H-16ax). 2.17, (1H, s, OH), 2.41 (3H, s, N- 
CH3). 2.54 (1H, dd, Jgem  = 12.2Hz and 7l6eq,15 = 2.9Hz, H-16eq), 2.69 (1H, dd, 
Jgem = 18.1Hz and 7100,9 = 5.9Hz, H-10a ), 2.94-2.97 (1H, m, H-9), 2.95 (1H, d,
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Jgem = 18.1Hz, H-lOp), 3.63 (1H, t, /  = 6.8Hz, C6(CH)5Qi20H), 3.83 (3H, s, O- 
CH3), 5.95 (1H, br. s, OH), 6.28 (1H, s, H-5), 6.58 (1H, d, / i ,2  = 8.3Hz, H-l), 6.65 
(1H, d, /2,1 = 8.3Hz, H-2).
8 c  (400MHz) : 23.91 (C-10), 24.29 (C-8), 25.54, 27.49, 28.63 and 28.70 (£H2), 
32.78 (C-l5), 37.00 (C-19), 37.22 (C-13), 37.28 (C-7), 42.45 (N-£H3), 43.59 (C-14),
48.18 (C-16), 55.99 (0-£H3), 58.09 (C-9), 63.01 (£H2-OH), 108.16 (C-2), 118.26 
(C-l), 124.18 (C-6), 127.75 (C -ll), 129.41 (C-5), 135.49 (C-12), 144.19 (C-3), 
144.87 (C-4).
HRMS (FAB): found 386.2682, C24H36NO3 (M++H) requires 386.2695.
Preparation o f 6~(n-hexyUdenyl)dihydrodeoxycodeine (162)
To a cooled, stirred suspension of n-hexyltriphenylphosphonium bromide (1.72g, 
4.02mmol) in THF (20ml) was added potassium rm-butoxide (0.45g, 4.01mmol) in 
one portion. After lhr, 117 (l.OOg, 3.34mmol) was added to the deep orange ylide 
solution. The mixture was stirred for 1 hr at 20°C before being heated at reflux for 5 
hr. After cooling, THF was removed in vacuo and the residue dissolved in chloroform 
and then washed with water (x3). The organic phase was dried (MgS04) and 
chloroform removed under reduced pressure. Purification by column chromatography 
using CHCl3:MeOH (94:6) as eluent afforded 162 as a colourless oil (775mg, 63%) in 
a 6.8:1 ratio of unseparable E:Z isomers.
(E)-162
Rf = 0.60 (CHCl3:MeOH = 9:1); mlz (FAB): 368.1 (M++H, 100%); IR (neat) = 1634 
(C=C), 1606 (ArC-C), 1501 (C-N), 1445, 1372, 1334, 1276 (ArC-0-CH3), 1201, 
1151,1105,1042,909, 862cm-l.
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8h  (400MHz) : 0.89 (3H, t, 7 = 6.8Hz, C6=CH(CH2)4CH3), 0.91-0.99 (1H, m, CH2), 
1.32-1.41 (6H, m, CH2, H-8ax and H-8eq), 1.45-1.52 (1H, m, CH2), 1.74 (1H, m, 
Jgem ~ 12.2Hz, /I5eq,16eq = 3.4Hz, H-15eq)» 1*88 (1H, td, Jgem ~ 12.2Hz and 
/15ax,16eq = 4.9Hz, H-15ax), 2.02-2.08 (2H, m, CH2), 2.16 (1H, mf /I4 ,8ax = 
12.2Hz, /I4,8eq = 5.4Hz and/14,9 = 2.9Hz, H-14), 2.20-2.35 (2H, overlap, CH2), 
2.25 (1H, m, / =  12.2Hz and J =3.9Hz, CH2), 2.33 (1H, dd, Jgem = 18.6Hz and 710,9 
= 5.9Hz, H-10a), 2.40 (3H, s, N-CH3), 2.50 (1H, dd, Jgem = 12.2Hz, /l6eq,15eq = 
3.4Hz, H-16eq), 2.98 (1H, d, Jgem = 18.6Hz, H-lOp), 3.07 (1H, dd, /9,10a = 5.9Hz, 
/9,14= 2.9Hz, H-9), 3.84 (3H, s, O-CH3), 5.19 (1H, s, H-5), 5.31 (1H, t, /  = 7.3Hz, 
C6=CH(CH2)4CH3), 6.58 (1H, d ,7 l,2  = 7.8Hz, H-l), 6.69 (1H, d, 72,1 = 7.8Hz, H- 
2).
8c  (400MHz) : 14.03 (C6=CH(CH2)4£H 3), 19.92 (C-10), 22.58 (C-8), 24.44,28.63, 
29.69, 31.45, 31.63 (5xCH2). 36.40 (C-15), 41.41 (C-14), 42.93 (N-£H3), 43.62 (C- 
13), 46.99 (C-16), 56.34 (0-£H3), 59.79 (C-9), 89.36 (C-5), 113.23 (C-2), 118.28 (C- 
1), 127.20 (C-ll), 129.83 (C-12), 132.16 (C6=£H(CH2)4CH3), 133.58 (C-6), 142.34 
(C-3), 145.42 (C-4).
HRMS (FAB): found 368.2591, C24H34NO2 (M++H) requires 368.2590.
(Z)-162
5h (400MHz) : contains 4.87 (1H, s, H-5), 5.73 (1H, t, 7  = 7.3Hz, 
C6=CH(CH2)4CH3).
8c  (400MHz) : 13.94 (C6=CH(CH2)4£H 3), 20.02 (C-10), 22.39 (C-8), 24.72,25.46, 
26.73,29.09, 31.01 (5xCH2), 35.69 (C-15), 41.23 (C-14), 42.86 (N-CH3), 44.10 (C- 
13), 47.47 (C-16), 56.68 (0 -£H3), 59.66 (C-9), 91.19 (C-5), 113.61 (C-2), 118.53 (C- 
1), 125.88 (C6=£H(CH2)4CH3), 127.09 (C-ll), 130.80 (C-12), 134.59 (C-6), 142.80 
(C-3), 145.42 (C-4).
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Diimide reduction of 162
To a cooled stirred mixture of 162 (585mg, 1.59mmol), hydrazine hydrate (0.99ml, 
32mmol) in 95% ethanol (4.5ml) was added hydrogen peroxide [27.5%] (1.97ml, 
16mmol) dropwise. The mixture was then stirred for 16 hr at 30-40*C before a further 
0.99ml of hydrazine hydrate (32mmol) and 1.97ml of hydrogen peroxide (16mmol) 
was added. After 7 hr, the mixture was cooled to ambient temperature and all solvent 
removed under reduced pressure. The resultant residue was purified by column 
chromatography using CHCl3:MeOH (95:5) as eluent affording 163 as a colourless oil 
(300mg, 51%).
6f$-(n-Hexyl)dihydrodeoxycodeine (163)
Rf = 0.60 (CHCl3:MeOH = 9:1); mtz (FAB): 370.3 (M++H, 100%); IR (neat) = 163?, 
1607 (ArC-C), 1500(C-N), 1443,1372,1341,1276 (A1C-O-CH3), 1202,1152,1042, 
926,855,795,752 cm*l.
8h (400MHz) : 0.87 (3H, t ,7  = MHz, C6H-C5Hio-CH3), 0.88-0.96 (2H, m, CH2), 
1.21-1.39 (10H, br. s, H-6 and CH2), 1.46-1.54 (1H, m, CH2). 1-66 (1H, br.d, Jgem = 
12.2Hz, H-15eq), 1.62-1.76 (2H, m, CH2), 1.77 (1H, m, Jgem = 12.2Hz and 
715ax,16eq = 4.9Hz, H-15ax), 2.12-2.17 (1H, m, H-14), 2.16 (1H, m, Jgem = 12.2Hz, 
7l6ax,15 = 3.4Hz, H-16ax), 2.35 (1H, dd, Jgem = 18.6Hz and 7i0a,9 = 5.4Hz, H- 
10a ), 2.39 (3H, s, N-CH3), 2.50 (1H, dd, Jgem = 12.2Hz, 7i6eq,15 = 3.9Hz, H-16eq),
2.99 (1H, d, Jgem = 18.1Hz, H-10p), 3.05 (1H, br.s, H-9), 3.87 (3H, s, 0-CH3), 4.15 
(1H, d, 75,6 = 7.8Hz, H-5), 6.59 (1H, d, 71,2 = 7.8Hz, H-l), 6.69 (1H, d, 72,1 = 
8.3Hz, H-2).
8c  (400MHz): 13.94 (C6H-C5H10-QH3), 19.98 (C-10), 22.47, 24.97,26.54, 27.57, 
29.32, 31.65, 34.61 and 35.61, (8xCH2), 35.58 (C-15), 39.95 (C-6), 42.44 (C-13),
42.71 (N-CH3), 43.35 (C-14), 47.39 (C-16), 56.55 (O-CH3), 59.57 (C-9), 95.38 (C-5),
-117-
113.67 (C-2), 118.20 (C-l), 126.84 (C-ll), 130.66 (C-12), 143.22 (C-3), 144.30 (C- 
4 ) *
HRMS (FAB): found 370.2724, C24H36NO2 (M++H) requires 370.2746.
Preparation o f 6-(dimethylaminoethylidenyljdihydrodeoxycodeine (165)
To a cooled, stirred suspension of dimethylaminoethyltriphenylphosphine bromide 
(4.15g, lOmmol) in THF (35ml) was added potassium fe/t-butoxide (1.12g, lOmmol) 
in one portion. After 1 hr, 117 (1.50g, 5.01 mmol) was added to the pale yellow ylide 
solution. The mixture was stirred for 1 hr at 208C before being heated at reflux for 6 
hr. After cooling, THF was removed in vacuo and the residue dissolved in chloroform 
and then washed with water (x3). The organic phase was dried (MgS04) and 
chloroform removed under reduced pressure. Purification by column chromatography 
using CHCl3:MeOH:NH3 (90:10:1) as eluent afforded 165 as a colourless oil (1.04g, 
58%) in a 8:1 ratio of unseparable E:Z isomers.
(E)-165
Rf = 0.26 (CHCl3:MeOH:NH3 = 90:10:1); m/z (FAB) : 355.3 (M++H, 100%); IR 
(neat) = 1635 (C=C), 1606 (ArC-C), 1503(C-N), 1440,1374,1337, 1320, 1276 (ArC- 
O-CH3), 1260,1198,1178,1148,1101,1056,1040,1020,911,860,790 cm-1.
8h  (400MHz) : 0.95 (1H, m, Jgem = 12.2Hz and 78,7 = 4.9Hz, H-8ax), 1.51 (1H, m, 
Jgem = 12.2Hz and 78,7 = 3.9Hz, H-8eq), 1.73 (1H, dd, Jgem  = 12.2Hz, H-15eq),
1.89 (1H, m, Jgem = 12.2Hz and 715ax,16eq = 4.9Hz, H-15ax), 2.10-2.24 (3H, m, H- 
7ax. H-7eq and H-14), 2.23 (1H, m, Jgem = 12.2Hz, 7l6ax,15 = 3.9Hz, H-16ax), 2.25 
(6H, s, C6=CHCH2N(CH3)2), 2.34 (1H, dd, Jgem = 18.6Hz and 7i0a,9 = 5.4Hz, H- 
10a ), 2.40 (3H, s, N-CH3), 2.52 (1H, dd, Jgem = 12.2Hz, 7i6eq,15 = 3.9Hz, H-16eq),
2.99 (1H, d, Jgem = 18.6Hz, H-10p), 3.08 (1H, dd, 79,10a = 5.4Hz and 79,14 = 
2.9Hz, H-9), 3.26 (2H, t, 7 = 6.8Hz, C6=CHCH2N(CH3)2), 3.85 (3H, s, O-CH3), 5.16
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(1H, s, H-5), 5.38 (1H, t, 7 = 6.83Hz, <^=CHCH2N(CH3)2), 6.60 (1H, d, J \£  = 
8.3Hz, H-l), 6.70 (1H, d, /2,1 = 8.3Hz, H-2).
8c  (400MHz): 19.94 (C-10), 24.62 (C-8), 32.07 (C-7), 36.16 (C-15), 41.91 (C-14),
42.93 (N-CH3), 43.86 (C-13), 45.38 (-N(CH3)2), 47.08 (C-16), 56.39 (0 -£H3), 57.43 
(C6=CH£H2N(CH3)2), 59.74 (C-9), 89.25 (C-5), 113.36 (C-2), 118.59 (C-l), 127.16 
(C-ll), 129.05 (C6=CHCH2N(CH3)2), 129.69 (C-12), 136.20 (C-6), 142.49 (C-3), 
145.00 (C-4).
HRMS (FAB): found 355.2378, C22H31N2O2 (M++H) requires 355.2386.
(Z)-165
8h  (400MHz) contains 4.89 (1H, s, H-5), 5.88 (1H, t, /  = 6.83Hz, 
C6=CHCH2N(CH3)2).
8c  (400MHz) contains 90.73 (C-5), 122.24 (C<5=£HCH2N(CH3)2).
Diimide reduction of 165
To a cooled stirred mixture of 165 (1.7 lg, 4.82mmol), hydrazine hydrate (3ml, 
96mmol) in 95% ethanol (8ml) was added hydrogen peroxide [27.5%] (5.96ml, 
48mmol) dropwise over 30 min. The mixture was then stirred for 3 hr at 30-40*C 
before a further 3ml of hydrazine hydrate (96mmol) and 5.96ml of hydrogen peroxide 
(48mmol) was added. The mixture was then stirred for a further 20 hr at 30-40*C. 
The mixture was then cooled, concentrated to half its original volume and then 
extracted with chloroform (x4). The organic phase was dried (MgS04), and the 
solvent removed under reduced pressure. The resultant residue was purified by 
column chromatography using as eluent CHCl3:MeOH:NH3 (90:10:2) and then 




Rf = 0.33 (CHCl3:MeOH:NH3 = 90:10:2); m/z (FAB) : 357.1 (M++H, 100%); IR 
(neat) = 1634, 1608 (ArC-C), 1500(C-N), 1443, 1276 (ArC-0-CH3), 1152, 1106,
1056.1044.924.852 cm-1.
8h  (400MHz) : 0.92 (1H, t, /  = 12.2Hz, H-7ax), 0.92 (1H, t, J  = 12.2Hz, H-8ax), 
1.27-1.36 (1H, m, H-6), 1.37-1.46 (1H, m, c6hCH2CH2N(CH3)2), 1.46-1.51 (1H, m, 
H-8eq), 1.64-1.68 (2H, m, H-7eq and H-15eq), 1.77 (1H, m, Jgem  = 12.2Hz and 
/I5ax,16eq = 4.9Hz, H-15ax), 1.88-1.96 (1H, m, C6HCH2CH2N(CH3)2), 2.11-2.17 
(1H, m, H-14), 2.16 (1H, m, Jgem = 12.2Hz, /I6ax,15 = 4.4Hz, H-16ax), 2.20 (6H, s, 
C6HCH2CH2N(CH3)2 ), 2.26 (1H, m, Jgem = 11.7Hz and J  = 4.4Hz, 
C6HCH2CH2N(CH3)2), 2.34 (1H, dd, Jgem = 18.1Hz and /I0a ,9  = 5.4Hz, H-10tx), 
2.35-2.42 (1H, m, C6HCH2CH2N(CH3)2), 2.39 (3H, s, N-CH3), 2.49 (1H, dd, Jgem 
= 12.2Hz, 7l6eq,15 = 3.9Hz, H-16eq), 2.99 (1H, d, Jgem = 18.1Hz, H-10p), 3.04 (1H, 
dd, / 9,10a  = 4.9Hz and /9,14 = 2.9Hz, H-9), 3.87 (3H, s, 0-CH3), 4.16 (1H, d, / 5,fr= 
8.3Hz, H-5), 6.59 (1H, d, / i ,2 = 8.3Hz, H-l), 6.69 (1H, d, / 2,1 = 8.3Hz, H-2).
8c  (400MHz) : 20.02 (C-10), 24.93 (C-8), 27.66 (C-7), 32.73 
(C%CH2CH2N(CH3)2), 35.65 (C-15), 38.23 (C-6), 42.58 (C-13), 42.82 (N-£H3),
43.41 (C-14), 45.31 and 45.31 (-N(£H3)2), 47.47 (C-16), 56.74 (0-£H3), 57.07 
(C6HCH2£H2N(CH3)2), 59.59 (C-9), 95.43 (C-5), 113.91 (C-2), 118.40 (C-l), 
127.05 (C-ll), 130.69 (C-12), 143.35 (C-3), 144.32 (C-4).
HRMS (FAB): found 357.2535, C22H33N2O2 (M++H) requires 357.2542.
6p-(Dimethylaminoethyl)dihydrodeoxycodeine-N-oxide (167)
Rf = 0.13 (CHCI3 :MeOH:NH3 = 90:10:2); mfz (FAB) : 373.1 (M++H, 100%); IR 
(neat) = 1634, 1610 (ArC-C), 1501 (C-N), 1444, 1373, 1326, 1276 (ArC-0-CH3),
1214.1152.1067.1048.922.852 cm'!.
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8h (400MHz) : 0.93 (1H, m, Jgem = 12.2Hz, / 8ax,7eq = 2.3Hz, H-8ax). 1-09 (1H, m, 
Jgem = 12.2Hz, J  = 1.5Hz, H-7ax), 1.28-1.38 (1H, m, H-6), 1.51-1.57 (1H, m, H-8eq), 
1.64-1.69 (2H, m, H-7eq andH-15eq), 1.79 (1H, m,Jgem = 12.2Hz and /I5ax,16eq = 
4.9Hz, H-15ax). 2.07 (2H, m, C6HCH2CH2N(CH3)2), 2.12-2.22 (1H, m, H-14), 2.15 
(1H, m, Jgem = 12.2Hz, 7l6ax,15eq = 4.4Hz, H-16ax)> 2.35 (1H, dd, Jgem — 18.6Hz 
and /I0a ,9  = 5.3Hz, H-10a), 2.39 (3H, s, N-CH3), 2.51 (1H, dd, Jgem -  12.2Hz, 
^16eq,15eq = 3.9Hz, H-16eq), 3.01 (1H, d, Jgem = 18.6Hz, H-10p), 3.07 (1H, dd, H- 
9), 3.19 (3H, s, C6HCH2CH2N(CH3)2), 3.22 (3H, s, c6hCH2CH2N(CH3)2), 2.29-
2.40 (1H, m, C6HCH2CH2N(CH3)2), 3.42-3.52 (1H, m, C6HCH2CH2N(CH3)2),
3.85 (3H, s, 0-CB3), 4.23 (1H, d, >5,6 = 8-3Hz, H-5), 6.64 (1H, d, 7l,2 = 8.3Hz, H-l),
6.71 (1H, d, 72,1 = 8.3Hz, H-2).
8c  (400MHz) : 20.03 (C-10), 24.89 (C-8), 28.53 (C-7), 29.41 
(C6HCH2CH2N(CH3)2), 35.63 (C-15), 38.50 (C-6), 42.87 (N-£H3), 42.90 (C-13), 
43.23 (C-14), 47.42 (C-16), 56.44 (0-£H3), 58.10 (C6HCH2CH2N(£H3)2), 59.35 
(C6HCH2CH2N(£H3)2), 59.51 (C-9), 69.62 (C6HCH2£H2N(CH3)2), 95.02 (C-5),
113.29 (C-2), 118.96 (C-l), 127.05 (C-ll), 130.30 (C-12), 143.42 (C-3), 143.79 (C- 
4).
HRMS (FAB): found 373.2489, C22H33N2O2 (M++H) requires 373.2489.
A ttem p ted  W ittig  reaction  betw een d ih ydrocodein on e  and  
cyclohexyltriphenylphosphonium bromide
To a stirred suspension of cyclohexyltriphenylphosphonium bromide (2.16g, 
5.08mmol) in THF (50ml), maintained at 20°C was added potassium rerf-butoxide 
(0.56g, 4.99mmol) in one portion. After 1 hr, dihydrocodeinone (l.OOg, 3.34mmol) 
was added to the deep red ylide solution. The mixture was stirred for a further 90 min 
at 20°C and then heated under reflux for 18 hr. THF was then removed in vacuo and
4
the residue dissolved in DCM and washed three times with water. The organic phase
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was dried (MgS04) and DCM removed under reduced pressure. Purification of the 
resultant residue by column chromatography using CHCl3:MeOH:NH3 (90:10:1) as 
eluent afforded 690mg (35%) of 173.
Codeine *dimer9 (173)
Rf = 0.20 (CHCI3:MeOH:NH3 = 90:10:1); m/z (FAB) 599.2 (M++H, 100%); IR 
(Nujol) 3333 (OH), 1709,1631,1604,1498,1376,1278 cnr*.
5h (270MHz) : 0.32-0.51 (1H, m), 0.85-1.14 (4H, m), 1.22-1.34 (1H, m), 1.57-1.67 
(1H, m), 1.88-2.15 (5H, m), 2.27 (1H, m, Jgem = 12.1Hz and /  = 3.5Hz, H-16a>D, 
2.36 (3H, s, N-CH3), 2.37 (3H, s, N-CH3), 2.35-2.73 (6H, m), 2.83 (2H, br. s), 2.99 
(1H, d, Jgem  = 18.7Hz, H-lOp), 3.18 (1H, m, 79,14 = 3.5Hz, H-9), 3.81 (3H, s, O- 
CH3), 3.90 (3H, s, O-CH3), 5.01 (1H, s, H-5), 5.96 (1H, s, OH), 6.59 (1H, d, J \ t2 = 
8.2Hz, H-l), 6.60 (1H, d, J\,2  = 8.1Hz, H-l), 6.65 (1H, d, 72,1 = 8.4Hz, H-2), 6.71 
( lH ,d ,/2,l  = 8.2Hz, H-2).
5C (400MHz) : 19.73 (C-10), 20.28, 21.51 (C-8, C-8), 24.29 (C-10), 27.25 (C-7), 
30.16 (C-14), 31.20,34.71 (C-15, C-15), 38.86 (C-14), 40.34 (C-13), 42.45,43.07 (N- 
£H 3, N-£H3), 43.29 (C-13), 46.45, 46.63 (C-16, C-16), 55.94, 57.13 (0-£H3, O- 
£H 3), 57.62, 59.40 (C-9, C-9), 82.95 (C-6), 85.37 (C-5), 88.26 (C-5), 108.45 (C-2),
114.54 (C-2), 115.38 (C-7), 118.98,119.04, (C-l, C-l), 125.46,126.92 (C -ll, C-ll),
ft
129.68,131.18 (C-12, C-12), 142.70,143.31 (C-3, C-3), 144.87 (C-6), 144.99,149.40 
(C-4, C-4).
HRMS (FAB): found 599.3104, C36H43N2O6 (M++H) requires 599.3121. 
Dehydration of 173
To a solution of 173 (281mg, 0.47mmol) in DCM (3ml) was added 2M HC1 (2ml) and 
the mixture stirred overnight at room temperature. The mixture was then adjusted to
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pH 9 by the addition of aqueous K2CO3 and extracted three times with DCM. The 
organic layer was dried (MgS04) and DCM removed under reduced pressure to afford 
a brown oil. Purification by column chromatography using CHCl3:CH30H:NH3 
(90:10:1) as eluent afforded 135mg (50%) of 174 as a pale brown solid.
Compound 174
Rf = 0.48 (CHCl3:MeOH:NH3 = 90:10:1); mlz (FAB) 581.2 (M++H, 100%); IR 
(neat) 3507 (OH), 1722,1676,1632 (C=C), 1605 (ArC-C), 1579,1503 (C-N) cnr*
Sh (270MHz) : 1.62-1.76 (2H, m, H-8ax, H-8eq), 1.82-2.01 (5H, m, H-8, H-14,3xH-
15), 2.38 (3H, s, N-CH3), 2.43 (3H, s, N-CH3), 2.12-2.58 (10H, m, 2xH-7, H-8, H-
10a , H-14, H-15,4xH-16), 2.71 (1H, dd, Jgem = 13.0Hz and /  = 5.1Hz, H-10a ), 2.93
(1H, dd, /  = 3.5Hz, H-9), 3.01 (1H, d, Jgem = 18.3Hz, H-lOp), 3.07 (1H, d, Jgem  =
18.3Hz, H-10p), 3.20 (1H, dd, /9,10a = 5.7Hz, /9,14 = 2.8Hz, H-9), 3.82 (3H, s, O-
*
CH3), 3.84 (3H, s, O-CH3), 5.53 (1H, s, H-5), 6.62 (1H, d, /  = 8.4Hz, H-l), 6.66 (1H, 
d, /  = 8.4Hz, H-l), 6.69 (1H, d, J = 8.4Hz, H-2), 6.73 (1H, d, J = 8.2Hz, H-2), 7.46 
(1H, br. s, OH).
6c  (400MHz) : 20.16 (C-7), 20.25 (C-10), 21.20 (C-8), 24.00 (C-10), 24.00 (C-8), 
33.37, 35.65 (C-15, C-15), 37.22 (C-13), 41.39 (C-14), 42.44, 42.93 (N-£H3, N- 
£H 3), 44.30 (C-14), 44.52 (C-13), 46.40, 46.81 (C-16, C-16), 55.73, 56.30 (0-£H3, 
0-£H3), 57.03, 59.44 (C-9, C-9), 84.50 (C-5), 109.52 (C-2), 113.39 (C-2), 118.42, 
118.53, 118.73 (C-l, C-l, C-7), 123.01, 124.60 (C-ll, C -ll), 126.95,128.48 (C-12, 
C-12), 128.68 (C-5), 143.06,144.54,144.74,145.25,146.46, (C-3, C-3, C-4, C-6, C-
6), 154.45 (C-4).
*
HRMS (FAB): found 581.3022, C36H41N2O5 (M++H) requires 581.3015.
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Attempted dimerisation of dihydrocodeinone (117) with potassium tert-butoxide
To a stiired solution of 117 (306mg, 1.02mmol) in THF (20ml) was added potassium 
ferf-butoxide (llOmg, 0.98mmol) in one portion. The reaction mixture was stirred at 
room temperature for 12 hr and then refluxed for further 8 hr. TLC analysis showed 
no reaction. THF was then removed in vacuo and the resultant residue partitioned 
between water and DCM. The mixture was extracted with DCM (x2), the combined 
organic extracts dried (MgS04) and DCM removed under reduced pressure to leave
t
an off white solid. Crystallisation using absolute ethanol afforded a quantitative yield 
of starting material.
Reaction between 117 and cyclohexyltriphenylphosphonium bromide
A stirred solution of 117 (300mg, l.OOmmol) and cyclohexyltriphenylphosphonium 
bromide (840mg, 1.98mmol) in THF (25ml) was refluxed for further 13 hr. TLC 
analysis showed no reaction and dihydrocodeinone was recovered quantitatively.
Reaction of dihydrocodeinone (117) with isopropyl triphenylphosphonium iodide
To a cooled, stirred suspension of isopropyltriphenylphosphonium iodide (1.44g, 
3.34mmol) in THF (20ml) was added potassium rerr-butoxide (0.37g, 3.34mmol) in 
one portion. After 1 hr, 117 (0.5g, 1.67mmol) was added to the deep orange ylide 
solution. A colour change to yellow was immediately observed and the mixture was 
stirred for a further hour at 20°C before being heated under reflux for 13 hr. After 
cooling, THF was removed in vacuo and the residue dissolved in chloroform and then 
washed three times with water. The organic phase was dried (MgS04) and 
chloroform removed under reduced pressure. Purification by column chromatography 
using CHCl3:MeOH (9:1) and then CHCl3:MeOH:NH3 (95:5:1) as eluent afforded 
143mg of unreacted dihydrocodeinone, 79mg (8%) of 184 and 32mg (3%) of 174.
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Aldolisation product 184
Rf = 0.30 (CHCl3:MeOH:NH3 = 90:10:1); mfz (FAB) : 599.3 (M++H, 100%); IR 
(neat) = 3337 (OH), 1722 (C=0), 1673,1636,1609 (ArC-C), 1501 (C-N), 1370,1329, 
1272 (ArC-0-CH3), 1199,1153,1052,920,794 cm-1.
8h  (400MHz) : 1.09-1.23 (3H, m, 3x H-8), 1.45 (1H, br. d, Jgem = 13.7Hz, H-7eq),
1.54 (1H, m, Jgem = !2.2Hz, H-15eq), 1.69 (1H, m, Jgem = !2.2Hz, H-7ax), 1.78 
(1H, m, Jgem = 12.7Hz, H-15eq), 1.89 (1H, m, Jgem = 12.2Hz and /15,16= 4.9Hz H- 
15ax), 2.06 (1H, m, Jgem = 12.2Hz and /  = 4.9Hz, H-15ax), 2.13-2.29 (5H, m, H-8, 
H-10a, H-14,2x H - ^ ) ,  2.35 (1H, dd, Jgem = 18.1Hz and /10a ,9 = 5.4Hz, H-10a ), 
2.38 (3H, s, N-CH3), 2.40 (3H, s, N-CH3), 2.48 (1H, m, Jgem = 12.2Hz and /  = 
3.9Hz, H-16ax)» 2.54 (1H, m, Jgem = 12.2Hz and /  = 3.9Hz, H-16ax), 2.61 (1H, m, 
Jgem = 12.2Hz and /  = 2.9Hz, H-14), 2.77 (1H, dd, Jgem = 12.7Hz and /  = 2.9Hz, H-
7), 2.98 (1H, d, Jgem  = 18.1Hz, H-lOp), 3.00 (1H, d, Jgem = 18.6Hz, H-lOp), 3.05 
(1H, br. s, H-9), 3.15 (1H, m, /9,14 = 2.4Hz, H-9), 3.86 (3H, s, O-CH3), 3.93 (3H, s, 
O-CH3), 4.56 (1H, s, H-5), 4.68 (1H, s, H-5), 6.62 (2H, d, J \£  = 8.3Hz, 2x H-l), 6.69 
(1H, d, /2,1 = 8.3Hz, H-2), 6.71 (1H, d, /2,1 = 8.3Hz, H-2).
8c  (400MHz): 19.73 (C-8), 20.12 and 20.15 (C-10), 26.74 (C-8), 29.76 (C-7), 35.41 
and 36.98 (C-15), 42.61 (C-14), 42.70 and 42.87 (N-CH3), 42.92 (C-14), 43.01 (C-
13), 46.85 and 47.20 (C-16), 48.32 (C-13), 56.16 and 56.86 (0-£H3), 57.13 (C-7), 
59.03 and 59.66 (C-9), 72.82 (C-6), 91.70 and 92.79 (C-5), 112.56 and 114.79 (C-2),
119.29 and 119.81 (C-l), 126.35 and 126.35 (C -ll), 127.10 and 130.34 (C-12),
141.44 and 142.81 (C-3), 145.23 and 145.30 (C-4), 208.34 (C-6).
HRMS (FAB): found 599.3152, C36H43N2O6 (M++H) requires 599.3121.
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Preparation of Robinson annulation product 193
a) using IN  NaOH105
To a stirred, cooled solution of dihydrocodeinone (117) hydrochloride (0.5g, 
1.49mmol) and IN NaOH (5.96ml, 5.96mmol) in methanol (10ml) was added MVK 
(0.29ml, 3.42mmol) dropwise. After the mixture had been stirred at room temperature 
for 14 hr under nitrogen, additional MVK (0.09ml, 1.03mmol) was added. The 
mixture was stirred for a further 2 hr and then made neutral by the addition of aqueous 
10% HC1. The resulting mixture was concentrated and extracted with CHCI3 (x3). 
The combined chloroform extracts were washed with brine, dried (MgS04), and the 
solvent removed under reduced pressure to give a brown oily residue. TLC analysis 
of the residue showed the presence of 4 new components which could not be separated 
by column chromatography. Analysis of the reaction mixture by mass spectrometry 
revealed a mass ion peak at miz-352, consistant with 193.
(b) using ethanolic sodium ethoxide106
A solution of ethanolic sodium ethoxide (9mg, 0.37mmol of sodium in 1ml EtOH)
was added to an efficiently stirred solution of 117 (506mg, 1.68mmol) in ethanol
_  *(12ml) maintained at -10°C. The reaction was left stirring for a further 0.5 hr before
MVK (0.17ml, 0.17mmol) was added dropwise to the mixture. After 20 hr, the 
reaction mixture was washed with saturated sodium chloride solution, water and then 
extracted with DCM. Evaporation of solvent after drying (MgS04) afforded a white 
solid. Purification by column chromatography using CHCl3:MeOH:NH3 (98:1:1) as 
eluent afforded the title compound (25mg, 4%) as a colourless oil.
(c) using sodium hydride
To a stirred solution of 117 (102mg, 0.34mmol) in dry THF (5ml) at 0°C was added 
NaH (lOmg, 0.34mmol). The mixture was stirred for 1 hr before MVK (0.03ml,
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0.34mmol) was added. TLC analysis of the reaction mixture after 24 hr showed litde 
conversion to the desired compound and attempted separation of the components by 
column chromatography using CHCl3:MeOH:NH3 (98:1:1) as eluent was 
unsuccessful.
(d) using potassium tert-butoxide107
To a cooled solution of 117 (138mg, 0.46mmol) in dry THF (15ml) was added 
potassium ferf-butoxide (52mg, 0.46mmol). The reaction was stirred for a further 0.5 
hr before MVK (0.04ml, 0.46mmol) was added. TLC analysis of the reaction mixture 
after 24 hr showed the presence of mainly unreacted 117 plus 4 different components. 
Attempted separation of the components by column chromatography using 
CHQ3:MeOH:NH3 (98:1:1) as eluent was unsuccessful.
(e) using lithium diisopropylamide 108
To a stirred solution of 117 (257mg, 0.86mmol) in THF (10ml) at -78#C was added
*
lithium diisopropylamide (0.43ml, 0.86mmol). The mixture was stirred for a further 
hour before MVK (0.07ml, 0.86mmol) was added. TLC analysis of the reaction 
mixture after 24 hr showed mainly unreacted starting material and also the presence of 
4 other components. THF was removed in vacuo and the resultant residue partitioned 
between water and chloroform. The organic layer was collected and the aqueous 
fraction extracted with CHCI3 (x2). The combined chloroform layers were dried 
(MgS04) and chloroform removed under reduced pressure. Purification by column 
chromatography using CHCl3:MeOH:NH3 (98:1:1) as eluent afforded 193 (lOmg, 
3%) as a colourless oil.
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Robinson annulation product 193 ft
Rf = 0.42 (CHCl3:CH30H:NH3 = 9:1:0.1); m/z (FAB) : 352.1 (M++H, 100%); IR 
(neat) = 1711 (C=0), 1636 (ArC-C), 1608,1501 (C-N), 1446,1372,1334,1278 (ArC- 
O-CH3), 1258,1215,1155,1108,1054 cm-1.
ft
5h (270MHz) : 1.25 (1H, ddd, Jgem  = 13.8Hz, /8ax,7 = 13.8Hz and /8ax,14 = 
10.8Hz, H-8ax)» 1.25 (1H, m, Jgem = 13.8Hz and /8eq,14 = 7.7Hz, H-8eq), 1.63 (1H, 
m, H-22ax), 1.82 (1H, m, Jgem = 12.1Hz and /l5eq,16ax = 3.8Hz, H-15eq), 1.94 (1H, 
m ,Jgem = 12.1Hz and/i5ax,16eq = 5.1Hz, H-15ax), 1.98 (1H, m, H-22eq), 2.15 (1H, 
ddd, /I4,8ax = 10.8Hz, /I4,8eq = 7.7Hz and /14,9 = 2.7Hz, H-14), 2.21-2.45 (4H, m, 
H-7, H-16ax» H-21ax, H-21eq), 2.40 (3H, s, N-CE3), 2.43 (1H, dd, Jgem = 18.7Hz 
and /I0a ,9  = 6.2Hz, H-10a), 2.53 (1H, dd, Jgem = 12.3Hz and /I6,15ax = 4.1Hz, H- 
16^), 3.05 (1H, d, Jgem = 18.7Hz, H-10p), 3.13 (1H, dd, /9,10a = 6.2Hz and /9,14 = 
2.7Hz, H-9), 3.86 (3H, s, O-CH3), 4.90 (1H, s, H-5), 6.09 (1H, d, /  = 1.7Hz, C^CH),
6.67 (1H, d, / l , 2 = 8.2Hz, H-l), 6.77 (1H, d, 72,1 = 8.2Hz, H-2).
8c (400MHz): 19.92 (C-10), 27.69 (C-7), 28.61 (C-22), 29.05 (C-8), 34.88 (C-21), 
37.43 (C-14), 37.43 (C-15), 43.04 (N-£H3), 44.56 (C-13), 45.78 (C-16), 56.30 (O- 
£H 3), 59.32 (C-9), 93.39 (C-5), 113.41 (C-2), 119.30 (C-l), 127.71 (C -ll), 128.77 
(C^CH), 129.76 (C-12), 141.89 (C-3), 146.00 (C-4), 158.32 (C-6), 199.51 (C=0).
HRMS (FAB): found 352.1905, C22H26NO3 (M++H) requires 352.1913.
Preparation o f 6-[(tert-butyldimethylsilyl)oxy]-6,7-didehydro-4£a-epoxy-3-hydroxy- 
17-methylmorphinan (206)
(a) using sec-butyllithium as base
To a stirred solution of 117 (941mg, 3.14mmol) in THF (20ml) at -78*C was added 
S£C-butyllithium (3.05ml, 3.77mmol). After 1 hr of stirring at the above temperature,
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rm-butyldimethylsilyl chloride (574mg, 3.81mmol) was added and the reaction 
temperature allowed to rise to ambient temperature. After 20 hr, THF was evaporated 
off under reduced pressure and the residue washed with saturated NaHC03, water and 
then extracted with DCM (x3). Column chromatography on silica gel using 
CHCl3:MeOH (95:5) afforded 206 as a colourless solid (571mg, 44%) and a 
diastereomeric mixture of 207 (184mg, 16%).
(b) using lithium diisopropylamide as base
Lithium diisopropylamide was prepared by the dropwise addition of w-butyllithiupi 
(7.54ml, 19mmol) to a solution of diisopropylamine (3.71ml, 28mmol) in dry THF 
(10ml) at -78°C under an atmosphere of nitrogen. After continuous stirring at -78*C 
for 1 hr, 117 (5.64g, 18.8mmol), dissolved in dry THF (140ml), was added dropwise 
to the LDA solution and the mixture stirred for 1 hr at -78°C before tert- 
butyldimethylsilyl chloride was added portionwise . The reaction temperature was 
then allowed to rise to room temperature. After 19 hr the reaction was quenched with 
sat. NH4CI and THF removed in vacuo. The residue was diluted with water and 
extracted with DCM (x4). The organic phase was dried (MgS04), evaporated off 
under reduced pressure and the resultant residue purified by column chromatography 
using CHCl3:CH30H (95:5) as eluent to afford 206 as a colourless solid (5.24g, 
67%). *
6-[(tert~Butyldimethylsilyl)oxy]-6j 7-didehydro-4,5 arepoxy-3-hydroxy-l 7- 
methylmorphinan (206)
Rf = 0.71 (CHCI3:MeOH:NH3 = 90:9:1); Mp. = 91-93°C; mlz (FAB): 414.2 (M++H, 
100%); IR (Nujol) = 1664, 1603 (Ar. C=C), 1497 (C-N), 1444,1338, 1250,1207 (C- 
OMe), 1148,1039,1020,959,911, 895, 837, 811,780 cm'1.
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8h  (270MHz) : 0.05 (3H, s, Si-CH3), 0.15 (3H, s, Si-CH3), 0.94 (9H, s, Si-C(CK3)3), 
1.58 (1H, m, Jgem = 12.5Hz, and /I5eq,16ax = 3.9Hz, H-15eq), 1.79 (1H, dm, Jgem 
= 12.5Hz, H-8p), 1.89 (1H, dd, Jgem = 12.5Hz and/8a,7 = 6.6Hz, H-8a ), 1.92 (1H,
m, Jgem ~ 12.5Hz and /l5ax,16eq = 4.8Hz, H-15ax)» 2.25 (1H, m, Jgem = 12.1Hz 
and/l6ax,15eq = 3.9Hz, H-16ax), 2.34 (1H, m, /14,9 = 2.8Hz, H-14), 2.38 (1H, dd, 
Jgem = 18.7Hz and /I0a,9  = 5.9Hz, H-10a ), 2.41 (3H, s, N-CH3), 2.52 (1H, dd, 
Jgem ~ 12.1Hz and /I6eq,15ax = 4.8Hz, H-16eq), 3.00 (1H, d, Jgem = 18.7Hz, H- 
10p), 3.12 (1H, dd, /9,10a = 5.7Hz and 79,14 = 2.8Hz, H-9), 3.85 (3H, s, O-CH3), 
4.75 (1H, s, H-5), 4.97 (1H, dd, / 7,8a  = 6.6Hz and /7,8p = 1.8Hz, H-7), 6.60 (1H, d, 
J \£  = 8.3Hz, H-l), 6.71 (1H, d, / 2,1 = 8.3Hz, H-2).
8C (400MHz): -4.82 (Si-£H3), -4.69 (Si-£H3), 18.06 (Si-£(CH3)3), 20.04 (C-10), 
23.95 (C-8), 25.70 (Si-C(£H3)3), 35.63 (C-15), 39.38 (C-14), 42.40 (C-13), 43.08 (N- 
£H 3), 46.46 (C-16), 56.77 (0-£H3), 58.99 (C-9), 89.69 (C-5), 109.15 (C-7), 114.09 
(C-2), 118.55 (C-l), 127.09 (C -ll), 130.86 (C-12), 143.17 (C-3), 145.23 (C-4), 
147.57 (C-6).





Rf = 0. 58 (CHCl3:MeOH:NH3 = 90:9:1); m/z (FAB) : 358.2 (M++H, 100%); IR 
(neat) = 3428 (OH), 1638, 1610 (ArC-C), 1503 (C-N), 1277 (A1C-O-CH3), 1215 
(ArC-O- AlkC) cm‘1.
8h (270MHz) : 0.92 (3H, s, CH3CH2CHCH3), 0.97 (3H, s, CH3CH2CHCH3),0.99-
1.45 (4H, m, H-7a . H-7p, H-8a  and H-8p ), 1.55-1.85 (3H, m CH3CH2CHCH3) and 
(3H, m, CH3CH2CHCH3), 1.64 (1H, m, Jgem = 12.5Hz, H-15eq), 1.94 (1H, m, Jgem
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= 12.5Hz and /l5ax,16eq = 4.9Hz, H-15ax), 2.23 (1H, m, H-14), 2.30 (1H, m, Jgem = 
12.3Hz and /I6ax,15eq = 3.9Hz, H-16ax), 2.43 (1H, dd, Jgem = 18.5Hz, H-10a ), 2.46 
(3H, s, N-CH3), 2.63 (1H, dd, Jgem = 12.3Hz and /I6eq,15ax = 4.9Hz, H-16eq), 3.00 
(1H, d, Jgem = 18.5Hz, H-10p), 3.18 (1H, m, H-9), 3.86 (3H, s, O-CH3), 4.51 (1H, s, 
H-5), 6.63 (1H, d, J \t2 = 8.3Hz, H-l), 6.70 (1H, d, /2,1 = 8.3Hz, H-2).
6C (400MHz): 12.52 (CH3), 12.92 (CH3), 19.65 (C-8), 19.96 (C-10), 22.59 (C-20), 
30.37 (C-15), 36.68 (C-7), 41.91 (C-13), 42.29 (N-CH3), 42.45 (C-14), 44.83 (C-19), 
47.06 (C-16), 56.08 (O-CH3), 59.74 (C-9), 74.48 (C-6), 90.97 (C-5), 113.10 (C-2), 
118.81 (C-l), 125.30 (C-ll), 129.87 (C-12), 144.45 (C-3), 145.34 (C-4).
HRMS (FAB): found 358.2388, C22H32NO3 (M++H) requires 358.2382. 
diastereomer B
ft
5h  (270MHz) contains 4.50 (1H, s, H-5).
5C (400MHz) contains 19.69 (C-8), 23.56 (C-20), 30.64 (C-15), 36.71 (C-7), 41.94 
(C-13), 42.55 (C-14), 45.16 (C-19), 74.39 (C-6), 91.52 (C-5).
Preparation of p-hydroxy ketone 192 from 206
a) using tetrabutylammonium fluoride and methylvinyl ketone
To a stirred solution of 206 (208mg, 0.50mmol) in dry THF (10ml) at -78’C was 
added MVK (0.04ml, 0.50mmol) and then TBAF (0.50ml, 0.50mmol) dropwise. The
ft
mixture was allowed to warm to room temperature and the reaction monitored by 
TLC. After 4 hr, complete disappearance of starting material was noted and the 
mixture partitioned with water. THF was then removed under reduced pressure and 
the aqueous phase extracted with DCM (x3). After drying (MgSC>4) and evaporation
-131-
of solvent the resultant residue was purified by column chromatography using 
CHG3:MeOH (9:1) as eluent to afford 117 (126mg, 84%).
b) using potassium fluoride and methylvinyl ketone
A solution of ‘naked* fluoride reagent^ ^  was prepared by dissolving 18-crown-6
(529mg, 2.00mmol) in dry acetonitrile (10ml) and then adding dry potassium fluoride
(141mg, 2.42mmol) [previously dried in an oven at 140°C at atmospheric pressure for
24 hr]. After the heterogeneous system was stirred for 30min, MVK (0.15ml,
1.81mmol) and then 206 (500mg, 1.21mmol) was added. The mixture was stirred
efficiently for 29 hr. Acetonitrile was then removed in vacuo and the resultant
mixture partitioned between water and chloroform. The organic layer was collected
and the aqueous layer extracted two times with chloroform. The combined extracts
were dried (MgSC>4) and removed under reduced pressure. Purification of the
*
resultant residue by column chromatography using CHCl3:MeOH:NH3 (95:5:1) as 
eluent afforded 67mg (15%) of 192 as a colourless oil.
13-hydroxy ketone 192
Rf = 0.35 (CHCl3:MeOH:NH3 = 90:9:1); m/z (FAB): 370.2 (M++H, 100%), 352.2 
(M++H - H2O, 18%), 300.2 (M++H - C4H7O, 8%); IR (neat) = 3424 (OH), 1711 
(C=0), 1637, 1608 (ArC-C), 1501 (C-N), 1447, 1372, 1278 (ArC-0-CH3), 1202, 
1154,1108,1054,962,919 cm'l.
8h  (400MHz) : 1.37-1.46 (1H, m, H-8), 1.50-1.61 (2H, m, H-8 and H-22), 1.67-1.71 
(2H, m, H-7 and H-15eq), 1.87 (1H, m, Jgem = 12.2Hz and /l5ax,16eq = 4.9Hz, H- 
15ax), 2.01-2.09 (1H, m, H-22), 2.24 (1H, m, Jgem = 12.2Hz and /I6ax,15eq = 
3.4Hz, H-16ax)» 2.32 (1H, d, Jgem = 13.7Hz, H-21), 2.34-2.49 (2H, m, H-14 and H- 
19), 2.35 (1H, dd, Jgem = 18.6Hz and / i 0a ,9 = 5.4Hz, H-10a ), 2.41 (3H, s, N-CH3),
2.45 (1H, dd, Jgem = 13.67Hz and / 21,22 = 4.9Hz, H-21), 2.53 (1H, dd, Jgem  = 
12.2Hz and /l6eq,15eq = 3.9Hz, H-16eq), 2.67 (1H, d, Jgem = 14.2Hz, H-19), 3.03
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(1H, d, Jgem = 18.6Hz, H-lOp), 3.14 (1H, dd, /9,10cx = 5.4Hz and /9,14 = 2.4Hz, H- 
9), 3.87 (3H, s, O-CH3), 4.22 (1H, s, H-5), 6.68 (1H, d, / l ,2  = 8.2Hz, H-l), 6.75 (1H, 
d, 72,1 = 8.2Hz, H-2).
8c (400MHz): 19.85 (C-10), 24.82 (C-8), 25.65 (C-22), 35.91 (C-7), 37.41 (C-14),
37.83 (C-15), 38.39 (C-21), 42.64 (C-13), 43.22 (N-£H3), 46.83 (C-16), 50.99 (C-19),
56.70 (0-£H3), 59.75 (C-9), 74.81 (C-6), 92.49 (C-5), 113.83 (C-2), 119.93 (C-l), 
127.21 (C-ll), 130.24 (C-12), 141.96 (C-3), 145.47 (C-4), 208.84 (C=0).
HRMS (FAB): found 370.2026, C22H28NO4 (M++H) requires 370.2018.
Attempted preparation of7-(methyl)dihydrocodeinone (204)
a) from dihydrocodeinone (117)
Dihydrocodeinone (500mg, 1.67mmol) dissolved in THF (15ml) was added dropwise 
to a stirred solution of lithium diisopropylamide at -78°C (prepared by the addition of 
/z-butyl lithium (0.67ml, 1.67mmol) to diisopropylamine (0.33ml, 2.50mmol) in THF 
(5ml) at -78°C and stined for 1 hr prior to use). After 1 hr, methyliodide (0.12ml, 
2.00mmol) was added dropwise to this mixture and the reaction allowed to warm to 
room temperature. After 24 hr, TLC analysis showed no depletion of starting material 
and after removal of THF and subsequent purification by column chromatography, 
unreacted dihydrocodeinone was recovered.
b) from 206
A solution of ‘naked* fluoride reagent was prepared by dissolving 18-crown-6 
(529mg, 2.00mmol) in dry acetonitrile (10ml) and then adding dry potassium fluoride 
(141mg, 2.42mmol). After the heterogeneous system was stirred for 30 mip, 
methyliodide (0.11ml, 1.82mmol) and then 206 (500mg, 1.21mmol) was added. The 
mixture was stirred efficiently for 24 hr. Acetonitrile was then removed in vacuo and
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the resultant mixture partitioned between water and chloroform. The organic layer 
was collected and the aqueous layer extracted two times with chloroform. The 
combined extracts were dried (MgSC>4) and removed under reduced pressure. 
Purification of the resultant residue by column chromatography using CHCl3:MeOH 
(9:1) as eluent afforded dihydrocodeinone (344mg, 95%).
Attempted preparation of7-(a!ly!)dihydrocodeinone
4
a) from dihydrocodeinone (117)
Dihydrocodeinone (466mg, 1.56mmol) dissolved in THF (15ml) was added dropwise 
to a stirred solution of lithium diisopropylamide at -78°C (prepared by the addition of 
/i-butyl lithium (0.62ml, 1.56mmol) to diisopropylamine (0.31ml, 2.33mmol) in THF 
(5ml) at -78*C and stirred for 1 hr prior to use). After 1 hr, allylbromide (0.16ml, 
1.87mmol) was added dropwise to this mixture and the reaction allowed to warm to 
room temperature. After 21 hr, TLC analysis showed no depletion of starting material 
and after removal of THF and subsequent purification by column chromatography, 
unreacted dihydrocodeinone was recovered.
b) from 206
A solution of ‘naked* fluoride reagent was prepared by dissolving 18-crown-6 
(529mg, 2.00mmol) in dry acetonitrile (10ml) and then adding dry potassium fluoride 
(141mg, 2.42mmol). After the heterogeneous system was stirred for lhr, allylbromide 
(0.16ml, 1.82mmol) and then 206 (500mg, 1.21mmol) was added. The mixture was 
stirred efficiently for 36 hr. Acetonitrile was then removed in vacuo and the resultant 
mixture partitioned between water and chloroform. The organic layer was collected 
and the aqueous layer extracted two times with chloroform. The combined extracts 
were dried (MgSC>4) and removed under reduced pressure. Purification of the
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resultant residue by column chromatography using CHCl3:MeOH (9:1) as eluent 
afforded dihydrocodeinone (333mg, 92%).
4
Preparation of vinyltri-n-butyltin115 (212)
A mixture of tri-zz-butyltin chloride (4.11ml, 15mmol) and vinylmagnesium bromide 
[1M solution in THF] (15.24ml, 15mmol) were heated at reflux for 20 hr. After 
subsequent cooling to room temperature, saturated aqueous NH4CI (15ml) was added 
to the mixture. The organic layer was separated and the residual salts washed with 
several portions of diethyl ether. The ether layers were combined with the organic 
layer, dried (MgS04) and then removed under reduced pressure. The residue was 
distilled under diminished pressure to afford the title compound as a colourless liquid 
(3.89g, 81%).
4
Bp. 93*C at 1.5mmHg; IR (neat): 1459, 1418,1378, 1341, 1289,1249, 1072, 1004, 
941,870cm-l.
8h (270Mz) : 0.89-0.96 (15H, m, /  = 7.3Hz), 1.27-1.41 (6H, m, /  = 7.3Hz), 1.49-1.61 
(6H, m, /  = 8.3Hz), 5.68 (1H, dd, Jtrans = 20.7Hz and Jgem = 3.7Hz, 
CH2=CHSnBu3), 6.16 (1H, dd, Jcis = 14.1Hz and Jgem = 3.7Hz, CH2=CHSnBu3),
6.48 (1H, dd, Jtrans = 20.7Hz and Jcis = 14.1Hz, CH2=CHSnBu3).
5c  (400M H z) : 9 .32  (CH2=CHSn(CH2)2CH2CH3)» 13.69
(CH2=CHSn(CH2)2CH2CH3 ), 27.35 (CH2=CHSnCH2CH2CH2CH3), 29.16 
(CH2=CHSn£H2(CH2)2CH3 ), 133.62 (CH2=CHSn(CH2)3CH3 ), 139.03
(CH2=CHSn(CH2)3CH3).
4
Found: C, 52.70; H, 9.53%. C l4H3()Sn requires: C, 53.03; H, 9.54%.
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Preparation of codeine triflate (211)
Dihydrocodeinone (l.OOg, 3.34mmol) dissolved in dry THF (22ml) was added to*a 
solution of lithium diisopropylamide (LDA) at -78°C. LDA was freshly prepared by 
the dropwise addition of /i-butyl lithium (1.47ml, 3.67mmol) to diisopropylamine 
(0.27ml, 3.67mmol) dissolved in THF (1ml) and stirred at -78CC for 1.5 hr prior to 
use. After a further 2^-hf "at -78*C, a solution o f N- 
phenyltrifluoromethanesulphonimide 1 1 4  (i£2g , 3.67mmol) in THF (6ml) was 
added over 15 min and the reaction'temperature allowed to warm to room 
temperature. The mixture was stirred for a further 17 hr before the solvent was 
removed. The resultant yellow oil was purified by column chromatography on silica 
gel using CHG3:MeOH (95:5) as eluent to afford the title compound as a colourless 
oil (853mg, 59%).
ft
Rf = 0.50 (CHCl3:MeOH = 9:1); mlz (FAB) = 432.1 (M++H, 100%); IR (neat) : 1636 
(C=C), 1606 (ArC-C), 1501 (C-N), 1417, 1279 (ArC-0-CH3), 1221, 1144, 1055, 
1030,955,913,884, 848,795,755, 608 cm‘1.
8h  (270Mz) : 1.70 (1H, m, Jgem = 17.6Hz, /8ax,14 = 11.4Hz and /8ax,7 = 2.0Hz, H- 
8ax)» 1.78 (1H, m, Jgem = 12.1Hz, H-15eq), 1.95 (1H, m, Jgem = 12.1Hz and 
Jr15ax,16eq = 5.0Hz, H-15ax), 2.13 (1H, m, Jgem = 17.6Hz and /8eq,7 = 6.4Hz, H- 
8eq), 2.24 (1H, m, Jgem = 12.1Hz, /l6ax,15eq = 3.7Hz, H-16ax)» 2.40 (1H, dd, Jgem 
= 18.7Hz and /I0a ,9  = 6.0Hz, H-10a ), 2.40 (3H, s, N-CH3), 2.38 - 2.50 (1H, m, H- 
14), 2.53 (1H, dd, Jgem = 12.1Hz and /l6eq,15ax = 3.5Hz, H-16eq), 3.01 (1H, d, 
Jgem = 18.9Hz, H-lOp), 3.18 (1H, dd, /9,10a = 5.9Hz and /9,14 = 2.8Hz, H-9), 3.83 
(3H, s, 0-CH3), 4.90 (1H, s, H-5), 5.88 (1H, dd, /7,8eq= 6.4Hz and /7,8ax = 2.0Hz, 
H-7), 6.63 (1H, d, / l ,2 = 8.2Hz, H-l), 6.71 (1H, d, / 2,1 = 8.2Hz, H-2).
5C (400MHz): 19.85 (C-10), 24.31 (C-8), 34.86 (C-15), 37.92 (C-14), 42.66 (N-£H3), 
43.39 (C-13), 45.97 (C-16), 56.74 (O-CH3), 58.38 (C-9), 85.78 (C-5), 114.87 (C-2),
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119.65 (C-l), 119.87 (CF3), 123.78 (C-7), 126.25 (C-ll), 127.95 (C-12), 143.44 (C-
3), 143.97 (C-6), 145.43 (C-4).
HRMS (FAB): found 432.1083, C19H20F3NO5 (M++H) requires 432.1093.
Stitte coupling between 211 and vinyltri-n-butyltin137
To a mixture of lithium chloride (83mg, 1.96mmol) and tetrakistriphenylphosphine 
palladium (0) (22mg, 0.02mmol) in dry THF (10ml) under nitrogen was added a 
solution of codeine triflate (416mg, 0.96mmol) in THF (5ml) and vinyltri-n-butyltin 
(0.29ml, 0.96mmol). The slurry was heated to reflux for 22 hr. After cooling, the 
solvent was removed in vacuo to give a yellow oil. Purification of the crude oil by 
column chromatography on silica gel using CHCl3:MeOH (95:5) as eluent afforded 
210 as a cream coloured solid (270mg, 90%).
+
Diene210
Rf = 0.51 (CHCl3:MeOH = 9:1); mlz (FAB) = 310.1 (M++H, 100%); IR (neat) = 
1733, 1631 (C=C), 1603 (ArC-C), 1497 (C-N), 1445, 1373, 1334, 1278 (ArC-O- 
CH3), 1205,1148,1103,1047,905, 862 cm'1.
8h  (270Mz) : 1.62 (1H, t, Jgem = 13.4Hz, H-8ax), 1.89 (1H, m, Jgem = 12.6Hz, H- 
15eq), 2.00-2.10 (1H, m, H-8eq), 2.07 (1H, m,J gem = 12.5Hz and /I5ax,16eq = 
4.8Hz, H-15ax), 2.40 (1H, m, Jgem = 12.1Hz, /I6ax,15eq = 3.7Hz, H-16ax), 2.45- 
2.55 (1H, m, H-14), 2.51 (3H, s, N-CH3), 2.52 (1H, dd, Jgem = 18.9Hz and 7l0a,9 = 
6.6Hz, H-10a), 2.69 (1H, dd, Jgem = 12.1Hz and 7l6eq,15ax = 3.9Hz, H-16eq), 3.05 
(1H, d, Jgem = 18.9Hz, H-10p), 3.27 (1H, dd, / 9,10a  = 6.4Hz and 79,14 = 2.2Hz, H- 
9), 3.82 (3H, s, O-CH3), 5.10 (1H, d, Jcis = 11.0Hz, C6CH=CH2), 5.24 (1H, s, H-5),
5.53 (1H, d, Jtrans = 17.6Hz, C6CH=CH2), 5.85 (1H, dd, /7,8eq= 6.4Hz and77,8ax = 
2.2Hz, H-7), 6.22 (1H, dd, Jtrans = 17-6Hz and Jcis = 11.0Hz, C6CH=CH2), 6.61 
(1H, d, 71,2 = 8.1Hz, H-l), 6.71 (1H, d, 72,1 = 8.3Hz, H-2).
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5c (400MHz): 20.29 (C-10), 24.92 (C-8), 35.14 (C-15), 38.16 (C-14), 40.99 (C-13), 
42.62 (N-£H3), 46.77 (C-16), 56.54 (0-£H3), 59.21 (C-9), 86.57 (C-5), 113.49 
(C6CH=£H2), 114.03 (C-2), 118.48 (C-l), 125.92 (C-ll), 128.90 (C-12), 132.10 (C- 
7), 133.97 (C-6), 136.84 (C6£H=CH2),143.06 (C-3), 145.05 (C-4).
HRMS (FAB): found 310.1822, C20H24NO2 (M++H) requires 310.1807.
ft
Attempted Diels-Alder reaction between 210 and maleic anhydride
a) at room temperature
A mixture of 210 (lOlmg, 0.33mmol) and maleic anhydride (32mg, 0.33mmol) 
dissolved in dry DCM (0.2ml), under an atmosphere of nitrogen was stirred at room 
temperature. TLC analysis of the reaction mixture after 15 hr showed no reaction had 
taken place and the starting material was recovered after purification by column 
chromatography.
b) under reflux ft
A mixture of 210 (lOlmg, 0.33mmol) and maleic anhydride, (32mg, 0.33mmol), 
dissolved in dry toluene (2ml), under an atmosphere of nitrogen was heated to reflux 
for 20 hr. After cooling, the organic solvent was removed and the reaction mixture 
purified by column chromatography. Starting material was recovered.
c) using aluminium chloride as catalyst
A mixture of 210 (102mg, 0.33mmol), maleic anhydride (32mg, 0.33mmol) and 
aluminium chloride (45mg, 0.34mmol) dissolved in dry DCM (1ml), was stirred at 
room temperature and the reaction monitored by TLC. No reaction was observed after 
12 hr and starting material was recovered.
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The above reaction was repeated using 2 equivalents of aluminium chloride (0.9mg, 
0.70mmol), 210 (lOlmg, O.33mmol), maleic anhydride (32mg, 0.33mmol) in dry 
DCM (1ml). Again no reaction was observed by TLC analysis after 16 hr.
d) using 30 equivalents of maleic anhydride
A mixture of maleic anhydride (4.27g, 44mmol) and 210 (450mg, 0.33mmol) under 
an atmosphere of nitrogen was dissolved in THF (1ml). The solution was warmed to 
75*C for 16 hr. After cooling, attempted purification of the resultant black tar by 
column chromatography using CHCl3:MeOH (9:1) as eluent was unsuccessful and no 
moiphinoid compound could be isolated.
Attempted Diels-Alder reaction of 210 with benzoquinone
A mixture of 210 (341mg, 1. lOmmol), benzoquinone (125mg, 1.16mmol) and boron 
trifluoride etherate (0.14ml, 1.14mmol) was dissolved in dry DCM (1.2ml). The 
mixture was stirred at room temperature under an atmosphere of nitrogen. After 15 
min a brown tar was formed. DCM was then removed in vacuo. Attempted 
purification of the tar by column chromatography on silica gel using CHCl3:MeOH 
(95:5) was unsuccessful.
ft
Diels-Alder Reaction between 210 and dimethyl acetylenedicarboxylate
a) at room temperature
A mixture of 210 (249mg, 0.81mmol), dimethyl acetylenedicarboxylate (0.1ml,
0.81 mmol) was stirred at room temperature for 72 hr. TLC analysis of the mixture 
showed no reaction and starting material was recovered.
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b) using aluminium chloride as Lewis acid catalyst116
»
A mixture of 210 (91mg, 0.29mmol), dimethyl acetylenedicarboxylate (0.04ml,
0.29mmol) and aluminium chloride (43mg, 0.32mmol) in dichloromethane (0.2ml) 
was stirred at room temperature for 48 hr. TLC analysis of the mixture showed no 
reaction.
(c) using 30 equivalents of dimethyl acetylenedicarboxylate
210 (450mg, 0.33mmol) under an atmosphere of nitrogen was dissolved in dimethyl 
acetylenedicarboxylate (4.27g, 44mmol). The solution was warmed to 80*C for 2 hr. 
After cooling, attempted purification of the resultant black tar by column 
chromatography using CHCl3:MeOH (95:5) as eluent was unsuccessful and no 
morphinoid compound could be isolated. *
Diels-Alder Reaction between 210 and tetracyanoethylene138
A mixture of tetracynanoethylene (78mg, 0.61mmol) and 210 (189mg, 0.61mmol) in 
dry tetrahydrofuran (1ml) was stirred at room temperature for 24 hr and then heated at 
reflux for 12 hr. After cooling, removal of solvent under reduced pressure gave a 
black residue which was purified by column chromatography on silica gel using 




Rf = 0.36 (CHCl3:MeOH = 9:1); m/z (FAB) = 438.1 (M++H, 43%). •
5 r  (270Mz) : 1.60-1.70 (1H, m), 1.81-2.08 (4H, m), 2.00-2.10 (1H, m, H-8eq), 2.32-
2.49 (2H, m), 2.45 (3H, s, N-CH3), 2.55-2.66 (1H, m, H-16eq), 2.92-2.99 (1H, m, H- 
7), 3.09 (1H, d, Jgem = 18.9Hz, H-lOp), 3.18-3.33 (3H, m), 3.85 (3H, s, O-CH3), 4.91
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(1H, s, H-5), 6.09-6.14 (1H, m, /  = 7.0Hz, C6=CHCH2), 6.72 (1H, d, J \y2 = 8.2Hz, 
H-l), 6.81 (1H, d ,/2,l = 8.2Hz, H-2).
8c (400MHz): 20.08 (C-10), 25.79 (C-8), 32.50 (C-20), 35.17 (C-7), 36.74 (C-14), 
36.94 (C-15), 37.33 (C(CN)2C(CN)2), 42.85 (C-13), 43.00 (N-£H3), 44.50 
(£(CN)2C(CN)2), 45.90 (C-16), 56.51 (O-CH3), 58.83 (C-9), 91.90 (C-5), 109.51, 
109.98,110.77,110.77 (4xCN), 114.39 (C-2), 120.02 (C-l), 123.70 (C6=£H), 126.92 
(C-ll), 127.71 (C-12), 131.98 (C-6), 142.26 (C-3), 145.52 (C-4).
HRMS (FAB): found 438.1916, C26H24N5O2 (M++H) requires 438.1930.
Diels-Alder Reaction between 210 and diethyl azodicarboxylate139
a) with 1 equivalent of DEAD
A mixture of diethyl azodicarboxylate (0.11ml, 0.71mmol), 210 (221mg, 0.71mmol) 
in dry toluene (2ml) was heated at reflux for 13 hr under nitrogen. After cooling, 
removal of solvent under reduced pressure afforded a black residue. Attempted 
purification of the residue by column chromatography on silica gel using 
CHCl3:MeOH (97:3) as eluent was unsuccessful and no morphinoid compound could 
be isolated.
b) with 20 equivalents of DEAD
To 210 (175mg, 0.56mmol), under an atmosphere of nitrogen, was added DEAD 
(1.78ml, llmmol). The mixture was warmed to 100°C for 14 hr and then allowed to 
cool to room temperature. Purification of the reaction mixture by column 
chromatography on silica gel using EtOAcrPetrol (1:1) as eluent afforded 225 as a 
colourless oil (38mg, 13%).
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Adduct225
Rf = 0.20 (EtOAc:Petrol = 1:1); mtz (FAB) = 541.2 (M+, 100%), 468.2 (M+-C02Et, 
11%); IR (neat) = 1726 (C=0), 1632 (C=C), 1605 (ArC-C), 1501 (C-N), 1420,1378, 
1320,1281 (ArC-0-CH3), 1222,1178,1126,1065,1020 cm*1.
8h  (270Mz) : 1.00-1.60 (10H, m), 1.80 (4H, hr. s), 2.08-2.20 (1H, m), 2.69 (1H, d, 
Jgem = 18.7Hz, H-10p), 2.80-3.00 (1H, m), 3.03-3.11 (1H, m), 3.86 (3H, s, 0-CH3), 
3.95-4.40 (10H, m), 4.87 (1H, s, H-5), 5.95 (1H, d, C6CH=CH2), 6.67 (1H, d, / l ,2  = 
8.2Hz, H-l), 6.80 (1H, 4  72,1 = 8.1Hz, H-2).
ft
HRMS (FAB): found 541.2400, C28H35N3O8 (M++H) requires 541.2424. 
Diels-Alder reaction between 210 and acrylonitrile
To 210 (125mg, 0.40mmol) was added acrylonitrile (0.80ml, 12mmol) under an 
atmosphere of nitrogen. The mixture was stirred at 85*C for 14 hr. After cooling, the 
resultant residue was purified by column chromatography on silica gel using 
CHG3:MeOH (97:3) as eluent to afford 231 as a colourless oil (13mg, 9%).
Adduct231
Rf = 0.48 (CHCl3:CH30H = 9:1); mJz (FAB) = 363.0 (M++H, 100%); IR (neat)*= 
2240 (C=N), 1631 (C=C), 1603 (ArC-C), 1501 (C-N), 1448, 1371,1330,1279 (ArC- 
O-CH3), 1205,1155,1106,1055,909 cm*1.
8h  (400MHz) : 1.26 (1H, m, Jgem = 12.7Hz and J  = 10.1Hz, H-20), 1.56 (1H, m, 
Jgem = 12.7Hz and /  = 8.7Hz, H-20), 1.66-1.78 (1H, m, H-8), 1.76 (1H, d 4  Jgem = 
12.8Hz, H-15eq), 1.87-1.95 (2H, m, H-8 and H-15ax), 2.03-2.15 (2H, m, H-7 and H- 
21), 2.17-2.24 (1H, m, H-14 and H-21), 2.32 (1H, m, Jgem = 12.2Hz, /I6ax,15eq = 
3.7Hz, H-16ax), 2.41 (3H, s, N-CH3), 2.47 (1H, dd, Jgem = 18.5Hz and 7l0a,9 =
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6.1Hz, H-10a), 2.52 (1H, dd, Jgem = 12.2Hz and /l6eq,15ax = 4.3Hz, H-16eq), 2.73 
(1H, ddd, J  = 11.6Hz and /  = 5.5Hz, and J = 3.1Hz, H-22), 3.01 (1H, d, Jgem = 
18.6Hz, H-lOp), 3.18 (1H, dd, /9,10a = 6.1Hz and /9,14 = 2.4Hz, H-9), 3.86 (3H, s, 
0-CH3), 4.79 (1H, s, H-5), 5.94 (1H, d, /  = 4.9Hz, C6=CH), 6.64 (1H, d, J \ £  = 
8.2Hz, H-l), 6.75 (1H, d, / 2,1 = 8.2Hz, H-2).
*
5c (400MHz): 19.93 (C-10), 21.84 (C-8), 23.85 (C-21), 27.47 (C-7), 27.62 (C-20), 
29.96 (C-22), 37.33 (C-14), 37.47 (C-15), 43.12 (N-£H3), 43.64 (C-13), 46.07 (C-16),
56.22 (0-£H3), 59.58 (C-9), 94.82 (C-5), 113.15 (C-2), 119.15 (C-l), 121.03 (C-6),
127.67 (O N ), 127.87 (C6=£H), 129.85 (C-ll), 133.87 (C-12), 141.75 (C-3), 146.21 
(C-4).
HRMS (FAB): found 363.2083, C23H27N2O2 (M++H) requires 363.2073. 
Diels-Alder reaction between 210 and methylvinyl ketone
To 210 (102mg, 0.33mmol) was added methylvinyl ketone (0.83ml, 9.93mmol) under 
an atmosphere of nitrogen. The mixture was heated to reflux for 22 hr. After cooling 
and subsequent removal of excess methylvinyl ketone in vacuo, the resultant residue 
was purified by column chromatography on silica gel using CHCl3:MeOH (95:5) as 
eluent to afford 233 as a colourless oil (46mg, 37%).
Adduct233
Rf = 0.20 (CHCl3:MeOH = 95:5); mlz (FAB) = 380.0 (M++H, 100%), 336.0 (M++H - 
C2H3O, 10%); IR (neat) = 1707 (C=0), 1630 (C=C), 1603 (ArC-C), 1500 (C-N), 
1447,1358,1277 (A1C-O-CH3), 1156,1106,1054, 892,794,753 cm'1.
5 r  (400MHz) : 0.67-0.76 (1H, m, Jgem = 13.2Hz, H-8ax). 1.23-1.31 (1H, m, H-8eq),
1.46 (1H, m, Jgem = 12.7Hz and 7 =  5.4Hz, H-21ax), 1.68 (1H, m, Jgem = 13.7Hz 
and J = 4.7Hz, H-21eq), 1.77 (1H, m, Jgem = 11.2Hz and /l5eq,16ax = 3.4Hz, H-
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15eq), 1.81 (3H, s, CH3C=0), 1.91 (1H, m, Jgem = 12.7Hz, /I5ax,16eq = 4.9Hz, H- 
15ax)» 1.96-2.04 (1H, m, H-20eq), 2.07-2.26 (3H, m, H-7, H-14, H-2Qax), 2.31 (1H, 
m, Jgem = 12.2Hz, /I6ax,15eq = 3.4Hz, H-16ax), 2.39 (3H, s, N-Cffi), 2.40 (1H, dd, 
Jgem = 18.6Hz and / l0 a ,9  = 6.3Hz, H-10a), 2.51 (1H, dd, Jgem = 12.2Hz and 
/l6eq,15ax = 4.4Hz, H-16eq), 2.60 (1H, m, /  = 12.7Hz and /  = 4.9Hz, and /  = 2.5Hz, 
H-22), 2.97 (1H, d, Jgem = 18.6Hz, H-lOp), 3.09 (1H, dd, /9,10a = 6.3Hz and /9,14 
= 2.9Hz, H-9), 3.88 (3H, s, O-CH3), 4.82 (1H, s, H-5), 5.92 (1H, d, /  = 4.9Hz, 
C6=CH), 6.63 (1H, d, 71,2 = 8.3Hz, H-l), 6.71 (1H, d, 72,1 = 8.3Hz, H-2).
5c (400MHz): 18.50 (C-21), 20.25 (C-10), 24.92 (C-20), 26.14 (C-8), 28.39 (C-7),
28.67 (£H3C=0), 37.44 (C-14), 37.66 (C-15), 43.35 (N-£H3), 43.95 (C-13), 46.13 
(C-16), 50.89 (C-22), 56.61 (O-CH3), 59.96 (C-9), 95.60 (C-5), 113.59 (C-2), 119.01 
(C-l), 127.93 (C -ll), 128.66 (C6=£H), 130.62 (C-12), 135.78 (C-6), 141.96 (C-3), 
146.86 (C-4), 210.54 (CH3£=0).
HRMS (FAB): found 380.2236, C24H30NO3 (M++H) requires 380.2226. 
Diels-Alder reaction between 210 and methylacrylate
To 210 (115mg, 0.37mmol) was added methylacrylate (1.00ml, llmmol) under an 
atmosphere of nitrogen. The mixture was stirred at 90°C for 21 hr. After cooling, the 
resultant residue was purified by column chromatography on silica gel using 
CHCl3:MeOH (97:3) as eluent to afford 120mg (82%) of 234 as a 1:1 mixture of 
isomers.
Adduct234
Rf = 0.33 (CHCl3:CH30H = 97:3); m/z (FAB) = 396.1 (M++H, 100%); IR (neat) = 
1731 (C=0), 1631 (C=C), 1603 (ArC-C), 1501 (C-N), 1446,1371, 1330, 1277 (ArC- 
O-CH3), 1196,1158,1104,1053,1023,906 cm 'I
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5h  (400MHz) : 0.87 (1H, m, /  = 10.3Hz), 1.14 (1H, dd, /  = 9.3Hz), 1.37 (1H, m, /  «
9.3Hz), 1.53 (1H, m, /  = 12.2Hz, /  = 5.4Hz), 1.59-1.94 (7H, m), 1.97-2.17 (6H, m, H- 
7, H-7), 2.21-2.43 (7H, m, H-10a , H-10a , H-14, H-14, H-16, H-16, H-22), 2.39
(3H, s, N-CH3), 2.40 (3H, s, N-CH3), 2.46-2.58 (3H, m, H-16, H-16, H-22), 2.97 (1H, 
d, Jgem = 18.6Hz, H-lOp), 2.99 (1H, d, Jgem = 18.6Hz, H-lOp), 3.06 (1H, dd, /9,10a  
= 6.4Hz and /9,14 = 2.4Hz, H-9), 3.09 (1H, dd, /9,10a = 6.4Hz and /9,14 = 2.4Hz, 
H-9), 3.54 (3H, s, CO2CH3), 3.60 (3H, s, CO2CH3), 3.86 (3H, s, O-CH3), 3.87 (3H, 
s, 0 -CH3), 4.79 (1H, s, H-5), 4.80 (1H, s, H-5), 5.91 (1H, d, 7 = 4.9Hz, C ^ Q D , 5.95 
(1H, d, 7 = 2.4Hz, C6=QD, 6.59 (1H, d, J \,2  = 8.3Hz, H-l), 6.60 (1H, d, J \,2  = 
8.3Hz, H-l), 6.73 (1H, d, 72,1 = 8.3Hz, H-2), 6.74 (1H, 4  72,1 = 8.3Hz, H-2).
5c (400MHz): 19.42 (CH2), 19.93 and 20.17 (C-10), 24.41, 24.58, 24.73, 26.24 
(CH2), 28.09 (C-14), 28.97 (012). 29.59 (C-14), 37.36 (C-15), 37.45 and 37.49 (C- 
7), 37.64 (C-15), 42.59 (C-13), 42.85 (C-22), 43.12 (N-CH3), 43.69 (C-13), 46.10 and
46.23 (C-16), 47.79 (C-22), 51.30 and 51.65 (CO2CH3), 56.31 and 56.42 (O-CH3),
59.53 and 59.73 (C-9), 95.34 and 95.61 (C-5), 113.31 and 113.31 (C-2), 118.60 and
118.65 (C-l), 127.71 and 127.87 (C-ll), 128.07 (C6=£H), 129.61 and 130.19 (C-12), 
130.36 (C6=£H), 134.00 and 135.39 (C-6), 141.66 and 141.81 (C-3), 146.49 and 
146.60 (C-4), 174.61 and 175.64 (£02CH3).
HRMS (FAB): found 396.2179, C24H30NO4 (M++H) requires 396.2175.
Attempted Diels-Alder reaction between 210 and thebaine
A stirred mixture of thebaine (103mg, 0.33mmol) and 210 (102mg, 0.33mmol) 
dissolved in toluene (3ml) was warmed to 50°C. The reaction was monitored by TLC 
and after 10 hr the mixture cooled and toluene removed under reduced pressure. 
Purification of the resultant residue by column chromatography using CHCl3:MeOH 
(95:5) proved unsuccessful. The mixture was subsequently analysed using mass 
spectrometry which showed the presence of both starting materials.
*
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Preparation of 6p-0-(phenyl)codeine (239) 124,125
To a stirred solution of codeine (503mg, 1.68mmol) in THF (10ml) was added diethyl 
azodicarboxylate (0.40ml, 2.52mmol). The reaction mixture was cooled to 0*C before 
PPh3 (671mg, 2.56mmol) and then phenol (0.5g, 1.67mmol) added. The reaction 
mixture was allowed to warm to room temperature and stirred for a further 24 hr. 
THF was then evaporated off under reduced pressure and the resultant residue purified 
by column chromatography on silica gel using CHCl3:MeOH (95:5) as eluent to gfoe 
the title compound (1 lOmg, 17%) as a colourless oil.
Rf = 0.45 (CHCl3:CH30H = 9:1); m/z (FAB) : 376.2 (M++H, 42%), 282.1 (M++H- 
C6H5 O, 8%); IR (neat) = 1729, 1636, 1595, 1497 (C-N), 1448, 1374, 1339, 1278 
(ArC-0-CH3), 1226,1156,1052 cm’1.
8h  (270MHz) : 1.70 (1H, d, Jgem = 12.3Hz, H-15eq), 2.12 (1H, m, Jgem ~ 12.3Hz 
and /I5ax,16eq = 5.0Hz, H-15ax)» 2.36 (1H, dd, Jgem = 18.7Hz and /l0 a ,9  = 5.5Hz, 
H-10a), 2.39 (1H, m, /l6ax,15ax = 12.5Hz, Jgem = 12.1Hz and /I6ax,15eq = 3.7Hz, 
H-16ax)» 2.45 (3H, s, N-CH3), 2.60 (1H, dd, Jgem = 12.1Hz and /l6,15ax = 4.3Hz, 
H-16eq), 3.08 (1H, d, Jgem = 18.7Hz, H-lOp), 3.18 (1H, dd, /14,9 = 3.3Hz, H-14), 
3.37 (1H, dd, /9,10a = 5.5Hz and /9 ,i4  = 3.3Hz, H-9), 3.88 (3H, s, O-CH3), 4.81 
(1H, d, / 6,7 = 5.7Hz, H-6), 4.92 (1H, d, / 5,6 = 0.7Hz, H-5), 5.75 (1H, dd, /8,7 = 
9.8Hz and /8,14 = 2.0Hz, H-8), 5.96-6.03 (1H, m, /7 t8 = 9.8Hz and /7,6 = 5.5Hz, H- 
7), 6.59 (1H, d, / l ,2 = 8.2Hz, H-l), 6.71 (1H, d, / 2,1 = 8.2Hz, H-2), 6.77 (1H, d, /  = 
8.8Hz, ^-ArCH), 6.95 (1H, d, Jm,o = 7.3Hz, m-ArCH), 6.98 (1H, d, /  = 8.3Hz, m- 
ArCH), 7.28 (1H, d, Jm,o =7.3Hz, m-ArCH), 7.29 (1H, d, Jm,o =7.3Hz, m-ArQi).
5C (400MHz): 20.20 (C-10), 35.67 (C-15), 39.88 (C-14), 42.97 (N-CH3), 44.17 (C- 
13), 46.79 (C-16), 56.32 (O-CH3), 58.84 (C-9), 72.36 (C-6), 91.12 (C-5), 112.86 (C- 
2), 115.75 (2xw-ArCH), 119.01 (C-l), 121.11 (2xp-ArCH), 127.15 (C-ll), 127.69 (C-
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4
7), 129.54 (2xo-ArCH), 130.47 (C-12), 135.38 (C-8), 142.03 (C-3), 145.73 (C-4), 
156.99 (i-ArCH).
HRMS (FAB): found 376.1913, C24H26NO3 (M++H) requires 376.1913. 
Preparation of 6p-0~(2-bromophenyl)codeine (88)
To a cooled, stirred solution of codeine (0.50g, 1.67mmol), PPI13 (0.88g, 3.34mmol)
ft
and 2-bromophenol (0.39ml, 3.34mmol) in THF (10ml) was added diethyl 
azodicarboxylate (0.53ml, 3.34mmol) dropwise. The reaction mixture was allowed to 
warm to room temperature and stirred for a further 22 hr. The reaction mixture was 
evaporated to dryness and the residue dissolved in a 10% solution of tartaric acid 
(30ml). The solution was washed with ethyl acetate (x3), made alkaline with conc. 
NH4OH (pH 10) and then extracted with CHCI3 (x3). The chloroform layer was 
dried (MgS04) and after removal of solvent, the resultant residue purified by column 
chromatography on silica gel using CHCl3:MeOH (95:5) as eluent to give the title 
compound as a colourless oil (312mg, 41%).
Rf = 0.39 (GHCl3:CH30H = 95:5); mlz (FAB): 453.8 (M++H, 59%), 281.9 (M++H- 
C6H40Br, 90%); IR (neat) = 1728,1635,1599,1582,1502 (C-N), 1471,1446,1340, 
1277 (ArC-0-CH3), 1239,1155,1115,1048,973,947,909 cm'1.
8h  (400MHz) : 1.84 (1H, m, Jgem = 12.2Hz, H-15eq), 2.19 (1H, m, 7l5ax,16ax = 
12.7Hz, Jgem = 12.2Hz and /I5ax,16eq -  5.4Hz, H-15ax)> 2.35 (1H, dd, Jgem  — 
18.6Hz and /I0a ,9  = 5.9Hz, H-10a), 2.40 (1H, m, /l6ax,15ax = 12.7Hz, Jgem = 
12.2Hz and /I6ax,15eq = 3.4Hz, H-16ax), 2.46 (3H, s, N-CH3), 2.60 (1H, dd, Jgem = 
12.2Hz and/l6eq,15ax = 3.9Hz, H-16eq), 3.08 (1H, d, Jgem = 18.6Hz, H-lOp), 3.28 
(1H, dd, 714,9 = 3.4Hz and /14,8 = 2.0Hz, H-14), 3.37 (1H, dd, /9,10a = 5.9Hz and 
/9,14 = 3.4Hz, H-9), 3.86 (3H, s, O-CH3), 4.87 (1H, d,/6,7 = 5.8Hz, H-6), 4.95 (1H, 
s, H-5), 5.79 (1H, dd, / 8,7 = 9.8Hz and /8,14 = 2.0Hz, H-8), 5.99-6.04 (1H, m, / 7,8 =
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9.8Hz, 77,6 = 5.9Hz and 77,14 = 1-OHz, H-7), 6.59 (1H, d, 7 i,2  = 8.3Hz, H-l), 6.69 
(1H, d, 72,1 = 8.3Hz, H-2), 6.85 (1H, ddd, 74’,3' = 7.8Hz, 74’,5’ = 7.3Hz and 7 = 
1.5Hz, H-4’), 7.06 (1H, dd, 76’,5’ = 8.3Hz and 7= 1.5Hz, H-6’), 7.25 (1H, ddd,75’,6' = 
8.3Hz, 75',4’ = 7.3Hz and 7 = 1.5Hz, H-5’), 7.55 (1H, dd, 73',4’ = 7.8Hz and 7 = 1.5Hz, 
H-3'). ft
8C (400MHz): 20.33 (C-10), 35.78 (C-15), 39.95 (C-14), 43.11 (N-CH3), 44.37 (C- 
13), 46.81 (C-16), 56.26 (O-CH3), 58.86 (C-9), 73.56 (C-6), 91.17 (C-5), 112.70 (C-
2), 113.67 (C-2'), 115.64 (C-6’), 119.04 (C-l), 122.57 (C-41), 127.04 (C-7), 127.37 (C- 
11), 128.41 (C-51), 130.44 (C-12), 133.53 (C-3’), 136.78 (C-8), 141.94 (C-3), 146.15 
(C-4), 153.44 (1*).
HRMS (FAB): found 454.1005, C24H25NC>3Br (M++H) requires 454.1018.
Radical coupling of 88129»130
To a stirred solution of 88 (lOOmg, 0.23mmol) in dry toluene (1ml) under nitrogen 
was added tri-n-butyltin hydride (0.08ml, 0.30mmol). The mixture was warmed to 
50*C before a catalytic amount of AIBN was added. The temperature was raised to 
reflux for 20 hr. After cooling, toluene was removed in vacuo, the resultant residue 
dissolved in EtOAc and the organic layer washed (x2) with a 10% aqueous solution of 
tartaric acid. The combined aqueous extracts were made alkaline (pH 9) with conc. 
NH4OH and then extracted with chloroform (x3). The combined chloroform layers 
were dried (MgS04) and removal of solvent afforded 82 as a colourless oil (78mg, 
90%).
6p,7fi-(2’J ’-Dihydrobenzofuran)deoxycodeine (82)
Rf = 0.30 (CHCl3:CH30H = 95:5); m/z (FAB) : 376.2 (M++H, 100%); IR (neat) = 
1731, 1633, 1601, 1501 (C-N), 1448, 1370, 1334, 1275 (ArC-0-CH3), 1218, 1155, 
1111,1052,930 cm-l.
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5 h  (400MHz) : 1.20-1.29 (1H, m, /8ax,14 = 13.7Hz, Jgem = 12.2Hz and / 8,7 =  7.3Hz 
H-8 ax), 1*62 (1H, ddd, Jgem -  12.2Hz, /8eq,14 = 3.4Hz, and/8eq,7 = 2.9Hz, H-8eq), 
1.69 (1H, m, Jgem =  12.2Hz and /I5eq,16ax = 3.4Hz, H-15eq), 1.83 (1H, m , 
•7l5ax,16ax = 13.7Hz, Jgem — 12.2Hz and J 15ax,16eq = 5.4Hz, H-15ax)» 2.12 (1H, dt,
4
/14,8ax = 13.7Hz, /I4,8eq = 3.4Hz and /14,9 = 2.9Hz, H-14), 2.27 (1H, m , Jgem = 
12.2Hz and /I6ax,15eq = 3.4Hz, H-16ax), 2.31 (1H, dd, Jgem = 19.1Hz and /I0a,9  = 
6.4Hz, H-10a), 2.34 (3H, s, N-CH3), 2.46 (1H, dd, Jgem = 12.2Hz and / l 6eq ,15ax = 
3.4Hz, H-16eq), 3.01 (1H, dd, /9,10a = 6.4Hz and /9,14 = 2.9Hz, H-9), 3.05 (1H, d, 
Jgem = 19.1Hz, H-lOp), 3.50 (1H, t, / 7,8 = 7.3Hz, H-7), 3.90 (3H, s, 0-CH3), 4.73 
(1H, d, /5,6 = 2.0Hz, H-5), 4.83 (1H, dd, / 6,7 = 9.3Hz and/6,5 = 2.0Hz, H-6), 6.65 
(1H, d, / l ,2 = 8.3Hz, H-l), 6.75 (1H, d, / 2,1 = 8.3Hz, H-2), 6.78 (1H, d, J6 '$  = 
7.8Hz, H-6’), 6.86 (1H, m, /4 ’,3’ = 7.3Hz, /4',6f = 1-OHz, H-4’), 7.08 (1H, d, /3',4’ = 
7.3Hz, H-3’), 7.10 (1H, t, /5 ’,6‘ = 7.8Hz, H-5').
6C (400MHz): 19.98 (C-10), 26.07 (C-8), 35.80 (C-7), 37.41 (C-15), 38.23 (C-14),
42.24 (C-13), 42.91 (N-CH3), 46.61 (C-16), 56.43 (O-CH3), 59.28 (C-9), 85.38 (C-6), 
92.20 (C-5), 109.48 (C-6*), 113.28 (C-2), 118.98 (C-l), 120.87 (C-4’), 123.65 (C-3'), 
127.13 (C-ll), 128.19 (C-51), 129.25 (C-2'), 130.38 (C-12), 142.27 (C-3), 145.34 (C-
4), 155.51 (1’).
HRMS (FAB): found 376.1931, C24H26NO3 (M++H) requires 376.1913.
Attempted coupling between codeine and cyclohexanol (248)
To a stirred solution of cyclohexanol (0.17ml, 1.67mmol) in THF (20ml) was added 
diethyl azodicarboxylate (0.26ml, 1.67mmol). The reaction mixture was cooled to 
0*C and PPh3 (438mg, 1.67mmol) added portionwise. After stirring for 1 hr at room 
temperature codeine (501mg, 1.67mmol) dissolved in THF (5ml) was added dropwise
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over 5 min. The reaction mixture was stirred for 48 hr. TLC analysis showed that no 
reaction had taken place and codeine was recovered quantitatively.
The above reaction was repeated using cyclohexanol (0.07ml, 0.67mmol) in THF 
(10ml) and codeine (201 mg, 0.67mmol) but 1.5 equivalents of diethyl 
azodicarboxylate (0.6ml, l.OOmmol) and PPh3 (264mg, l.OOmmol). No reaction was 
observed by TLC analysis (48 hr) and codeine was recovered quantitatively.
In a further reaction, diethyl azodicarboxylate (0.79ml, 5.01mmol) was added to a
ft
stirred solution of cyclohexanol (0.17ml, 1.67mmol) in THF (20ml) and the mixture 
cooled to 0°C before PPh3 (1.31g, 5.01mmol) added in small portions. A colour 
change to deep orange was observed. After stirring for 1 hr at room temperature 
codeine (0.5g, 1.67mmol) dissolved in THF (5ml) was added dropwise over 5 min. A 
colour change to yellow was observed. The reaction mixture was stirred for a further 
67 hr before THF was evaporated off under reduced pressure. The resultant residue 
was purified by column chromatography on silica gel using CHCl3:MeOH:NH3 




Rf = 0.46 (CHCl3:CH30H = 9:1); m/z (FAB): 458.1 (M++H, 62%), 282.1 (M++H- 
C6H11N2O4, 19%); IR (neat) = 1733,1709,1638 (C=C), 1607 (ArC-C), 1502 (C-N), 
1447, 1410, 1379, 1325, 1283 (A1C-O-CH3), 1258, 1223, 1174, 1152, 1123, 1093, 
1056,933,914,866cm-l.
8h  (270MHz): 1.27 (3H, t, J = 7.0Hz, CO2CH2CH3), 1.29 (3H, t, /  = 7.0Hz, 
CO2CH2CH3), 1.73 (1H, d, Jgem = 12.5Hz, H-15eq), 2.07 (1H, m, Jgem = 12.5Hz, 
H-15ax). 2.27 (1H, m, Jgem = 12.2Hz and /I6ax,15eq = 3.2Hz, H-16ax). 2.37 (1H, 
dd, Jgem = 18.3Hz, and /l0 a ,9  = 5.7Hz, H-10a ), 2.38 (3H, s, N-CH3), 2.55 (1H, dd, 
Jgem = 12.2Hz and /I6,15ax = 4.1Hz, H-16eq), 2.98 (1H, br. s, H-14), 3.02 (1H, d,
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Jgem = 18.3Hz, H-10p), 3.27 (1H, dd, /9,10a = 5.7Hz and /9,14 = 2.8Hz, H-9), 3.87 
(3H, s, 0-CH3), 4.10-4.34 (4H, m, CO2CH2CH3), 4.76 (1H, br. s, H-8), 5.12 (1H, br. 
s, H-5), 5.68 (2H, s, H-6 and H-7), 6.55 (1H, d, / i ,2 = 8.1Hz, H-l), 6.68 (1H, d, / 2,1 
= 8.2Hz, H-2), 7.38 (1H, br. s, NHCO2CH2CH3).
5 c  (270MHz): 14.43 2(N-C02CH2£H3), 20.11 (C-10), 34.74 (C-15), 39.96 (C-14), 
42.78 (N-Me), 44.05 (C-13), 47.05 (C-16), 56.66 (O-Me), 59.06 (C-9), 62.05 (N- 
CO2CH2CH3), 62.65 (N-C02£H 2CH3), 77.21 (C-8), 91.52 (C-5), 113.81 (C-?),
118.70 (C-l), 127.15 (C-7), 128.73 (C-ll), 130.41 (C-12), 132.63 (C-6), 142.31 (C-
3), 145.26 (C-4), 155.43 (N-£02CH2CH3), 156.94 (N-£02CH2CH3).
HRMS (FAB): found 458.2326, C24H32N3O6 (M++H) requires 458.2291. 
Preparation of2-bromo-cyclohexan~l-ol (249) 133
A mixture of cyclohexene (5.0g, 0.06mmol), N-bromosuccimide (10.85g, 0.06mmol) 
and water (25ml) was stirred vigorously at room temperature until the solid NBS had 
disappeared (45 min). The reaction was left stirring overnight. The bromohydrin 
layer was separated and the aqueous layer extracted with toluene (x3). Distillation of 
the combined product gave 8.4g (77%) of the title compound.
Bp. = 86.6-88.4°C (10mm); IR (neat) = 3398 (C-OH); m/z (El): 178.0 (M+, 8%), 99.1 
(M+-Br, 75%), 81.1 (M+ - BrH20,100%).
5h  (270MHz) : 1.19-1.46 (3H, m), 1.62-1.92 (3H, m), 2.06-2.21 (1H, m), 2.29-2.40 
(1H, m), 3.28 (1H, s, OH), 3.57-3.68 (1H, m), 3.86-3.98 (1H, m).
Attempted coupling between codeine and 249
To a stirred solution of 2-bromocyclohexan-l-ol (599mg, 3.35mmol) in THF (15ml) 
was added DEAD (0.77ml, 4.92mmol) and PPI13 (1.29g, 4.92mmol). The reaction
ft
-151-
mixture was left stirring for 0.5 hr before codeine (982mg, 3.28mmol) in THF (5ml) 
was cannulated into the reaction vessel. After 41 hr, THF was removed in vacuo and 
the crude mixture purified by column chromatography on silica gel using 
CHCl3:MeOH (95:5) as eluent to afford 95(3 (185mg, 16%) and unreacted codeine 
(468mg).
Attempted preparation of 6p-(2-bromoanttine)codeine (89) 135
To a cooled, stirred solution of codeine (0.50g, 1.67mmol), PPI13 (0.88g, 3.34mmol)
and 2-bromoaniline (0.57g, 3.34mmol) in THF (10ml) was added diethyl
azodicarboxylate (0.53ml, 3.34mmol) dropwise. The reaction mixture was allowed to
*
warm to room temperature and stirred for a 40 hr. THF was then evaporated under 
reduced pressure and the resultant residue purified by column chromatography on 
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5.1. X-Rav Crystallography Data for Compound 159
A crystal of approxim ate d im en sion s 0 .3  x 0 .3  x 0 .3 5  mm w a s  u sed  for data  
collection.
Crystal data: C2*H33N 0 3, M = 3 8 3 .5 1 , O rthorhom bic , a = 11 .135 (3 ), b 
= 12 .0 8 7 (3 ), c  =  15 .4 6 4 (3 ) A, U = 2 0 8 1 .3 (9 ) A3, s p a c e  group P 2 12 12 1, Z  =  4 ,
Dc = 1 .224  gem '3, (jM o-KJ  = 0 .0 8 0  mm'1, F (000) = 832 . Crystallographic 
m ea su rem en ts  w ere  m a d e  at 293(2)° K  on a C A D 4 autom atic four-circle 
diffractom eter in th e  range 2.13<0<23.9O °. D ata (3 7 2 6  reflections) w ere  
corrected  for Lorentz and polarization but not for absorption.
In the final lea st  sq u a res  c y c le s  all a tom s w ere  allow ed to vibrate 
anisotropically. H ydrogen a tom s w ere  included at calcu lated  positions w h ere  
relevant.
T he solution o f th e  structure (SH E LX 86)1 and refinem ent (SH ELX 93)2 
con verged  to a  conventional [i.e. b a se d  on 1827 with F o> 4a(F o)] R1 =0.0519  
and wR2 = 0.1279. G o o d n e ss  o f fit = 0.922. T h e m ax. and min. residual 
d en sitie s  w ere  0.184 and -0.180eA'3 resp ectively . T h e asym m etric  unit (sh ow n  
in F ig . ...), a long with th e  labelling s c h e m e  u se d  w a s  produced using O RTEX.3 
Final fractional a tom ic  co-ord inates and isotropic therm al param eters, bond
d is ta n c e s  and a n g le s  are g iven  in T a b le s  and ... resp ectively . T ab les o f
anisotropic tem perature factors are available a s  supp lem entary  data.
1. Sheldrick G.M ., A cta Cryst., A 46, 4 6 7 -7 3 , 1990.
2 . Sheldrick G.M ., J.Appl.C ryst., 1995  (In preparation.)
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Crystal system  








Theta range for data collection 
Index ranges 
Reflections collected  
Independent reflections 
Refinement method 
Data / restraints / parameters 
Goodness-of-fit on F2 
Final R indices [l>2cy(l)]
R indices (all data)
Absolute structure parameter 




C .H .N O ,
383.51  
293 (2 )'K 
0 .70930 A 
Orthorhombic 
P2 2 2
a = 11.135(3)A  
b = 12.087(3)A  
c = 15.464(3)A  
2081.3(9) A3 
4
1.224 M g/m3 
0.080 mm '1 
832
0.3 x 0.3 x 0 .35  mm 
2 .13 to 23.90*
-12<=h<=12; 0<=k<=13; -17<=l<=0 
3726
3247 [R(int) = 0.0259]
Full-matrix least-squares on F2
3 2 4 5 / 0 / 2 5 6
0.922
R 1 =  0 .0519  wR2 = 0 .1279  
R1 = 0 .1 4 1 7  wR2 = 0 .1905  
1(4)





Table 2. Atomic coordinates ( x 104) and equivalent isotropic 
displacem ent param eters (A2 x 103) . U (eq) 
is defined a s  one third of the trace of the orthogonalized Uij ten sor
Atom X y z U(eq)
N(1) -2782(4) -868(4) -6422(3) 43(1)
0 (1 ) -2299(4) -5159(4) -3394(3) 71(1)
0 (2 ) -2329(3) -4860(3) -5352(2) 45(1)
0 (3 ) -1791(4) -9126(4) -3251(3) 82(2)
C(1) -3026(7) -5984(5) -3756(5) 80(2)
C(2) -2153(5) -4186(5) -3831(3) 42(1)
C(3) -1922(5) -3235(5) -3354(3) 47(2)
0(4 ) -1681(5) -2221(5) -3728(3) 43(1)
0(5 ) -1695(5) -2100(4) -4619(3) 38(1)
0(6 ) -1978(5) -3035(4) -5086(3) 37(1)
0(7) -2185(5) -4058(4) -4717(3) 38(1)
0(8) -1836(5) -4366(4) -6154(3) 41(1)
0(9 ) -2109(5) -3119(4) -6052(3) 34(1)
0 (10) -1252(5) -2292(4) -6479(3) 37(1)
0(11) 56(5) -2651(4) -6383(3) 41(1)
0 (12) 212(5) -3813(5) -6722(4) 49(2)
0 (13) -500(5) ■4672(4) -6210(4) 42(1)
0(14) -1559(5) -1158(4) -6116(3) 41(1)
0 (15) -1365(5) -1070(4) -5127(3) 45(1)
0 (16) -3401(5) -2826(5) -6312(4) 44(1)
0(17) -3687(5) -1633(5) -6073(4) 50(2)
0 (18 ) -3105(6) 283(5) -6245(4) 66(2)
0 (19) -307(6) -5824(5) -6590(4) 53(2)
C(20) -814(6) -6793(5) -6085(4) 54(2)
0 (21) -640(6) -7981(5) -4723(4) 55(2)
C(22) -137(6) -8087(5) -3831(4) 63(2)
C(23) -525(6) -9111(6) -3344(4) 61(2)
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lengths [A] and 
angles 
[*]
Table 4. Anisotropic displacem ent parameters (Ax 103) .
The anisotropic displacem ent factor exponent takes the form: 
-2 pi2 [ h2 a* 2 U 11 + ... + 2 h k a* b* U12 ]
Atom U11 U22 U33 U23 U13 U12
N(1) 41(3) 43(3) 45(3) 3(2) -2(2) 4(2)
0 (1 ) 90(3) 72(3) 50(2) 27(2) -♦(2) -14(3)
0 (2 ) 55(2) 43(2) 38(2) 4(2) 9(2) -11(2)
0 (3 ) 68(3) 116(4) 62(3) 15(3) 1(2) -24(3)
0(1) 99(6) 62(5) 79(5) 18(4) 14(5) -26(4)
C(2) 36(3) 51(3) 39(3) 13(3) 7(3) 6(3)
0(3) 40(4) 71(4) 30(3) 6(3) 4(3) 7(3)
0(4) 39(3) 54(4) 36(3) -10(3) -1(2) 0(3)
0(5) 35(3) 41(3) 38(3) 0(3) -3(2) 3(3)
0(6) 34(3) 44(3) 33(3) 3(2) 5(2) . 1(3)
0(7) 35(3) 40(3) 40(3) 1(3) 6(2) 2(3)
0 (8 ) 46(3) 45(3) 33(3) 5(2) 1(3) -7(3)
0(9) 35(3) 40(3) 27(3) -1(2) 1(2) -3(2)
0 (10) 37(3) 41(3) 34(3) 6(2) 2(2) -6(3)
0 (11) 34(3) 46(3) 42(3) 8(3) 1(3) -3(3)
0 (12) 43(3) 57(4) 45(3) 4(3) 2(3) 1(3)
0 (13) 44(3) 43(3) 40(3) 0(3) 6(3) 3(3)
0 (14) 41(3) 39(3) 44(3) 5(3) 1(3) -5(3)
0(15) 50(4) 44(3) 42(3) -2(3) -13(3) -2(3)
0 (16) 34(3) 58(4) 40(3) 5(3) 0(2) -7(3)
0(17) 38(3) 65(4) 48(3) 12(3) 0(3) 0(3)
0 (18) 71(5) 58(4) 70(4) 1(3) -10(4) 17(4)
0 (19) 62(4) 53(4) 43(4) -5(3) 7(3) -1(3)
C(20) 64(4) 41(3) 57(4) -9(3) 4(3) 0(3)
0 (21) 70(4) 47(4) 47(4) 0(3) -5(3) -4(3)
C(22) 70(5) 61(4) 57(4) 0(3) -9(3) -11(4)
C(23) 64(5) 70(5) 50(4) -4(3) -2(3) -2(4)
0 (24) 69(4) 43(4) 56(4) 1(3) -3(3) -1(3)
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Table 5. Hydrogen coordinates ( x 104) and isotropic 
displacem ent parameters (Ax 103)
Atom X y z U(e
H(3A) -1993(4) -9684(4) -2986(3) 123
H(1A) -2691(25) -6217(30) -4298(17) 120
H(1B) -3819(14) -5695(14) -3850(30) 120
H(1C) -3067(37) -6604(18) -3370(16) 120
H(3) -1931(5) -3283(5) -2753(3) 56
H(4) -1507(5) -1615(5) -3379(3) 52
H(8) -2264(5) -4661(4) -6657(3) 50
H(10) -1437(5) -2279(4) -7098(3) 45
H(11A) 571(5) -2149(4) -6702(3) 49
H(11B) 287(5) -2623(4) -5779(3) 49
H(12A) 1057(5) -4006(5) -6703(4) 58
H(12B) -42(5) -3836(5) -7322(4) 58
H(13) -181(5) -4678(4) -5619(4) 51
H(14) -1005(5) -631(4) -6386(3) 50
H(15A) -527(5) -899(4) -5019(3) 54
H(15B) -1839(5) -456(4) -4910(3) 54
H(16A) -3499(5) -2926(5) -6930(4) 53
H(16B) -3957(5) -3318(5) -6020(4) 5 3 .
H(17A) -4471(5) -1437(5) -6298(4) 60
H(17B) -3714(5) -1562(5) -5448(4) 60
H(18A) -2504(23) 764(5) -6482(27) 100
H(18B) -3156(43) 395(11) -5631(4) 100
H(18C) -3868(21) 446(12) -6505(27) 100
H(19A) -658(6) -5836(5)- -7164(4) 63
H(19B) 550(6) -5939(5) -6657(4) 63
H(20A) -1670(6) -6681(5) -6007(4) 65
H(20B) -708(6) -7463(5) -6422(4) 65
H(21A) -1510(6) -7977(5) -4686(4) 66
H(21B) -408(6) -8628(5) -5055(4) 66
H(22A) -373(6) -7442(5) -3499(4) 75
H(22B) 732(6) -8085(5) -3869(4) 75
H(23A) -265(6) -9765(6) -3655(4) 74
H(23B) -151(6) -9119(6) -2777(4) 74
H(24A) -415(6) -6313(5) -4854(4) 67










Group mean response time (s ± sd) at time (h) post-dose

































































































































































Response time (s) at time (h) post-dose
Pre-dose 0.5 1 2 4 6
1 Vehicle - 1 10.4 7.0 9.5 6.6 6.3 11.5
2 15.3 9.3 7.1 8.2 8.1 6.4
3 9.1 10.9 10.6 6.2 8.7 12.7
4 11.5 8.5 13.0 8.5 13.1 11.7
2 Codeine 5 5 11.9 10.9 6.9 12.5 10.9 11.3
(2) 6 7.5 11.4 7.4 12.1 9.2 7.6
7 10.5 10.0 5.7 6.6 7.0 8.4
8 8.4 11.1 5.4 10.8 11.0 10.5
j Dihydrocodeinone 5 9 8.7 12.0 12.3 9.6 4.8 • 6.8
(117) 10 12.4 7.3 15.1 7.4 6.6 7.9
11 9.6 10.6 12.4 11.4 10.7 11.6
12 10.7 11.6 16.4 8.5 11.8 13.1
4 125 5 13 8.3 8.0 10.2 10.0 8.5 10.1
14 8.7 6.9 12.1 8.4 8.1 9.7
15 12.0 11.6 11.1 10.1 6.9 6.4
16 9.6 6.2 10.5 8.1 10.6 8.4
5 138 5 17 9.6 8.9 9.7 7.8 13.0 9.2
18 12.2 13.9 12.3 13.3 13.2 9.4
19 7.2 8.2 8.4 7.5 10.1 8.1
20 10.7 10.5 11.1 7.5 9.7 11.2
6 126(3 5 21 9.1 9.7 9.1 12.8 6.3 6.2
22 7.2 10.6 8.2 9.0 10.1 8.9
23 13.5 9.5 13.5 10.5 10.3 8.2
24 12.0 9.6 9.6 10.2 8.1 11.4
7 159 5 25 7.5 6.3 10.4 5.2 7.2 9.9
26 12.2 7.5 13.2 6.5 7.4 8.6
27 7.6 8.8 11.6 13.1 5.7 * 12.4
28 14.6 10.0 12.6 14.0 8.6 12.9
8 162 5 29 6.3 8.0 6.5 8.4 6.9 4.6
30 9.7 12.8 9.0 14.3 9.3 6.9
31 10.3 10.5 8.4 11.5 5.0 5.8








Response time (s) at time (h) post-dose
Pre-dose 0.5 1 2 4 6
9 163 5 J J 11.4 11.1 7.3 11.0 10.8 6.9
34 8.0 6.9 9.2 8.8 9.6 7.8
35 12.2 8.6 14.0 12.3 11.5 11.0
36 11.9 10.9 13.3 10.3 12.4 10.7
10 165 5 37 9.4 6.7 7.1 7.9 7.0 5.5
38 11.8 7.7 11.4 12.2 9.0 J2.0
39 9.0 14.1 7.0 8.2 10.6 7.9
40 13.7 12.1 11.7 13.8 10.7 10.9
11 166 5 41 8.9 12.7 12.0 9.7 9.4 9.9
42 9.4 13.4 10.6 12.1 9.8 10.1
43 13.3 8.9 10.3 12.2 11.9 12.5
44 12.3 15.7 10.8 9.3 6.4 5.6





























5.3. X-Rav Crystallography Data for Compound 210 
A crystal o f approxim ate d im en sion s 0 .4  x 0 .3  x  0 .3  mm w a s  u se d  for data  
collection.
Crystal data: C20H23 N 0 2,JW =  3 0 9 .3 9 , Triclinic , a  =  7 .8 3 5 (2 ), b = 8 .4 0 2 (4 ), 
c  = 13 .259 (3 ) A , a  =  1 0 5 .4 8 (3 ), /3 =  9 4 .6 3 (2 ), y  =  94 .93 (2 )° , U = 8 3 3 .2 (5 ) A3, 
s p a c e  group P1, Z = 2 , Dc = 1 .233  gem '3, ^(M o-K J = 0 .0 7 9  mm'1, F (000) = 3 3 2 .  
Crystallographic m ea su r e m en ts  w ere  m ad e  at 2 9 3 (2 )°  K  on  a C A D4 autom atic  
four-circle d iffractom eter in th e  range 2 .5 3 < 0 < 2 2 .9 3 ° . D ata (2 5 1 5  reflections) 
w ere corrected  for Lorentz and polarization but not for absorption.
T h e asym m etric  unit w a s  s e e n  to co n s is t  o f  2  m o le c u le s  which are  
identical within th e  b ou n d s o f exp er im en ta l error. I n th e  final lea st sq u a r e s  c y c le s  
all a tom s w e r e  a llow ed  to  vibrate anisotropically. H ydrogen  a tom s w ere  included  
at calcu lated  p osition s w h ere  relevant.
T h e solu tion  o f  th e  structure (SH E LX 86)1 an d  refinem ent (SH ELX 93)2 
con verged  to  a  conventional [i.e. b a se d  on  1380  F8 data  with F o>4a(F o)] R1 =
0 .0 4 9 4  and wR2 = 0 .1 1 7 1 . G o o d n e ss  o f fit = 1 .0 2 9 . T h e  m ax. and min. residual 
d en sities  w e r e  0 .1 7 2  and  -0 .1 9 3  eA'3 resp ectively . T h e  asym m etric  unit (sh ow n  in 
F ig . ...), a long with th e  labelling s c h e m e  u se d  w a s  produced  using O RTEX.3 Final 
fractional a tom ic  co -ord in a tes and isotropic therm al p aram eters, bond d is ta n c e s
and a n g les  are g iven  in T a b le s  and ... resp ective ly . T ab les  o f an isotropic
tem perature factors are  available a s  su p p lem en tary  data.
1. Sheldrick G .M ., A cta Cryst., A 46, 4 6 7 -7 3 , 1990 .
2. Sheldrick G .M ., SHELXL, a com puter program  for crystal structure  
refinem ent, U niversity o f G ottingen , 1 9 9 3 .
3. M cArdle P ., J.Appl.C ryst., 2 7 , 4 3 8 , 1 9 9 4
(8)0
( Z  i - )0
(03)0
T ab le 1. Crystal d a ta  an d  structure refinem ent
Empirical formula 
Formula w eight 
Tem perature  
W avelen gth  
Crystal sy stem  
S p a c e  group  
Unit cell d im en sion s
V olum e
Z
D ensity  (calculated)
Absorption coeffic ien t  
F (000)
Crystal s iz e
T h eta  range for data  co llection  
Index ran ges  
R eflections co llected  
Independent reflection s  
R efinem ent m ethod  
D ata /  restraints /  p aram eters  
G ood n ess-o f-fit on  F2 
Final R ind ices [l>2a(l)]
R ind ices (all data)
A b so lu te  structure p aram eter  
L argest diff. peak  an d  h o le  
W eighting s c h e m e
Extinction coeffic ien t  
Extinction ex p ress io n






a  = 7.835(2)A a  = 105.48(3)° 
b = 8.402(4)A p = 94.63(2)° 
c =  13.259(3)A y = 94.93(2)°
833.2(5) A3 
2
1.233 M g/m 3 
0.079 mm'1 
332
0.4 x  0.3 x  0.3 mm  
2.53 to  22.93 °.
0< = h< = 8; -9<=k<=9; -14<=l<=14 
2515
2515 [R(int) = 0 .0 0 0 0 ]
Full-matrix lea st-sq u a re s  on  F2
2 5 0 5 / 3 / 4 2 0
1 .0 2 9
R1 = 0 .0 4 9 4  w R 2 =  0 .1171  
R1 = 0 .1 3 6 9  w R 2 = 0 .1 8 4 4  
3(4 )
0.172 a n d -0.193 eA*3
c a lc  w =  1 /[a 2(F o2)+ (0 .0991  P)2+ 0 .0 0 0 0 P ]
w h er e  P = (F o2+ 2 F c  )/3
0.0014(49)
Fc*=kFc[1 + 0 .001  xF c2A.3/sin (20)]‘1/4
-175-
T ab le 2. Atom ic coo rd in a tes  ( x  104) and  eq u iva len t isotropic  
d isp lacem en t param eters (A2 x  103) . U (eq) 
is defined a s  o n e  third o f th e  trace  o f  th e  orth ogonalized  Uij ten sor .
Atom X y z U (eq)
N(1) 5960(11) 10508(10) -345(6) 66(2)
0(1) 7877(8) 5836(8) 1206(5) 64(2)
0(2) 6381(10) 5293(9) 2984(5) 72(2)
C(1) 6947(11) 6935(12) 1826(6) 56(2)
C(2) 6270(11) 6767(12) 2737(6) 53(2)
0(3) 5540(12) 8121(13) 3317(7) 60(3)
0(4) 5529(13) 9586(12) 3019(6) 60(3)
C(5) 6126(12) 9698(11) 2078(7) 58(2)
C(6) 6804(10) 8348(10) 1500(6) 47(2)
C(7) 5676(17) 5135(16) 3926(9) 91(4)
0(8) 8780(12) 6782(12) 557(7) 60(2)
0(9) 7625(12) 8128(13) 505(6) 57(3)
0(10) 6279(12) 7592(11) -450(6) 58(2)
0(11) 5045(13) 8882(14) -486(8) 71(3)
0(12) 7124(14) 11045(14) 628(8) 72(3)
0(13) 8535(12) 9846(13) 551(8) 63(3)
0(14) 9989(14) 10393(15) 1432(9) 81(3)
0(15) 11068(14) 9067(17) 1465(7) 74(3)
0(16) 10582(13) 7458(15) 1105(7) 65(3)
0(17) 11815(14) 6277(17) 1199(8) 74(3)
0(18) 11516(19) 4707(21) 964(10) 99(4)
0(19) 6273(15) 11235(14) 1682(8) 75(3)
C(20) 4830(17) 11737(16) -447(10) 95(4)
N(1A) 9801(14) 4831(14) 8002(7) 94(3)
0(1 A) 8079(9) -1435(9) 6337(5) 73(2)
0(2A) 9745(10) -3049(11) 4580(5) 83(2)
0(1 A) 9014(12) -586(13) 5750(7) 60(3)
C(2A) 9781(13) -1382(14) 4848(8) 66(3)
C(3A) 10512(15) -269(18) 4324(8) 83(3)
C(4A) 10442(16) 1412(17) 4653(8) 85(4)
C(5A) 9726(14) 2170(14) 5566(8) 71(3)
C(6A) 9080(12) 1084(14) 6101(7) 62(3)
0(7A) 10501(15) -3838(18) 3660(9) 96(4)
C(8A) 7118(13) -147(12) 6992(6) 66(3)
C(9A) 8214(12) 1496(14) 7094(7) 68(3)
C(10A) 9594(14) 1947(14) 8067(7) 77(3)
C(11A) 10749(16) 3482(18) 8086(8) 91(4)
C(12A) 8623(16) 4380(16) 7024(9) 84(3)
C(13A) 7 2 7 3 (1 5 ) 3 0 0 1 (1 5 ) 7 1 0 4 (9 ) 8 1 (3 )
C(14A ) 5 7 8 7 (1 7 ) 2 5 7 7 (1 5 ) 6 2 0 4 (1 2 ) 103(4 )
C (15A ) 4 7 6 5 (1 7 ) 9 8 1 (1 8 ) 6 1 4 0 (1 1 ) 9 4 (4 )
C(16A ) 5 3 2 6 (1 2 ) -2 5 5 (1 6 ) 6 4 5 4 (8 ) 7 2 (3 )
C (17A ) 4 1 3 9 (1 8 ) -1 7 7 4 (2 0 ) 6 3 1 2 (1 0 ) 9 4 (4 )
C (18A ) 4 5 3 9 (2 1 ) -3 0 8 9 (2 2 ) 6 4 8 9 (1 2 ) 113(5 )
C(19A) 9 5 2 2 (1 7 ) 3 9 3 5 (1 5 ) 5 9 8 8 (9 ) 83 (3 )
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T ab le  4. A nisotropic d isp la cem en t param eters (A2 x  103) . 
T h e anisotropic d isp la cem en t factor ex p o n en t ta k e s  th e  form: 
-2  pi2 [ h2 a* 2  U 1 1 + ... +  2  h k a* b* U 12 ]
A tom U11 U 22 U 33 U 23 U 13 U 12
N (1) 68(5) 8 2 (6 ) 5 4 (5 ) 2 4 (4 ) 11(4) 2 1 (5 )
0 ( 1 ) 71(4) 7 1 (4 ) 57 (4 ) 2 6 (3 ) 19(3) 13(3)
0 ( 2 ) 94(5) 7 2 (4 ) 6 2 (4 ) 3 5 (4 ) 26 (4 ) 11(4)
C (1) 4 1 (5 ) 8 4 (7 ) 3 6 (5 ) 6(5) 8(4) 1(5)
C (2) 42 (5 ) 7 1 (7 ) 4 2 (5 ) 10(5) 9(4) -1 (5 )
C (3) 56(6) 8 4 (7 ) 4 1 (5 ) 18(5) 14(4) 3 (5 )
C (4) 67 (6 ) 7 0 (7 ) 3 7 (5 ) 3(4) 14(4) 11(5)
C (5) 51(5) 6 4 (6 ) 56 (6 ) 11(5) 11(5) 2 (5 )
C (6) 4 4 (5 ) 5 3 (6 ) 4 2 (5 ) 9(4) 8(4) 5(4)
C (7) 104(9) 108(9 ) 7 9 (8 ) 4 9 (7 ) 36 (7 ) 14 (7 )
C (8) 55(6) 7 6 (6 ) 5 1 (5 ) 19(5) 19(5) 8 (5 )
C (9) 63 (6 ) 7 8 (6 ) 3 7 (4 ) 2 4 (4 ) 16(4) 8 (5 )
C (10) 57(6) 7 5 (7 ) 38 (5 ) 10(4) 7(4) 4 (5 )
C (11) 46(5) 102 (9 ) 6 3 (6 ) 2 1 (6 ) 5(5) 10(6)
C (12) 74(7) 8 1 (7 ) 72 (7 ) 3 7 (6 ) 28 (6 ) 2 (6 )
C (13) 52(6) 7 8 (7 ) 6 4 (6 ) 2 9 (5 ) 15(5) 0(5)
C (14) 57(6) 1 0 0 (8 ) 9 1 (8 ) 3 5 (7 ) 8(6) 4 (6 )
C (15) 55(6) 1 1 2 (1 0 ) 54 (6 ) 2 7 (6 ) 3(5) -4 (7 )
C (16) 58(6) 1 05 (9 ) 51 (5 ) 4 1 (6 ) 2 3 (5 ) 3 0 (6 )
C (17) 61 (7 ) 1 0 0 (1 0 ) 6 6 (7 ) 30 (6 ) 11(5) 9 (6 )
C (18) 97(10) 121 (12 ) 9 3 (9 ) 4 1 (8 ) 3 5 (8 ) 2 3 (9 )
C (19) 76(7) 8 1 (7 ) 6 4 (6 ) 10(5) 13(5) 14(6)
C (20) 88(9) 1 1 5 (1 0 ) 9 7 (8 ) 4 7 (7 ) 13(7) 4 2 (8 )
N(1A) 88(7) 1 02 (8 ) 7 2 (6 ) -2 (5) 2 5 (6 ) -29 (6 )
0 (1 A ) 68 (5 ) 9 1 (5 ) 6 7 (4 ) 2 8 (4 ) 21 (4 ) 7(4 )
0 (2 A ) 86(5) 107(6 ) 6 1 (4 ) 2 3 (4 ) 22 (4 ) 18(4)
C(1A) 51(6) 8 5 (8 ) 4 9 (6 ) 2 5 (5 ) 6 (5) 5(5)
C (2A ) 54(6) 8 8 (8 ) 6 3 (6 ) 3 0 (6 ) 7(5) 10(5)
C (3A ) 80(8) 1 2 4 (1 1 ) 5 5 (6 ) 3 7 (7 ) 21 (6 ) 17(7)
C (4A ) 92(8) 1 1 5 (1 1 ) 5 8 (7 ) 3 9 (7 ) 20 (6 ) -2 (8 )
C (5A ) 67(6) 9 1 (8 ) 54 (6 ) 2 6 (6 ) 7(5) -11 (6 )
C (6A ) 57(6) 8 4 (8 ) 4 6 (5 ) 19(5) -1 (5) 4 (5 )
C (7A ) 68(7) 1 4 0 (1 1 ) 76 (8 ) 16(7) 19(6) 19(7)
C (8A ) 72(7) 9 2 (7 ) 3 1 (4 ) 11(5) 13(5) 4 (6 )
C (9A ) 48 (6 ) 1 06 (9 ) 4 9 (6 ) 2 1 (5 ) 7 (5) -1 (6 )
C (10A ) 76(7) 113(9 ) 3 8 (5 ) 13(5) 14(5) 7(7)
C (11A ) 78(8) 1 3 6 (1 1 ) 4 8 (6 ) 13(6) 9(6) -8(8)
C (12A ) 81(8) 84 (8 ) 81 (8 ) 16(6) 10(7) -1 (6 )
-180-
C(13A) 62(7) 97(9) 81(7) 20(6) 11(6) 3(6)
C(14A) 84(8) 73(8) 138(12) 25(8) -33(8) 0(7)
C(15A) 66(7) 105(10) 106(9) 21(8) 2(7) 20(7)
C(16A) 42(6) 104(9) 56(6) 1(6) 11(5) -10(6)
C(17A) 87(9) 113(10) 80(8) 17(8) 31(7) 11(9)
C(18A) 105(11) 112(12) 111(11) 14(9) 37(9) -14(9)
C(19A) 92(8) 86(9) 65(6) 18(6) 4(6) -16(6)
C(20A) 136(13) 116(11) 97(9) -14(8) 39(9) -52(9)
-181-
T ab le 5. H ydrogen co o rd in a tes  ( x 104) and  isotropic  
d isp lacem en t param eters (A2 x  10 3)
Atom X y z U (eq)
H(3) 5 0 4 7 (1 2 ) 8 0 4 6 (1 3 ) 3 9 2 0 (7 ) 7 2
H(4) 5 1 1 7 (1 3 ) 1050 2 (1 2 ) 3 4 5 4 (6 ) 7 2
H(7A) 6 0 9 6 (9 2 ) 6 0 9 4 (5 6 ) 4 4 9 9 (1 8 ) 136
H(7B) 6 0 2 0 (9 9 ) 4 1 5 5 (6 4 ) 4 0 9 0 (4 1 ) 136
H(7C) 4 4 4 1 (1 7 ) 5 0 4 9 (1 1 2 ) 3 8 1 8 (2 5 ) 136
H(8) 8 8 4 6 (1 2 ) 6 0 5 8 (1 2 ) -1 5 1 (7 ) 7 2
H (10A) 6 8 6 0 (1 2 ) 7 3 7 5 (1 1 ) -1 0 8 4 (6 ) 7 0
H (10B) 5 6 2 2 (1 2 ) 6 5 6 3 (1 1 ) -4 4 3 (6 ) 7 0
H(11A) 4 3 3 7 (1 3 ) 8 5 5 1 (1 4 ) -1 1 5 8 (8 ) 8 5
H (11B) 4 2 8 9 (1 3 ) 8 9 3 3 (1 4 ) 6 4 (8 ) 8 5
H (12) 7 7 0 2 (1 4 ) 1 2 1 4 0 (1 4 ) 6 5 7 (8 ) 8 6
H (13) 9 0 2 7 (1 2 ) 9 7 6 3 (1 3 ) -1 1 6 (8 ) 7 6
H(14A) 1 0 6 9 7 (1 4 ) 1 1 3 3 9 (1 5 ) 1 3 4 1 (9 ) 9 7
H (14B) 9 5 1 0 (1 4 ) 1 0 7 4 5 (1 5 ) 2 0 9 9 (9 ) 9 7
H (15) 1 2 2 0 1 (1 4 ) 9 3 8 8 (1 7 ) 1 7 67 (7 ) 8 9
H (17) 1 2 9 4 1 (1 4 ) 6 7 2 8 (1 7 ) 1460 (8 ) 8 9
H(18A) 1 0 4 1 2 (1 9 ) 4 1 9 0 (2 1 ) 7 0 0 (1 0 ) 119
H (18B) 1 2 4 0 2 (1 9 ) 4 0 7 2 (2 1 ) 1 0 5 6 (1 0 ) 119
H (19A) 6 9 4 0 (1 5 ) 121 3 3 (1 4 ) 2 2 2 5 (8 ) 9 0
H (19B) 5 1 2 7 (1 5 ) 1 1 5 6 0 (1 4 ) 158 1 (8 ) 9 0
H(20A) 5 4 8 3 (2 8 ) 1 2 8 1 2 (2 3 ) -2 7 2 (7 1 ) 142
H (20B) 3 9 5 5 (7 5 ) 1 1 7 5 0 (8 4 ) 2 1 (5 5 ) 142
H (20C) 4 2 9 9 (9 3 ) 1 1 4 6 6 (6 5 ) -1 1 5 9 (2 1 ) 142
H(3A) 1 1 0 6 4 (1 5 ) -6 9 7 (1 8 ) 3 7 3 2 (8 ) 9 9  •
H(4A) 1 0 8 8 7 (1 6 ) 2 0 7 2 (1 7 ) 4 2 5 3 (8 ) 103
H(7A1) 1 01 4 1 (9 4 ) -5 0 1 0 (2 3 ) 3 4 6 3 (4 2 ) 145
H(7A2) 1 1 7 3 4 (1 5 ) -3 6 5 0 (9 6 ) 3 8 0 2 (2 3 ) 145
H(7A3) 1013 9 (9 3 ) -3 3 8 4 (8 0 ) 3 0 9 6 (2 1 ) 145
H(8A) 7 0 5 6 (1 3 ) -3 2 8 (1 2 ) 7 6 8 9 (6 ) 7 9
H (10C) 9 0 2 9 (1 4 ) 2 1 3 8 (1 4 ) 8 7 0 6 (7 ) 9 2
H (10D) 1 0 2 7 8 (1 4 ) 1 0 2 9 (14 ) 8 0 3 7 (7 ) 9 2
H (11C) 1 1 5 1 3 (1 6 ) 3 8 2 0 (1 8 ) 8 7 3 7 (8 ) 109
H (11D) 1 1 4 5 5 (1 6 ) 3 2 2 5 (1 8 ) 7 5 0 7 (8 ) 109
H(12A) 8 0 1 6 (1 6 ) 5 3 5 0 (1 6 ) 7 0 1 8 (9 ) 101
H(13A) 6 7 9 2 (1 5 ) 3 3 5 6 (1 5 ) 7 7 7 8 (9 ) 9 7
H (14C) 5 0 4 2 (1 7 ) 3 4 5 8 (1 5 ) 6 3 2 1 (1 2 ) 123
H (14D) 6 2 5 8 (1 7 ) 2 5 1 0 (1 5 ) 5 5 4 1 (1 2 ) 123
H(15A) 3 6 2 2 (1 7 ) 8 4 0 (1 8 ) 5 8 5 0 (1 1 ) 113
H(17A) 2 9 9 6 (1 8 ) -1 7 5 2 (2 0 ) 6 0 7 1 (1 0 ) 112
-182-
H (18C ) 5 6 6 9 (2 1 ) -3 1 6 4 (2 2 ) 6 7 3 1 (1 2 ) 1 3 5
H (18D ) 3 7 0 6 (2 1 ) -3 9 9 4 (2 2 ) 6 3 7 9 (1 2 ) 1 3 5
H (19C) 8 8 5 8 (1 7 ) 4 2 8 9 (1 5 ) 5 4 5 4 (9 ) 1 00
H (19D ) 1 0 6 5 3 (1 7 ) 4 5 6 5 (1 5 ) 6 1 2 0 (9 ) 1 0 0
H (20D ) 1 0 1 5 9 (2 4 ) 7 2 3 4 (3 8 ) 8 1 4 5 (9 8 ) 191
H (20E) 1 1 6 1 6 (1 2 0 ) 6 2 5 7 (5 5 ) 7 6 1 3 (5 9 ) 191
H (20F) 1 1 5 5 0 (1 1 6 ) 6 6 2 7 (7 9 ) 8 8 3 1 (4 7 ) 191
-183-
